# 1Cell.Ai

> Revolutionizing Next-Gen Translational Research


## Pages

- [Faqs](https://1cell.ai/in/faqs/)
- [Events Conferences](https://1cell.ai/in/events-conferences/): Events & Conferences Scientific engagement, knowledge exchange, and precision oncology leadership — all in one place.
- [Media Recognition](https://1cell.ai/in/media-recognition/): Recognized Excellence Leading the Future of Precision Oncology Recognized innovator at the intersection of deep cell science and AI-driven oncology....
- [Our lab](https://1cell.ai/in/our-lab/): OUR LAB Built for Precision, Quality & Transparency Our laboratory integrates advanced molecular workflows, NGStechnology, and computational analytics to deliver...
- [](https://1cell.ai/clinical-data-2026/): TechnologySolutionsContact Us Unlocking SINGLECELL BIOLOGYBeyond ctDNA An integrated platform combining live single-cell CTC multi-omics with matched ctDNA—from a single blood...
- [Oncolndx® 360° Endometrium](https://1cell.ai/in/products/oncoindx-360/): WHO-Aligned Molecular Classification One Test. One Snapshot. Complete Clarity. The first integrated molecular profiling assay for endometrial cancer—delivering biology-driven treatment...
- [AACR 2026](https://1cell.ai/aacr-2026/): Join 1Cell.ai at AACR 2025 to discover AI-powered single cell multi omic solutions advancing biomarker discovery and therapy monitoring.
- [POLES2026](https://1cell.ai/poles2026/): POLES 2026 (Precsision Oncology Leadership Conference) — where new ideas spark global collaborations and the future of precision oncology takes shape.
- [OncoIndx® TBx](https://1cell.ai/in/oncoindx-tbx/): OncoIndx TBx combines DNA and RNA sequencing of 1 000+ genes with AI-powered iCARE™ reporting. Clinically validated insights for precision oncology and personalized therapy.
- [RSVP-ESMO-Dinner](https://1cell.ai/rsvp-esmo-dinner/): RSVP Today Please complete the form below to reserve your spot and let us know when you’d like to connect.
- [RSVP](https://1cell.ai/rsvp/): Schedule a Meeting Today Please complete the form below to reserve your spot and let us know when you’d like...
- [IASLC WCLC 2025](https://1cell.ai/iaslc-wclc-2025/): Schedule A Meeting With Our Team Today!
- [ASCO 2025 POSTER PDAC MCW Download](https://1cell.ai/asco-2025-poster-pdac-mcw-download/): Download Our ASCO 2025 PDAC MCW POSTER
- [1Cell.ai ASCO PDFs](https://1cell.ai/1cell-ai-asco-pdfs/): Click to download and view each poster: ASCO 2025 POSTER PDAC MCW ASCO 2025 HNC ICI TMH
- [Solutions](https://1cell.ai/in/solutions/): Explore 1Cell.ai India’s solutions—AI-driven single cell multi omic applications in biomarker discovery, therapy monitoring, diagnostics, and clinical research.
- [Technology](https://1cell.ai/in/technology/): Explore the innovative AI and multi-omic technology behind 1Cell.ai India’s single cell solutions, enabling advanced biomarker discovery and precision medicine.
- [OncoIndx®](https://1cell.ai/in/oncoindx/): Discover OncoINDx India’s AI-powered single cell analysis for therapy response insights, patient selection, and personalized oncology solutions.
- [OncoIndx® prime+](https://1cell.ai/in/prime-plus/): Explore Prime Plus India—AI-driven single cell sample preparation for multi omic analysis, enabling precision workflows and reproducible results.
- [OncoMonitor®](https://1cell.ai/in/oncomonitor/): A Novel Liquid Biopsy for Longitudinal Cancer Monitoring and MRD Detection OncoMonitor® is an advanced blood-based solution designed for real-time...
- [OncoHRD®](https://1cell.ai/in/oncohrd/): Discover OncoHRD India, AI-powered single cell HRD biomarker analysis to enhance therapy monitoring and patient stratification in precision oncology.
- [OncoTarget®](https://1cell.ai/in/oncotarget/): OncoTarget India enables AI-powered profiling of actionable oncology targets using single cell analysis to guide personalized cancer therapy decisions.
- [OncoRisk®](https://1cell.ai/in/oncorisk/): OncoRisk India offers AI-powered cancer risk assessment using single cell analytics, helping identify high-risk patients for early intervention.
- [Terms and Conditions](https://1cell.ai/in/terms-and-conditions/): Review 1Cell.ai India’s terms and conditions, including service use, data handling, liability, and compliance for our AI-powered single cell platforms.
- [Team](https://1cell.ai/in/team/): Meet the 1Cell.ai India team—experts in AI-powered single cell multi-omic platforms driving innovation in biomarker discovery and precision oncology.
- [Careers](https://1cell.ai/in/careers/): Search careers at 1Cell.ai India to contribute to AI-driven single cell multi omic research, diagnostics, and cutting-edge biotech development.
- [Privacy Policy](https://1cell.ai/in/privacy-policy/): Read 1Cell.ai India’s privacy policy—learn how we collect, store, and protect single cell multi omic data in compliance with local regulations.
- [Resources](https://1cell.ai/in/resources/): Access 1Cell.ai India’s resource hub—white papers, case studies, webinars, and data insights on AI-powered single cell analysis for oncology research.
- [Products](https://1cell.ai/in/products/): Explore 1Cell.ai India’s portfolio—AI-powered single cell multi omic products for biomarker discovery, therapy monitoring, and precision oncology.
- [Patents](https://1cell.ai/in/patents/): Explore 1Cell.ai India’s patents on AI-driven single cell multi omic technologies and see how our innovations protect advanced oncology applications.
- [About](https://1cell.ai/in/about/): Discover 1Cell.ai India’s mission in AI-powered single cell multi omic diagnostics—empowering biomarker discovery, therapy monitoring, and clinical impact.
- [Contact](https://1cell.ai/in/contact/): Reach out to 1Cell.ai India for AI-driven single cell multi omic solutions, diagnostics partnerships, and precision oncology support.
- [IN-Home](https://1cell.ai/in/): Explore 1Cell.ai India’s advanced single cell analysis and multi-omic solutions to accelerate biomarker discovery and precision medicine locally.
- [1 Cell iCore](https://1cell.ai/in/1-cell-icore/): 1Cell iCore delivers AI powered single cell informatics in India, optimizing biomarker-driven oncology trials with data integration and real‑time insights.
- [Careers](https://1cell.ai/careers/): Join 1Cell.ai to advance AI powered single cell multi omic analysis and help shape the future of biomarker discovery and precision medicine.
- [ASCO 2025](https://1cell.ai/oncology-annual-meeting-2025/): Join 1Cell.ai at ASCO 2025 to explore AI powered single cell multi omic analysis for biomarker discovery, therapy monitoring, and patient selection.
- [AACR 2025](https://1cell.ai/aacr-2025/): Join 1Cell.ai at AACR 2025 to discover AI-powered single cell multi omic solutions advancing biomarker discovery and therapy monitoring.
- [1 Cell iCore](https://1cell.ai/icore/): Explore 1Cell iCore, the AI-powered platform for single cell multi omic analysis, enabling therapy monitoring, biomarker discovery, and patient stratification.
- [Patents](https://1cell.ai/patents/): Explore 1Cell.ai’s patents on AI-powered single cell multi‑omic platforms, showcasing our innovation and leadership in oncology diagnostics and research.
- [OncoIncytes](https://1cell.ai/oncoincytes/): 1Cell.ai offers live circulating tumor cell analysis for liquid biopsy, rare cell capture, and functional testing to advance precision oncology.
- [1 Cell SOLO](https://1cell.ai/solo/): 1Cell SOLO enables easy, efficient single cell sample preparation for multi omic analysis, empowering translational and clinical research workflows.
- [Solutions](https://1cell.ai/solutions/): Explore how 1Cell.ai applies AI-powered single cell oncology solutions in biomarker discovery, live CTC analysis, therapy monitoring, and precision care.
- [Products](https://1cell.ai/products/): Explore 1Cell.ai’s products—AI-powered single cell oncology solutions for biomarker discovery, live CTC analysis, therapy monitoring, and precision diagnostics.
- [Technology](https://1cell.ai/technology/): Single Cell Multi-Omics with 1Cell.ai. Our AI-driven platforms integrate multi-omic analysis to advance biomarker discovery, therapy monitoring, and precision oncology.
- [Terms and Conditions](https://1cell.ai/terms-and-conditions/): Review 1Cell.ai’s terms and conditions outlining user agreements, data usage, and service guidelines for our AI-powered single cell platforms.
- [Mohan Uttarwar​](https://1cell.ai/mohan-uttarwar/): Chief Executive Officer Mohan Uttarwar Serial entrepreneur who co-founded 5 companies, raised over $50M in investment and created the share-holder...
- [Team](https://1cell.ai/team/): Meet the 1Cell.ai leadership team—visionaries in AI-powered single cell oncology research, diagnostics, and multi omic innovation.
- [Resources](https://1cell.ai/resources/): Access 1Cell.ai’s resources—white papers, case studies, and webinars on AI-powered single cell oncology analysis, biomarker discovery, and diagnostics.
- [Global Styles](https://1cell.ai/global-styles/): Global Styles Colors Fonts buttons This page previews Global Fonts and Colors for this Kit. Changes made in Site Settings...
- [About](https://1cell.ai/about/): Learn how 1Cell.ai uses AI powered single cell multi omic analysis to advance biomarker discovery, therapy monitoring, and patient selection.
- [Home](https://1cell.ai/): Unlock advanced patient insights with AI-powered single-cell multi-omic analysis for therapy monitoring, biomarker discovery, and patient selection.
- [Contact](https://1cell.ai/contact/): Connect with 1Cell.ai to learn how AI powered single cell multi omic analysis can advance your research and clinical programs.
- [Privacy Policy](https://1cell.ai/privacy-policy/): Review 1Cell.ai’s privacy policy outlining how we collect, use, and protect data within our AI-powered single cell platforms and oncology solutions.


## Posts

- [Analytical Validation and Clinical Implementation of a 1080-Gene Comprehensive Genomic Profiling Assay with Integrated Cloud-Based Analysis for Solid Tumor Molecular Oncology ](https://1cell.ai/analytical-validation-and-clinical-implementation-of-a-1080-gene-comprehensive-genomic-profiling-assay-with-integrated-cloud-based-analysis-for-solid-tumor-molecular-oncology/): The Problem With Small Panels Precision oncology depends on knowing the full genomic landscape of a patient’s tumour. Yet most...
- [1Cell ERA Newsletter | June 2026](https://1cell.ai/1cell-era-newsletter-june-2026/): ASCO 2026 delivered a defining moment for precision oncology, and the 1Cell. Ai June 2026 Edition Newsletter captures why. From...
- [Potential of urine liquid biopsy in detecting of clinically relevant genomic alterations in advanced genitourinary cancers. ](https://1cell.ai/potential-of-urine-liquid-biopsy-in-detecting-of-clinically-relevant-genomic-alterations-in-advanced-genitourinary-cancers/): When Plasma Can’t Find It; Urine Can Plasma-based liquid biopsy has transformed how we detect and monitor cancer genomically. But...
- [1Cell ERA Newsletter | May 2026](https://1cell.ai/1cell-era-newsletter-may-2026/): The fast-moving world of precision oncology demands an operational engine that is just as sophisticated as the science behind it....
- [Single-Cell Circulating Tumor Cell Genomics Reveals KRAS-Independent Oncogenic Sub-Populations and Longitudinal Clonal Evolution in Metastatic Pancreatic Adenocarcinoma ](https://1cell.ai/single-cell-circulating-tumor-cell-genomics-reveals-kras-independent-oncogenic-sub-populations-and-longitudinal-clonal-evolution-in-metastatic-pancreatic-adenocarcinoma/): Pancreatic Cancer’s Moving Target:- Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers and one of the hardest...
- [Tissue Genomic Profiling in a Case of Endometrioid Adenocarcinoma of the Endometrium](https://1cell.ai/tissue-genomic-profiling-in-a-case-of-endometrioid-adenocarcinoma-of-the-endometrium/): 74y female diagnosed with metastatic endometrioid carcinoma. • Findings: Total hysterectomy with BSO & B/L pelvic lymph nodes dissection. Histopathology...
- [High-Risk Endometrial Carcinosarcoma in a Heavily Pretreated Breast Cancer Survivor: Molecular Insights Guiding Targeted Strategies](https://1cell.ai/high-risk-endometrial-carcinosarcoma-in-a-heavily-pretreated-breast-cancer-survivor-molecular-insights-guiding-targeted-strategies/): 74y female diagnosed with metastatic endometrioid carcinoma. • Findings: Total hysterectomy with BSO & B/L pelvic lymph nodes dissection. Histopathology...
- [Comprehensive Tissue Genomic Profiling Reveals ALK-EML4 Fusionand TP53 Splice-Site Mutation in Metastatic Lung Adenocarcinoma](https://1cell.ai/comprehensive-tissue-genomic-profiling-reveals-alk-eml4-fusionand-tp53-splice-site-mutation-in-metastatic-lung-adenocarcinoma-2/): 74y female diagnosed with metastatic endometrioid carcinoma. • Findings: Total hysterectomy with BSO & B/L pelvic lymph nodes dissection. Histopathology...
- [Liquid Biopsy Reveals ERBB3-PIK3CA Activation and MYC Amplification Driving Resistance in Metastatic Cervical Cancer](https://1cell.ai/liquid-biopsy-reveals-erbb3-pik3ca-activation-and-myc-amplification-driving-resistance-in-metastatic-cervical-cancer/): 50 y/ female diagnosed with poorly differentiated squamous cell carcinoma of cervix • Initial Treatment: Initially treated with chemotherapy, brachytherapy,...
- [Comprehensive Liquid Biopsy Profiling Reveals Dual PIK3CA and ESR1 Mutations in Hormone Receptor–Positive Metastatic Breast Carcinoma](https://1cell.ai/comprehensive-liquid-biopsy-profiling-reveals-dual-pik3ca-and-esr1-mutations-in-hormone-receptor-positive-metastatic-breast-carcinoma-2/): 73-year-old female, invasive ductal carcinoma (IDC) of the right breast (ER 7, PR 8, HER2/neu +1, Ki-67 20%), luminal B–like,...
- [Molecular Drivers of Tumorigenesis and Metastasis in Squamous Cell Lung Carcinoma](https://1cell.ai/molecular-drivers-of-tumorigenesis-and-metastasis-in-squamous-cell-lung-carcinoma/): A 50-year-old male suspected of lung carcinoma. Biopsy of the left scapular lesion was done. Histopathological findings consistent with metastatic...
- [A Tale of Two Primaries: Hepatocellular and Pancreatic Carcinomas Integrating Tissue and Liquid Biopsy Insights](https://1cell.ai/a-tale-of-two-primaries-hepatocellular-and-pancreatic-carcinomas-integrating-tissue-and-liquid-biopsy-insights/): 70y Male diagnosed with dual malignancy of hepatocellular carcinoma & pancreatic carcinoma • Findings: Histopathology of pancreas lesion - ductal...
- [Relapsed Metastatic Ewing’s Sarcoma with ComprehensiveGenomic Profiling](https://1cell.ai/relapsed-metastatic-ewings-sarcoma-with-comprehensivegenomic-profiling/): Diagnosis: 16 year old male, Ewingʼs sarcoma (right 10th rib), CD99+/FLI1+/NKX2. 2+, skeletal metastases at presentation. • Treatment: Progressed through...
- [Rare or Uncommon Cancers: Where tissue-specific guidelines are limited and broad genomic insight is critical](https://1cell.ai/rare-or-uncommon-cancers-where-tissue-specific-guidelines-are-limited-and-broad-genomic-insight-is-critical/): Precision Reclassification and Targeted Intervention in Advanced Hepatocellular Carcinoma Patient Profile: • Age/Sex: 66-year-old male with chronic hepatitis B. •...
- [From Fragmented Results to Precision Care:An Endometrial Cancer Case Study](https://1cell.ai/from-fragmented-results-to-precision-carean-endometrial-cancer-case-study/): Co-Morbidities: Obesity, Hypertension, Type 2 diabetes presented with intermittent postmenopausal bleeding. Initial Diagnosis: Transvaginal ultrasound revealed a heterogeneous endometrial thickening...
- [Circulating Tumor Cell (CTC) Analysis Identifies Actionable DNA Repair Deficiency in Advanced NSCLC Undetected by ctDNA](https://1cell.ai/circulating-tumor-cell-ctc-analysis-identifies-actionable-dna-repair-deficiency-in-advanced-nsclc-undetected-by-ctdna/): A 67-year-old male with Stage IV non–small cell lung cancer (NSCLC) experienced disease progression following standard-of-caretherapies. A comprehensive circulating tumor...
- [Circulating Tumor Cell (CTC) Analysis Identifies Actionable DNA Repair Deficiency in Advanced NSCLC Undetected by ctDNA](https://1cell.ai/circulating-tumor-cell-ctc-analysis-identifies-actionable-dna-repair-deficiency-in-advanced-nsclc-undetected-by-ctdna-2/): A 67-year-old male with Stage IV non–small cell lung cancer (NSCLC) experienced disease progression following standard-of-care therapies. A comprehensive circulating...
- [OncoIncytes® White Paper: Real-Time Cancer Insights with Integrated Single-Cell Multi-Omics](https://1cell.ai/oncoincytes-white-paper-real-time-cancer-insights-with-integrated-single-cell-multi-omics/): Cancer treatment is evolving rapidly, but one major challenge still remains — tumors constantly change. Traditional tissue biopsies and standard...
- [Redefining Precision Oncology: Insights from Dr. Razelle Kurzrock on the Future of Cancer Care](https://1cell.ai/redefining-precision-oncology-insights-from-dr-razelle-kurzrock-on-the-future-of-cancer-care/): In this insightful Expert Insights webinar, globally recognized precision oncology leader Dr. Razelle Kurzrock shares her perspective on how precision...
- [Uncovering Tumor Evolution in Multi-Treated Breast Cancer Using Liquid Biopsy and Longitudinal NGS](https://1cell.ai/uncovering-tumor-evolution-in-multi-treated-breast-cancer-using-liquid-biopsy-and-longitudinal-ngs/): A 52-year-old pre-menopausal woman was diagnosed in November 2015 with stage T2N2M0 breast carcinoma. She underwent surgery, chemotherapy, radiotherapy, and...
- [Genomic Profiling of Rapidly Dedifferentiating MSI-HighEndometrial Carcinoma](https://1cell.ai/genomic-profiling-of-rapidly-dedifferentiating-msi-highendometrial-carcinoma/): 64y Female diagnosed with Grade 3 Endometrioid adenocarcinoma; history of left axillary lump • Initial Treatment: Underwent total uterine hysterectomy...
- [Multi-Omics Insights Driving Personalized Therapy in Breast Cancer](https://1cell.ai/multi-omics-insights-driving-personalized-therapy-in-breast-cancer/): A 55-year-old female was diagnosed with carcinoma of the left breast. She underwent neoadjuvant chemotherapy followed by surgery. Post-treatment imaging...
- [Molecular Risk Reclassification in Stage II Endometrial Carcinoma-When Biology Redefines Prognosis](https://1cell.ai/molecular-risk-reclassification-in-stage-ii-endometrialcarcinoma-when-biology-redefines-prognosis/): 64-year-old female diagnosed with High Grade Endometrial Carcinoma. • Findings Histopathology confirmed pT1b pN0 disease (FIGO Stage II C), favoring...
- [Metastatic Prostate Adenocarcinoma withTMPRSS2-ERG Fusion and MSI-High Immunogenic Profile](https://1cell.ai/metastatic-prostate-adenocarcinoma-withtmprss2-erg-fusion-and-msi-high-immunogenic-profile/): Clinical History & Chronological Summary: • Diagnosis: 70-year-old male with metastatic prostate adenocarcinoma (T3bN3M1), Gleason 9 (5+4), with seminal vesicle...
- [From Genomics to Therapy: A Precision Medicine Approachin Advanced Endometrial Cancer](https://1cell.ai/from-genomics-to-therapy-a-precision-medicine-approachin-advanced-endometrial-cancer/): 74y female diagnosed with metastatic endometrioid carcinoma. • Findings: Total hysterectomy with BSO & B/L pelvic lymph nodes dissection. Histopathology...
- [Concurrent Tissue–Liquid–Normal MatchedMulti-Omics Analysis Enables Precision Targeting inAdvanced Lung Cancer](https://1cell.ai/case-study-05-lung-cancer-2/): Clinical Testing: Treatment Options: Osimertinib is standard of care (NCCN) for Non-small cell lung cancer with brain metastases. Mutations in...
- [OncoPredikt: A Deep-Learning Framework for Tumor Detection and Biomarker Quantification in Breast Cancer IHC Whole-Slide Images ](https://1cell.ai/abstract-78-9-aacr-annual-meeting-2026/): San Diego Presented by Dr.  Gowhar Shafi et al | April 19, 2026 | Session PO. BCS01. 06: Digital Pathology Seeing What Pathologists Miss In breast cancer...
- [OncoIndx® Whitepaper: The Science Behind Smarter Cancer Treatment](https://1cell.ai/oncoindx-whitepaper-the-science-behind-smarter-cancer-treatment/): Cancer treatment works best when it is guided by a clear understanding of a patient’s unique tumor biology. OncoIndx® is...
- [OncoTarget® Whitepaper: Smarter Cancer Testing, Built for Every Patient](https://1cell.ai/oncotarget-whitepaper-smarter-cancer-testing-built-for-every-patient/): Cancer treatment works best when it is guided by the right information. OncoTarget® by 1Cell. Ai is a targeted genomic...
- [OncoHRD® WhitePaper: Smarter Cancer Treatment Starts with the Right Test](https://1cell.ai/oncohrd-whitepaper-smarter-cancer-treatment-starts-with-the-right-test/): Not all cancers are the same, and neither should their treatment be. OncoHRD® by 1Cell. Ai is an advanced genomic...
- [OncoMonitor® White Paper: Smarter Cancer Monitoring Starts with a Blood Test](https://1cell.ai/oncomonitor-white-paper-smarter-cancer-monitoring-starts-with-a-blood-test/): Cancer treatment is not a one-time decision, it is an ongoing journey that requires constant monitoring. OncoMonitor® by 1Cell. Ai...
- [1𝘾𝙚𝙡𝙡.𝘼𝙞 𝙎𝙝𝙤𝙬𝙘𝙖𝙨𝙚𝙨 𝘽𝙧𝙚𝙖𝙠𝙩𝙝𝙧𝙤𝙪𝙜𝙝 𝙈𝙪𝙡𝙩𝙞-𝙊𝙢𝙞𝙘 𝙊𝙣𝙘𝙤𝙡𝙤𝙜𝙮 𝙄𝙣𝙨𝙞𝙜𝙝𝙩𝙨 𝘼𝙘𝙧𝙤𝙨𝙨 7 𝙎𝙩𝙪𝙙𝙞𝙚𝙨 𝙖𝙩 𝘼𝘼𝘾𝙍 2026](https://1cell.ai/1%f0%9d%98%be%f0%9d%99%9a%f0%9d%99%a1%f0%9d%99%a1-%f0%9d%98%bc%f0%9d%99%9e-aacr-2026/): 1Cell. Ai, a leader in precision oncology diagnostics, is proud to announce the presentation of seven research studies at the...
- [1Cell ERA Newsletter | April 2026](https://1cell.ai/1cell-era-newsletter-april-2026/): Cancer care is not just about reports, scans, and treatments. It is also about the long journey patients, caregivers, and...
- [NGS Testing FAQs for Oncologists](https://1cell.ai/ngs-testing-faqs-for-oncologists/): FAQ #1 – When should NGS testing be ordered in cancer patients? NCCN guidelines strongly recommend broad-panel Next-Generation Sequencing (NGS)...
- [Liquid Biopsy & ctDNA FAQs](https://1cell.ai/ctdna-testing-faqs-for-oncologists/): FAQ #1 – When should ctDNA testing be preferred over tissue biopsy? NCCN guidelines generally recommend tissue biopsy as the...
- [ctDNA, Multi-Omics & AI in NGS Testing](https://1cell.ai/ctdna-multi-omics-ai-ngs-testing-faqs/): FAQ #1 – Why is circulating tumor DNA (ctDNA) important? Circulating tumor DNA (ctDNA) is essential as a non-invasive “liquid...
- [How to Order NGS Tests & Get Support](https://1cell.ai/order-ngs-test-support-faqs-1cell-ai/): FAQ #1 – How can I order for an NGS test from 1Cell. Ai? Tests can be ordered by reaching...
- [CTC Testing FAQs](https://1cell.ai/ctc-vs-ctdna-testing-oncology-faqs/): FAQ #1 – What is the clinical role of CTC testing in oncology? A circulating tumor cell (CTC) is a...
- [NGS Tissue Requirements, Test Failures & FFPE Quality](https://1cell.ai/ngs-tissue-requirements-test-failures-ffpe-faqs/): FAQ #1 – What is the minimum tissue requirement for NGS? The minimum tissue requirement for NGS generally requires 10–50...
- [Reading NGS Reports: VAF, Actionable Mutations, VUS & More](https://1cell.ai/ngs-report-interpretation-vaf-actionable-mutations-vus-faqs/): FAQ #1 – How should low VAF variants be interpreted? Low VAFs often suggest subclonal populations that might not be...
- [Precision Profiling of TP53 Alterations in Advanced Cancers: Real-World Evidence Linking Mutation Class to Genomic Instability and Co-occurring Actionable Drivers ](https://1cell.ai/abstract-lb118-5-aacr-annual-meeting-2026/): Why TP53 Matters More Than We Thought TP53 is the most frequently altered tumour suppressor gene in human cancer. Yet for all its...
- [MIRAGE: A ctDNA Methylation-Driven Computational Algorithm Designed for Sensitive Detection of Minimal Residual Disease ](https://1cell.ai/mirage-a-ctdna-methylation-driven-computational-algorithm/): The Problem That Drives MIRAGE A patient finishes surgery. Their scans look clear. Their ctDNA levels appear low. By conventional measures, they...
- [Enhancing Variant Interpretation Through Multi-Database and Systematic Variant Classification: Reducing Uncertainty in Clinical Genomics ](https://1cell.ai/abstract-6272-2-aacr-annual-meeting-2026/): The Challenge We Set Out to Solve One of the most persistent challenges in precision oncology today is the interpretation...
- [Integrative Genomic Analysis Reveals Pharmacogenomic Determinants of Chemotherapy Response ](https://1cell.ai/abstract-3141-9-aacr-annual-meeting-2026/): The Problem With One-Size-Fits-All Chemotherapy Every oncologist knows the reality:- Two patients with the same cancer diagnosis can respond very...
- [Comprehensive Genomic Profiling Drives Precision Oncology and Expands Accessibility to Targeted Therapies in Uzbek Populations ](https://1cell.ai/abstract-2510-17-aacr-annual-meeting-2026/): Precision Oncology Must Be Global At 1Cell. ai, we believe that the benefits of precision oncology should not be confined...
- [OncoAlibrex: Ultrasensitive cfDNA Fragmentomics Assay for Early Treatment Response Assessment in Solid Tumors ](https://1cell.ai/abstract-1035-3-aacr-annual-meeting-2026/): The Gap in Treatment Monitoring For patients undergoing cancer treatment, one of the most critical and underserved clinical questions is...
- [Join Us at AACR - April 17-22, 2026](https://1cell.ai/join-us-at-aacr-april-17-22-2026/): Discover how 1Cell. Ai is advancing precision oncology at the intersection of science and technology Our team is leading the...
- [1Cell ERA Newsletter | March 2026](https://1cell.ai/1cell-era-newsletter-march-2026/): The March edition of the 1Cell. Ai Newsletter takes a closer look at how AI is changing the future of...
- [1Cell ERA Newsletter | February 2026](https://1cell.ai/1cell-era-newsletter-february-2026/): The February edition of the 1Cell. Ai Newsletter brings together some of the most important conversations shaping the future of...
- [1Cell ERA Newsletter | January 2026](https://1cell.ai/1cell-era-newsletter-january-2026/): Cancer care is not just about reports, scans, and treatments. It is also about the long journey patients, caregivers, and...
- [Directory of Services](https://1cell.ai/directory-of-services-2/): Directory of Services of all diagnostic tests offered across our company’s portfolio.
- [1Cell ERA Newsletter | December  2025](https://1cell.ai/1cell-era-newsletter-december-2025-2/): The December 2025 edition of the 1Cell. Ai Newsletter reflects on a year that brought major changes in precision oncology...
- [Beyond the Hype: The Real Bottlenecks in Breast Cancer Innovation](https://1cell.ai/beyond-the-hype-the-real-bottlenecks-in-breast-cancer-innovation/): A Deep Dive into the Current Landscape of SERDs, ADCs, and Precision Oncology The pace of breast cancer drug development...
- [Crossing barriers with CSF-based sequencing for leptomeningeal disease in EGFR mutant NSCLC ](https://1cell.ai/ctcs-as-prognostic-markers-in-oral-squamous-cell-carcinoma-2/): When Blood Can’t See It: CSF Can For patients with EGFR-mutant non-small cell lung cancer (NSCLC) who develop leptomeningeal metastases,...
- [1Cell.Ai Partners with AccuGenomics to Expand Ultra-Sensitive Liquid Biopsy Testing Across Asia](https://1cell.ai/1cell-ai-partners-with-accugenomics-to-expand-ultra-sensitive-liquid-biopsy-testing-across-asia/): Strategic collaboration aims to advance early cancer detection and precision oncology through AI-powered liquid biopsy solutions 1Cell. Ai has announced...
- [AccuGenomics and 1Cell.Ai Partner to Bring Ultra-Sensitive Liquid Biopsy Testing Across Asia, with Plans for U.S. Expansion](https://1cell.ai/accugenomics-and-1cell-ai-partner-to-bring-ultra-sensitive-liquid-biopsy-testing-across-asia-with-plans-for-u-s-expansion/): Collaboration integrates per-sample NGS internal standards with multi-omic precision oncology platform to enhance cancer diagnostics accuracy and access WILMINGTON, N....
- [Join Us at ESMO 2025](https://1cell.ai/join-us-at-esmo-2025/): Poster ePostersOur team will share new data across multiple tumor types using AI-powered single cell analysis. Explore Our Full Lineup...
- [Join Us at ISLB 2025 – Orlando, FL | November 1–3](https://1cell.ai/islb-2025-orlando-fl-november-1-3/): Booth #307 – Learn how live single circulating tumor cell capture is redefining biomarker discovery and precision oncology. Poster PresentationPP....
- [Join Us at World ADC – San Diego, CA | November 5–6](https://1cell.ai/world-adc-san-diego-ca-november-5-6/): Booth #86 – See how 1Cell. Ai technology supports translational research and biomarker validation for next-generation ADC programs. Visit Us...
- [Join Us at SABCS – San Antonio, TX | December 9–12](https://1cell.ai/sabcs-san-antonio-tx-december-9-12/): Booth #1446 – Discover our latest breast cancer research and AI-driven insights shaping precision oncology. Plan Your Visit to SABCS
- [Single live circulating tumor cells capture and their genomic profile reveal enriched mutations of PIK3CA and HRR pathway in breast cancer patients](https://1cell.ai/live-ctc-genomic-profile-pik3ca-hrr-breast/): Genomic profiling of true live single circulating tumor cells (CTCs) identified significant enrichment of PIK3CA mutations and homologous recombination repair...
- [AI-Powered HRD Prediction from H&E Histopathology Images in Breast and Ovarian Cancer](https://1cell.ai/ai-hrd-prediction-histopathology-breast-ovarian-cancer/): AI-driven HRD biomarker prediction using OncoPredikt® deep learning inference engine trained on 1,892 whole slide images (WSIs) from TCGA datasets,...
- [1Cell.Ai Completes CLIA Validation Study of OncoIncytes 1080-Gene NGS Panel](https://1cell.ai/1cell-ai-completes-clia-validation-study-of-oncoincytes-1080-gene-ngs-panel/): FOSTER CITY, Calif. , May 28, 2025 /PRNewswire/ — 1Cell. Ai, a precision oncology company developing advanced cell and molecular profiling platforms, announced...
- [1Cell.Ai, Formerly OneCell Diagnostics, Launches OncoIncytes Integrating Multi-Modal Data for Precision Oncology](https://1cell.ai/1cell-ai-formerly-onecell-diagnostics-launches-oncoincytes-integrating-multi-modal-data-for-precision-oncology-2/): AI-powered precision oncology leader to enhance early-stage clinical studies with the introduction of next-generation technology Foster City, CA. & Mumbai,...
- [1Cell.Ai Featured in the Journal of Liquid Biopsy](https://1cell.ai/1cell-ai-featured-in-the-journal-of-liquid-biopsy/): Advancing the Science of ctDNA and CTC-Based Diagnostics Across Cancer Types We’re proud to be featured in five recent publications...
- [ISLB Annual Congress, 2024](https://1cell.ai/islb-annual-congress-2024-3/): Join us as we look back on an incredible gathering of scientists, clinicians, and innovators shaping the future of cancer...
- [Join Us At Medlab Asia 2024](https://1cell.ai/join-us-at-medlab-asia-2024-2/): Expanding Access to Precision Diagnostics in Asia 1Cell. Ai was proud to participate in Medlab Asia 2024, where we showcased...
- [Oncology Think Tank Conclave – Delhi](https://1cell.ai/oncology-think-tank-conclave-delhi-2/): Collaborating to Shape the Future of Cancer Care At the 2024 Oncology Think Tank Conclave in Delhi, 1Cell. Ai joined...
- [Artificial Intelligence Redefining Patient’s Eligibility for Immunotherapy](https://1cell.ai/artificial-intelligence-redefining-patients-eligibility-for-immunotherapy-2/): Watch Now: Dr. Gowhar Shafi at Indian Cancer Congress 2023 Artificial Intelligence Redefining Patient Eligibility for Immunotherapy Hear from Dr....
- [AI-Based Prediction of Homologous Recombination Deficiency (HRD)](https://1cell.ai/ai-based-prediction-of-homologous-recombination-deficiency-hrd-2/): Published in Journal of Clinical Oncology, 2022 | Abstract #3019, ASCO This study showcases the use of artificial intelligence (AI)...
- [OncoRisk® WhitePaper: Understanding Your Hereditary Cancer Risk](https://1cell.ai/oncoindx-ai-powered-genomic-profiling-for-precision-oncology-2-2/): Some cancers are passed down through families, and knowing your genetic risk early can make all the difference. OncoRisk® by...
- [AACR 2024, San Diego](https://1cell.ai/aacr-2024-san-diego-2/): Pioneering the Future of Translational Cancer Research At AACR 2024, 1Cell. Ai showcased how AI, live-cell analytics, and multi-omics platforms...
- [Effect of Cell Proliferation Pathway on Accessibility to Targeted Therapeutics in the Spectrum of Co-occurring Prognostic Cellular Pathways in Pan-Cancers ](https://1cell.ai/effect-of-cell-proliferation-pathway-on-accessibility-to-targeted-therapeutics-in-the-spectrum-of-co-occurring-prognostic-cellular-pathways-in-pan-cancers/): The Promise and the Complexity- of Targeted Therapy Targeted therapies represent one of the greatest advances in modern oncology, offering...
- [Mutational Spectrum of Cell Proliferation Genes as Early Predictive Markers for Aggressive Disease in Endometrial Cancers ](https://1cell.ai/mutational-spectrum-of-cell-proliferation-genes-as-early-predictive-markers-for-aggressive-disease-in-endometrial-cancers/): The Challenge of Predicting Aggressiveness in Endometrial Cancer Endometrial cancer is one of the most molecularly heterogeneous malignancies in oncology....
- [Circulating Tumor Cells and Clusters Exhibiting PD-L1 Expression in Colorectal Cancer Patients ](https://1cell.ai/circulating-tumor-cells-and-clusters-exhibiting-pd-l1-expression-in-colorectal-cancer-patients/): A Gap in Colorectal Cancer Surveillance Colorectal cancer (CRC) is one of the most common and deadly cancers worldwide and yet,...
- [ctDNA-Based Clinicogenomic Analysis of Advanced Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors ](https://1cell.ai/ctdna-based-clinicogenomic-analysis-of-advanced-head-and-neck-cancer-patients-treated-with-immune-checkpoint-inhibitors/): A Cancer With an Urgent Unmet Need Head and Neck Cancer (HNC) is the most prevalent malignancy in Southeast Asia and one of...
- [Using a Dynamic Blood Flow Device with Affinity Ligands to Capture Circulating Tumor Cells in Cancer Patients ](https://1cell.ai/using-a-dynamic-blood-flow-device-with-affinity-ligands-to-capture-circulating-tumor-cells-in-cancer-patients/): The Challenge We Set Out to Solve Metastasis: the spread of cancer from its primary site to distant organs accounts for...
- [Circulating Tumor Cell Distribution and PD-L1 Expression Across Cancer Types; Insights from 5,935 Patients ](https://1cell.ai/circulating-tumor-cell-distribution-and-pd-l1-expression-across-cancer-types-insights-from-5935-patients/): Presented by Jayant Khandare, PhD | Actorius Innovations and Research | Publication Only: Developmental Therapeutics:- Immunotherapy The Largest CTC Study of Its Kind in the...
- [PD-L1 Expression on Circulating Tumor Cells and CTC Clusters as Minimal Cellular Residual Disease in Breast Cancer Patients](https://1cell.ai/pd-l1-expression-on-circulating-tumor-cells-and-ctc-clusters-as-minimal-cellular-residual-disease-in-breast-cancer-patients/): Beyond the Scan: What Imaging Cannot Tell Us A patient completes surgery for breast cancer. Their imaging looks clear. Their oncologist...
- [TRINITY AI - Genomics-Grade Breast Cancer Recurrence Stratification Directly From H&E Images, No Sequencing Required ](https://1cell.ai/trinity-ai-genomics-grade-breast-cancer-recurrence-stratification-directly-from-he-images-no-sequencing-required/): The Problem That Millions of Patients Face Every Day Every year, thousands of women diagnosed with early-stage breast cancer face...
- [Live Single Circulating Tumor Cell Capture for Multi-Omics Cancer Analysis](https://1cell.ai/single-circulating-tumor-cell-multi-omics-assay/): Highlights a live single circulating tumor cell (sCTC) capture assay for contamination-free cancer cell isolation. Demonstrates multi-omics profiling using isolated...
- [2025 ASCO Annual Meeting](https://1cell.ai/2025-asco-annual-meeting-3/): 1Cell. Ai at ASCO 2025: Explore Our Latest Research We’re excited to share 19 new posters and abstracts at the...
- [True live single circulating tumor cell capture with no leukocytecontaminant assay for multiomics in large cancer patient population](https://1cell.ai/live-single-ctc-capture-multiomics-cancer/): A novel assay for true live single circulating tumor cell (CTC) capture was developed to isolate individual tumor cells from...
- [1Cell.Ai and BioSkryb Announce Strategic Partnership to Advance Single Cell Multi-omics Innovation](https://1cell.ai/1cell-ai-and-bioskryb-announce-strategic-partnership-to-advance-single-cell-multi-omics-innovation/): FOSTER CITY, Calif.  and DURHAM, N. C. , April 24, 2025 /PRNewswire/ — 1Cell. Ai, a global leader in single cell precision diagnostics, has...
- [Join Us at AACR - April 25-30, 2025](https://1cell.ai/join-us-at-aacr-april-25-30-2025-2/): Discover how 1Cell. Ai is advancing precision oncology at the intersection of science and technology Our team is leading the...
- [Join Us: Europe Launch Dinner Reception](https://1cell.ai/join-us-europe-launch-dinner-reception-2/): Celebrating the Launch of 1Cell. Ai in Europe You’re invited to an exclusive evening of connection, conversation, and innovation as...
- [1Cell.Ai, Formerly OneCell Diagnostics, Launches OncoIncytes Integrating Multi-Modal Data for Precision Oncology](https://1cell.ai/1cell-ai-formerly-onecell-diagnostics-launches-oncoincytes-integrating-multi-modal-data-for-precision-oncology/): AI-powered precision oncology leader to enhance early-stage clinical studies with the introduction of next-generation technology Foster City, CA. & Mumbai,...
- [Join Us at AACR - April 25-30, 2025](https://1cell.ai/join-us-at-aacr-april-25-30-2025/): Discover how 1Cell. Ai is advancing precision oncology at the intersection of science and technology Our team is leading the...
- [1Cell.Ai Featured in the Journal of Liquid Biopsy](https://1cell.ai/ctdna-based-liquid-biopsy-uncovers-broader-mutational-landscape-in-early-stage-breast-cancer/): Advancing the Science of ctDNA and CTC-Based Diagnostics Across Cancer Types We’re proud to be featured in five recent publications...
- [Single-Cell Genomics Reveals Resistance Signatures in Colorectal Cancer](https://1cell.ai/single-cell-genomics-reveals-resistance-signatures-in-colorectal-cancer/): Presented at ESMO Congress 2024 – Barcelona, Spain This abstract highlights how true single-circulating tumor cell (CTC) genomics can identify...
- [OncoIndx: AI-Powered Genomic Profiling for Precision Oncology](https://1cell.ai/oncoindx-ai-powered-genomic-profiling-for-precision-oncology/): OncoIndx is a first-in-class comprehensive genomic profiling solution developed by OneCell Diagnostics. It leverages next-generation sequencing (NGS) to analyze over...
- [ISLB Annual Congress, 2024](https://1cell.ai/islb-annual-congress-2024/): Join us as we look back on an incredible gathering of scientists, clinicians, and innovators shaping the future of cancer...
- [ESMO Congress 2024](https://1cell.ai/esmo-congress-2024/): Shaping the Future of Precision Oncology From Barcelona, 1Cell. Ai joined global leaders at ESMO 2024 to showcase our latest...
- [Join Us: Europe Launch Dinner Reception](https://1cell.ai/join-us-europe-launch-dinner-reception/): Celebrating the Launch of 1Cell. Ai in Europe You’re invited to an exclusive evening of connection, conversation, and innovation as...
- [ISLB Annual Congress 2024](https://1cell.ai/islb-annual-congress-2024-2/): Advancing Lung Cancer Diagnostics Through Innovation 1Cell. Ai was proud to join global experts at the ISLB Annual Congress 2024...
- [Therapy resistance detected in colorectal cancer by single circulating tumor cell genomics](https://1cell.ai/therapy-resistance-detected-in-colorectal-cancer-by-single-circulating-tumor-cell-genomics/): Highlights single circulating tumor cell (sCTC) genomic profiling in advanced colorectal cancer patients. Demonstrates detection of therapy-resistance signatures missed by...
- [Join Us At Medlab Asia 2024](https://1cell.ai/join-us-at-medlab-asia-2024/): Expanding Access to Precision Diagnostics in Asia 1Cell. Ai was proud to participate in Medlab Asia 2024, where we showcased...
- [Longitudinal ctDNA monitoring with resistance genomic signatures show poor prognostication in EGFR-mutated advanced NSCLC patients](https://1cell.ai/longitudinal-ctdna-egfr-nsclc-prognosis/): Serial circulating tumor DNA (ctDNA) monitoring enabled detection of resistance-associated genomic signatures in patients with EGFR-mutated advanced non–small cell lung...
- [Oncology Think Tank Conclave – Delhi](https://1cell.ai/oncology-think-tank-conclave-delhi/): Collaborating to Shape the Future of Cancer Care At the 2024 Oncology Think Tank Conclave in Delhi, 1Cell. Ai joined...
- [ASCO 2024 Recap](https://1cell.ai/asco-2024-recap/): Driving Impact Through AI and Single-Cell Innovation At the world’s largest oncology meeting, 1Cell. Ai joined global leaders to present...
- [Single-Cell Genomics Reveals Resistance Signatures in Colorectal Cancer](https://1cell.ai/single-cell-genomics-reveals-resistance-signatures-in-colorectal-cancer-2/): When ctDNA Comes Back Negative, the Story Isn’t Over Plasma ctDNA has become a go-to biomarker for detecting genomic alterations...

#
# Detailed Content


## Pages

- Published: 2026-06-05
- Modified: 2026-06-05
- URL: https://1cell.ai/in/faqs/

Faqs - 1Cell.Ai Faqs - 1Cell.Ai Skip to content Connect on +91 9022 1379 32 1800 1231 2355 Request a Callback Home Solutions Technology Products Oncolndx® 360° Endometrium OncoIndx® – CGP Test OncoIndx® prime+ – NexGen Sequencing OncoRisk® – Germline Test OncoHRD® – NexGen Assistive HRD test OncoMonitor® – Longitudinal Monitoring Test OncoTarget® – Tailored Genomics Test 1 Cell iCore Resources Resources Publication Peer-reviewed research and manuscripts Whitepapers & Reports In-depth technical analyses Guide & Explainers Educational content for all audiences Coming Soon FAQs Answers to common questions Case Studies Real-world clinical impact stories Expert Insights Articles and webinars from our team Newsletters Latest developments delivered to you Blogs Latest developments delivered to youComing Soon We’ve just launched a new product! Integrated NGS + IHC with WHO-aligned treatment guidance in 10–12 days.  Explore Oncolndx® 360° Endometrium Press & News Press & News Press Releases Official announcements and statements In the News Media coverage and mentions Company Updates Latest news and developments Events & Conferences Events, talks, and participation Coming Soon About Us About Us Our Mission  Why we do, what we do Our Team  Leadership, advisors, and board Our Lab  Certifications and capabilities Careers  Join our team We’re hiring! Media & Recognition  Awards and press coverage Home Solutions Technology Products Oncolndx® 360° Endometrium OncoIndx® – CGP Test OncoIndx® prime+ – NexGen Sequencing OncoRisk® – Germline Test OncoHRD® – NexGen Assistive HRD test OncoMonitor® – Longitudinal Monitoring Test OncoTarget® – Tailored Genomics Test 1 Cell iCore Resources Resources Publication Peer-reviewed research...


- Published: 2026-06-05
- Modified: 2026-06-05
- URL: https://1cell.ai/in/events-conferences/

Events & Conferences Scientific engagement, knowledge exchange, and precision oncology leadership — all in one place. Upcoming Past FLAGSHIP EVENT 1Cell. Ai’s annual precision oncology leadership summit — POLES 2026 Upcoming ASCO 2026 Advancing Global Collaboration in Precision Oncology 29–2 June, 2026 Chicago, USA A global platform bringing together oncologists, researchers, and industry leaders to explore breakthroughs in cancer research and precision medicine. Register now Speakers 1000+ Delegates 40000+ Upcoming POLES 2026 Precision Oncology Leadership Summit 1 August, 2026 Mumbai, India A flagship annual summit bringing together global oncology leaders, clinicians, researchers, and innovators to shape the future of precision cancer... Register now Speakers 35+ Delegates 90+ Browse All Upcoming Events 2 events found hosted Upcoming ASCO 2026 29–2 June, 2026 Chicago, USA A global platform bringing together oncologists, researchers, and industry leaders to explore breakthroughs in cancer research and precision medicine. Register Slides hosted Upcoming POLES 2026 1 August, 2026 Mumbai, India A flagship annual summit bringing together global oncology leaders, clinicians, researchers, and innovators to shape the future of precision cancer... Register Slides Past AACR 2026 AACR Annual Meeting 2026 17–22 April, 2025 San Diego, USA A premier global platform for cutting-edge cancer research, featuring advances in genomics, immunotherapy, and precision oncology. View highlights Speakers 35+ Delegates 22000+ Browse All Past Events 1 events found Participated PAST AACR 2026 17–22 April, 2025 San Diego, USA A premier global platform for cutting-edge cancer research, featuring advances in genomics, immunotherapy, and precision oncology. Watch Recording Slides Legacy Previous POLES Editions...


- Published: 2026-06-05
- Modified: 2026-06-15
- URL: https://1cell.ai/in/media-recognition/

Recognized Excellence Leading the Future of Precision Oncology Recognized innovator at the intersection of deep cell science and AI-driven oncology. Our work in true single-cell multi-omics and cell-biopsy technology has received global attention across academia, clinical oncology, and industry. Featured In Scientific Publications & Thought Leadership 1Cell. Ai has established itself as a thought leader in oncology through impactfulpublications and presentations: 27 09 01 05 Recent Research Featured Research Recent high-impact work includes a 2026 publication in the journal Cancers regarding multi-omics detection in CTCs View Full Research Key Collaborators Our technologies are being evaluated and validated across leading global cancer institutions. These collaborations support multi-center validation studies, longitudinal research studies Global Network of KOLs 1Cell is guided by globally recognized scientific and medical leaders. The distinguished panel of KOLs reinforces 1Cell Ai's authority as a trusted innovator in the oncology space Dr. James Rothman Board of Director, 1Cell. Ai Chairman of Medical Advisory Board, 1Cell. Ai Nobel Prize in Physiology or Medicine (2013) Kavli Prize in Neuroscience (2010) Albert Lasker Basic Medical Research Award (2002) Member, National Academy of Sciences Fellow, American Academy of Arts and Sciences David Carbone The Ohio State University Wexner Medical Center Kenneth Bloom Nucleai Ravindra Kolhe Augusta University Craig Gedye Genito-Urinary, Brain Charles Cobbs NSCLC and multi cancer David Gandara NSCLC and multi cancer Dr Santosh Kesari NSCLC and multi cancer Mandana Kamgar University of Wisconsin Asrar Alahmadi The Ohio State University Dr. Umberto Malapelle Università degli Studi di Napoli Federico II Charu Aggarwal...


- Published: 2026-06-05
- Modified: 2026-06-05
- URL: https://1cell.ai/in/our-lab/

OUR LAB Built for Precision, Quality & Transparency Our laboratory integrates advanced molecular workflows, NGStechnology, and computational analytics to deliver oncology insights thatare reliable and clinically actionable. Watch Lab Walkthrough FACILITY OVERVIEW Inside the 1Cell. Ai Lab The laboratory is designed for high-complexity molecular diagnostics, withstringent contamination controls, optimized workflow zoning, and multi-layer quality checks to ensure reliable and reproducible results. Validated wet-lab workflows are seamlessly integrated with advanced bioinformatics and standardized clinical interpretation frameworks. From sample accessioning to clinical reporting — see how precision is built into every step. LABORATORY WORKFLOW OVERVIEW Sample Accessioning & QC ID verification, QC checks, storage Intake Analyte Isolation / Nucleic Acid Extraction Isolation of ccfDNA, gDNA, FFPE-derived DNA & RNA Wet Lab Library Preparation NGS library construction Wet Lab NGS Sequencing Molecular profiling & variant detection Genomics Bioinformatics Analysis Pipeline, annotation, classification Computational Clinical Interpretation Report generation & validation Clinical PRECISION WORKFLOW Every Step, Engineered Sample Accessioning & QC Identity verification, viability assessment, and pre-analytical QC CTC / ctDNA Isolation Validated enrichment and high-sensitivity extraction protocols Library Preparation Targeted NGS library construction withrigorous QC checkpoints NGS Sequencing & Molecular Profiling High-depth sequencing with real-timequality monitoring Bioinformatics Analysis Validated pipelines: alignment, calling,annotation, AI prioritization Clinical Interpretation & Reporting Evidence-based variant classificationand structured oncology reporting INSIDE OUR LABORATORY A Lab Built for Clinical Precision From sample intake to molecular reporting, explore how our laboratory delivers precision at every stage. https://www. youtube. com/watch? v=XjoqO63TIxg SCIENTIFIC LEADERSHIP Pune Laboratory Dr. Hrishita Kothavade Pune Laboratory Director A pathology...


- Published: 2026-05-31
- Modified: 2026-05-31
- URL: https://1cell.ai/clinical-data-2026/

TechnologySolutionsContact Us Unlocking SINGLECELL BIOLOGYBeyond ctDNA An integrated platform combining live single-cell CTC multi-omics with matched ctDNA—from a single blood draw. TRUE CELL BIOPSY® - ONE CELL AT A TIME Kaplan–Meier Overall Survival By Mutation Signature OncoIncytes® detects bypass mutations in single circulating tumor cells (sCTC) at baseline—capturing private, sub-clonal variants invisible to ctDNA, enabling earlier resistance profiling. Patients with bypass pathway mutations have dramatically worse overall survival, indicating a 4× higher risk of death compared to hotspot-only carriers. Key Finding: Baseline detection of EGFR bypass pathway mutations in sCTC predicts early TKI resistance and significantly reduced overall survival — outperforming ctDNA alone. Clinical Rationale & Evidence TKI therapy is the standard of care for EGFRm NSCLC, yet many patients develop acquired resistance—often driven by EGFR bypass pathway mutations missed by conventional ctDNA testing. Key Finding: Baseline detection of EGFR bypass pathway mutations in sCTC predicts early TKI resistance and significantly reduced overall survival — outperforming ctDNA alone. Discover OncoIncytes® Transforming Precision Oncology Learn more about how OncoIncytes® is unlocking the power of true single-cell multi-omics to guide better clinical decisions. Learn More About OncoIncytes Contact Us © 2026 1Cell. Ai. All rights reserved.


- Published: 2026-05-18
- Modified: 2026-06-05
- URL: https://1cell.ai/in/products/oncoindx-360/

WHO-Aligned Molecular Classification One Test. One Snapshot. Complete Clarity. The first integrated molecular profiling assay for endometrial cancer—delivering biology-driven treatment decisions from a single tissue sample. 2,000 ×Sequencing Depth12-14 DaysTurnaround Time6Molecular Sub types Sample report Case study The Challenge Fragmented Testing. Fragmented Decisions. Current workflows are sequential, slow, and tissue-intensive—leading to delays and missed treatment opportunities. Prolonged Turnaround Molecular tests ordered sequentially across multiple labs. Results arrive at different times, delaying critical treatment decisions. Over & Under Treatment Without complete molecular context, POLE-mutated patients face unnecessary chemo while TP53-abnormal cases may be undertreated. Tissue Exhaustion Repeated testing consumes precious tissue—especially in small biopsies—leaving nothing for additional analyses when most needed. Missed Therapies Incomplete molecular profiling means patients may miss eligibility for immunotherapy, targeted therapy, or hormone therapy entirely. "Endometrial cancer care can no longer afford fragmented diagnostics. " The Solution A Single, Integrated Molecular Snapshot OncoIndx 360° Endometrium replaces fragmented workflows with one comprehensive, biology-driven report that links molecular subtype to prognosis and treatment strategy. Testing Upfront, Integrated Testing NGS + IHC + MSI performed together—not sequentially. Eliminates TAT delays and tissue exhaustion from the start. Report Single Molecular Snapshot One sample. One test. One report. No compromises. Aligned with ESGO/ESTRO/ESP guidance for early molecular classification. Biology Biology That Drives Decisions Molecular subtypes are not just reported—they are interpreted and translated into actionable treatment pathways for each patient. Innovation NSMP, Finally Actionable ER-stratified NSMP classification transforms a "leftover category" into biologically meaningful, clinically actionable information. Guidelines Guidelines, Made Practical Fully...


> Join 1Cell.ai at AACR 2025 to discover AI-powered single cell multi omic solutions advancing biomarker discovery and therapy monitoring.

- Published: 2026-04-14
- Modified: 2026-05-29
- URL: https://1cell.ai/aacr-2026/

Revolutionizing Next-Gen Translational Research Meet Us at AACR 2026 JOIN US AT AACR APRIL 17-22, 2026 Discover how 1Cell. Ai is advancing precision oncology at the intersection of science and technology Our team is leading the way with AI-powered, single cell multi-omic solutions designed to help in patient selection, therapy monitoring and biomarker exploration. Visit us at Booth #510 to learn more about our cutting-edge advancements. Featured Poster Presentation: Explore the latest in live single circulating tumor cell capture and precision oncology breakthroughs. Discover how innovation is redefining the future of oncology care! Schedule a Meeting today Join us to discuss how 1Cell. Ai can help your precision oncology initiatives: Cutting-Edge Platforms: Learn how our proprietary OncoIncytes and iCORE platforms can enhance your clinical and research outcomes. Revolutionizing Precision Oncology: Explore our Cell Biopsy technology with more than 82% single-cell capture efficiency. Customized Solutions: Discover tailored partnership opportunities designed to meet your specific needs. Poster title: True live single circulating tumor cell capture with no leukocyte contaminant assay for multi-omics in large cancer patient population Session Title: Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2Poster Abstract Number: 10881Location: Poster Section 52Poster Board Number: 13Abstract Presentation Number: LB350 We look forward to connecting with you and sharing how 1Cell. Ai is shaping the future of oncology. Don’t miss the chance to experience firsthand the power of precision.


> POLES 2026 (Precsision Oncology Leadership Conference) — where new ideas spark global collaborations and the future of precision oncology takes shape.

- Published: 2025-11-13
- Modified: 2025-11-13
- URL: https://1cell.ai/poles2026/

https://youtu. be/oYVo1bpdyLA Countdown Begins Days Hours Minutes Seconds POLES 2026 is live now Registration Opens Soon


> OncoIndx TBx combines DNA and RNA sequencing of 1 000+ genes with AI-powered iCARE™ reporting. Clinically validated insights for precision oncology and personalized therapy.

- Published: 2025-11-10
- Modified: 2025-11-11
- URL: https://1cell.ai/in/oncoindx-tbx/

Comprehensive Genomic and Transcriptomic Profiling for Precision Oncology OncoIndx® TBx is an integrated NGS-based test designed to provide a complete genomic and transcriptomic profile of solid tumors. It delivers clinically actionable insights that help oncologists personalize treatment strategies, identify resistance mechanisms, and improve patient outcomes. Explore Our Technology Unlock Deeper Insights into Cancer Genomics OncoIndx® TBx combines DNA (1080 genes) and RNA sequencing to reveal the full molecular landscape of a tumor. The test integrates advanced AI interpretation, offering a single comprehensive report that includes mutations, fusions, copy number variations, and gene expression data — all aligned with the latest evidence-based therapies and clinical trials. OncoIndx® TBx empowers clinicians by providing a unified, AI-powered view of tumor biology to guide personalized and targeted treatment decisions with confidence. Comprehensive NGS panel covering 1000+ clinically relevant genes Detects SNVs, INDELs, CNVs, and gene fusions Includes HRD, MSI, TMB, and other key genomic signatures Integrates RNA-based fusion detection for enhanced accuracy AI-driven reporting through the iCARE™ platform How It Works Comprehensive Genomic and Transcriptomic Analysis Simultaneous sequencing of DNA and RNA enables broad detection of variants, including single-nucleotide variants, indels, copy number variations, and fusions. Integrated Biomarker Profiling Delivers key biomarkers — HRD, MSI, LOH, and TMB — to assess genomic instability and predict response to immunotherapy or targeted therapy. Advanced AI-Powered Interpretation The iCARE™ AI engine consolidates variant data, literature evidence, and clinical guidelines into clear, actionable reports for therapy selection and trial matching. Optimized Clinical Guidance Provides oncologists with precision insights...


- Published: 2025-10-14
- Modified: 2025-10-15
- URL: https://1cell.ai/rsvp-esmo-dinner/

RSVP Today Please complete the form below to reserve your spot and let us know when you’d like to connect.


- Published: 2025-10-02
- Modified: 2025-10-28
- URL: https://1cell.ai/rsvp/

Schedule a Meeting Today Please complete the form below to reserve your spot and let us know when you’d like to connect.


- Published: 2025-08-06
- Modified: 2025-08-06
- URL: https://1cell.ai/iaslc-wclc-2025/

Schedule A Meeting With Our Team Today!


- Published: 2025-07-31
- Modified: 2025-07-31
- URL: https://1cell.ai/asco-2025-poster-pdac-mcw-download/

Download Our ASCO 2025 PDAC MCW POSTER


- Published: 2025-07-07
- Modified: 2025-07-28
- URL: https://1cell.ai/1cell-ai-asco-pdfs/

Click to download and view each poster: ASCO 2025 POSTER PDAC MCW ASCO 2025 HNC ICI TMH


> Explore 1Cell.ai India’s solutions—AI-driven single cell multi omic applications in biomarker discovery, therapy monitoring, diagnostics, and clinical research.

- Published: 2025-05-26
- Modified: 2026-06-10
- URL: https://1cell.ai/in/solutions/

Cancer is dynamic Your decisions should be too. Make earlier calls. Choose better therapies. Track disease in real time. Real-time, multi-omics intelligence for diagnosis, treatment selection,& monitoring-engineered for the way modern cancer evolves. The Problems We Solve Cancer care and research face the same fundamental challenge: Tumors evolve faster than decisions. Static snapshots Single-point biopsies miss evolution. Fragmented data Genomics, imaging, & labs live in silos. Reactive care Resistance is detected too late. Built for every cancer decision One platform. Three perspectives. Oncologists Pharma Researchers For Oncologists Turn complex molecular data into clear decisions Get actionable answers, not just data. Earlier detection through molecular signal. Precise, evidence-led treatment selection. Continuous monitoring across the care arc. We enable earlier detection, precise treatment selection, and continuous monitoring. For Pharma Design smarter trials and accelerate approvals Enrich trials with the right patient cohortsMonitor molecular response in real timeDiscover and validate biomarkers We help identify the right patients, track response, and validate targets. For Researchers Decode cancer biology like never before Single-cell insights into tumor evolutionMulti-dimensional datasetsLongitudinal tracking of disease progression We provide deep, single-cell multi-omics insights across disease progression. For Oncologists Turn complex molecular data into clear decisions Get actionable answers, not just data. Earlier detection through molecular signal. Precise, evidence-led treatment selection. Continuous monitoring across the care arc. We enable earlier detection, precise treatment selection, and continuous monitoring. For Pharma Design smarter trials and accelerate approvals Enrich trials with the right patient cohortsMonitor molecular response in real timeDiscover and validate biomarkersWe help...


> Explore the innovative AI and multi-omic technology behind 1Cell.ai India’s single cell solutions, enabling advanced biomarker discovery and precision medicine.

- Published: 2025-05-26
- Modified: 2026-06-19
- URL: https://1cell.ai/in/technology/

Built Around Clinical Decisions Technology Powering Every Stage of Cancer An integrated ecosystem that transforms genomic, clinical, and real-world data into actionable oncology insights Explore Platforms 4+ Integrated Platforms 360° Care Coverage Real-time Decision Support Longitudinal PATIENT INSIGHTS Our Approach From Signal to Clinical Decision Every platform in the 1Cell. Ai ecosystem is purpose-built for precision oncology — connecting genomic signals, clinical data, and patient context into a single, coherent intelligence layer. Integrated data acrossdiagnostics, clinical records, & real-world evidence Decision-support tools designed for clinical workflow, not around it Patient-centered intelligence that follows the care journey end to end Platform Suite Four Platforms. One Vision. Each platform addresses a distinct layer of the precision oncology workflow — together, they form a seamless clinical intelligence system. Physician Platform DrG Precision oncology workflows designed for clinicians Coming soon Clinical Intelligence iCare Real-time treatment intelligence for oncology decisions Explore Platform Patient Companion OSakhi Continuous patient engagement across the care journey Coming soon Research Intelligence iDiscover Translating oncology data into research insights Coming soon Unified Ecosystem A Unified Technology Ecosystem All platforms work together to enable seamless data flow, insights, and clinical decision-making across every stage of care. Data Flow iCare Clinical Intelligence Unified patient view Molecular insights AI-guided recommendations Point-of-Care Decisions Clinical Intelligence DrG Physician Platform Voice-assisted reports Interactive AI assistant Real-time interpretations Real-Time Decisions Insights OSakhi Patient Companion Treatment navigation Patient engagement Longitudinal follow-up Full Journey Care AI Guidance iDiscover Research Intelligence Biomarker exploration Cohort analytics Data-to-insight workflows Research Intelligence Interoperability FHIR...


> Discover OncoINDx India’s AI-powered single cell analysis for therapy response insights, patient selection, and personalized oncology solutions.

- Published: 2025-05-23
- Modified: 2025-07-07
- URL: https://1cell.ai/in/oncoindx/

Comprehensive Genomic Profiling for Precision Oncology OncoIndx® is a next-generation sequencing (NGS) test designed to support treatment planning for patients with complex, advanced, or treatment-resistant solid tumors. With over 1,000 genes, deep sequencing, and AI-powered reporting, OncoIndx® offers a powerful foundation for personalized oncology, enabling therapeutic decision-making across the entire cancer care journey. Explore Our Technology NGS-Powered Precision. Clinically Actionable Insights. Unlike limited panel tests, OncoIndx® delivers broad genomic coverage to help oncologists uncover targetable mutations, resistance mechanisms, and therapy guidance for cancers that are refractory or progressing on standard treatments. With the ability to process both tissue and blood (liquid biopsy) samples, the test makes it easier to evaluate patients even when invasive sampling is not possible. Proprietary 1,000+ gene panel targeting all major solid tumors Compatible with both tissue (FFPE) and liquid biopsy (cfDNA) Enables therapy selection, resistance analysis, and trial matching Integrated AI reporting via iCare™ platform High-depth sequencing: 2000x (tissue) / 10000x (liquid) Includes markers for TMB, MSI, HRD, CNVs, fusions, and pharmacogenomics How It Works Comprehensive NGS Panel Covers SNVs, INDELs, CNVs, gene fusions, TMB, MSI, HRD scoring, and pharmacogenomics. Sample Flexibility Uses either blood (cfDNA) or FFPE tissue, expanding accessibility and reducing procedural delays. AI-Powered Reporting The iCare™ analysis platform delivers real-time reports with integrated clinical evidence and therapy suggestions, including ongoing trial relevance. Precision Decision Support Outputs include mutation-level details, LOH, TAI, LST for HRD, and immunotherapy readiness (PD-L1 via IHC or CTCs). Applications For OncologistsGuide advanced and refractory cases with therapeutic insightStratify...


> Explore Prime Plus India—AI-driven single cell sample preparation for multi omic analysis, enabling precision workflows and reproducible results.

- Published: 2025-05-23
- Modified: 2025-07-07
- URL: https://1cell.ai/in/prime-plus/

Tissue–Liquid–Normal Match NGS Test for Comprehensive Cancer Profiling OncoIndx® Prime+ is a next-generation genomic test designed for oncologists managing complex, advanced, or treatment-refractory solid tumors. This powerful platform delivers high-resolution insights through simultaneous analysis of tissue, liquid biopsy, and matched normal DNA—enabling confident therapeutic decisions with unmatched precision. Explore Our Technology One Test. Three Matched Inputs. Maximum Clarity. OncoIndx® Prime+ enables integrated somatic and germline mutation analysis, transcriptomics, and real-time resistance monitoring from a single test. By combining tumor DNA (tDNA), circulating tumor DNA (ctDNA), and germline DNA, it offers deep visibility into tumor behavior, resistance mechanisms, and actionable targets—supported by the iCare™ AI reporting platform. 1,000+ gene proprietary panel including 50+ fusion drivers Tissue, liquid biopsy, and germline matched in a single test RNA-based fusions, expression analysis, splice variants, and CHIP detection Genome-wide profiling: TMB, MSI, HRD (LOH, LST, TAI) 36 pharmacogenomics markers for drug response High accuracy: >99% coverage, 2000x (tissue) / 10000x (liquid) depth & AI-enhanced report with curated, therapy-ready insights How It Works Sample Collection Tissue (FFPE), blood (plasma and buffy coat), or CSF/pleural fluid samples are collected and processed in a CLIA-certified environment. Library Preparation & Sequencing NGS is performed using a paired-end approach to sequence tumor, liquid, and matched normal DNA—followed by high-throughput RNA analysis for fusion detection and gene expression. Bioinformatics Pipeline Mutations are precisely segmented into true somatic, true germline, CHIP, and mosaic categories using proprietary algorithms. Comprehensive Report Generation Final reports are powered by iCare™, featuring fusion detection, actionable variants, pharmacogenomic...


- Published: 2025-05-23
- Modified: 2025-05-23
- URL: https://1cell.ai/in/oncomonitor/

A Novel Liquid Biopsy for Longitudinal Cancer Monitoring and MRD Detection OncoMonitor® is an advanced blood-based solution designed for real-time monitoring of treatment response, emergence of resistance, and longitudinal tracking of disease progression. By measuring CTCs and ctDNA levels over time, OncoMonitor® provides actionable insights to guide therapy adjustments and detect disease relapse earlier. Stay Ahead of Cancer Progression Cancer is dynamic, and timely monitoring is critical for better outcomes. OncoMonitor® enables oncologists to track disease activity and residual disease in real time — allowing early interventions before clinical relapse becomes visible. OncoMonitor® TRM: Treatment Response Monitoring and Resistance TrackingOncoMonitor® MRD: Minimal Residual Disease Detection after therapy Longitudinal tracking of disease dynamics using blood-based biomarkers Real-time assessment of treatment efficacy and emerging resistance Early detection of minimal residual disease (MRD) Supports prognosis prediction based on CTC and ctDNA trends AI-powered reporting for rapid, comprehensive insights How It Works CTC and ctDNA Quantification Measures circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) levels from plasma samples. Longitudinal Monitoring Regular blood draws allow dynamic assessment of disease burden, therapy response, and relapse risk over time. Minimal Residual Disease Detection Trace amounts of ctDNA and CTCs post-treatment signal the presence of residual disease before clinical or radiological signs. Real-Time AI Reporting Swift, accurate, and dynamic reports generated through the iCARE™ AI-powered analysis platform. Applications For Clinicians & OncologistsMonitor cancer patients throughout their treatment journeyAdjust therapies based on molecular response or resistance markersDetect relapse earlier than conventional imagingFor Patients Seeking Personalized TherapyMinimize invasive...


> Discover OncoHRD India, AI-powered single cell HRD biomarker analysis to enhance therapy monitoring and patient stratification in precision oncology.

- Published: 2025-05-23
- Modified: 2025-07-07
- URL: https://1cell.ai/in/oncohrd/

Next-Generation HRD Testing for Precision Oncology OncoHRD® is a cutting-edge genomic test specifically designed to detect homologous recombination deficiency (HRD) in solid tumors. It provides critical insights to guide the use of PARP inhibitors and platinum-based chemotherapy, helping oncologists personalize treatment strategies and improve patient outcomes. Explore Our Technology Unlock Deeper Insights into DNA Repair Defects HRD refers to a defect in the ability of cancer cells to repair DNA double-strand breaks through the homologous recombination repair pathway. It is commonly associated with breast, ovarian, pancreatic, and prostate cancers, but can be found across a range of solid tumors. OncoHRD® empowers clinicians by offering a comprehensive, affordable, and AI-powered solution to detect HRD and guide therapy decisions with confidence. Affordable NGS-based solution with deep sequencing of 50+ HRR pathway genes Detects SNVs, INDELs, CNVs, structural variants, and HRD-specific genomic scars Provides HRD scores with LOH, TAI, and LST measurements Supports selection of targeted therapies including PARP inhibitors Rapid, AI-powered reporting through the iCARE™ platform How It Works Comprehensive Genomic Analysis Detection of mutations, deletions, and structural variants across key HRR pathway genes, including BRCA1/2. Advanced HRD Scoring Delivers HRD scores based on analysis of Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-Scale State Transitions (LST) — key indicators of homologous recombination deficiency. Optimized Treatment Guidance HRD-positive status helps identify patients likely to respond to PARP inhibitors and platinum-based chemotherapy. AI-Powered Reporting Comprehensive, easy-to-interpret reports generated through the iCARE™ platform with dynamic AI-supported interpretation. Applications For Clinicians & OncologistsIdentify...


> OncoTarget India enables AI-powered profiling of actionable oncology targets using single cell analysis to guide personalized cancer therapy decisions.

- Published: 2025-05-23
- Modified: 2025-07-07
- URL: https://1cell.ai/in/oncotarget/

Affordable, Targeted Genomic Testing for Precision Oncology in India OncoTarget® is a disease-specific targeted NGS panel designed to identify key genomic alterations in major cancers, including Bladder, Breast, Colon, GI, Lung, Melanoma, Ovary, Prostate, Rectal, and Thyroid. It offers a practical, affordable solution for guiding personalized therapy decisions in real-world clinical practice. Explore Our Technology Accessible Genomic Insights for Every Patient Not every case needs expensive, broad genomic panels. OncoTarget® focuses on detecting guideline-recommended, clinically actionable mutations — making precision oncology more accessible, affordable, and easy to implement across India’s healthcare landscape. Affordable targeted genomic testing customized to major cancer types Deep sequencing of critical disease-specific genes Easily understandable reports for quicker treatment planning Option to customize up to 20 genes per cancer type Optional add-on for PD-L1 expression testing (tissue only) Analysis and active reporting powered by the iCare™ AI platform How It Works 1) Disease-Specific Target Capture Hybrid capture-based sequencing focused on clinically relevant genes, reducing unnecessary data and cost. 2 ) Customizable Panel Design Ability to customize up to 20 high-priority genes for each cancer type based on clinical need. 3) AI-Driven Interpretation Proprietary AI-based platform simplifies data interpretation, providing clear clinical recommendations aligned with NCCN, ASCO, and ESMO guidelines. 4) Actionable Reporting Reports include tiered variant classification, pharmacogenomics insights (limited to DPYD), and appropriate therapy suggestions. Applications For Clinicians & Oncology TeamsGuide therapy selection based on actionable genomic mutationsImprove speed of decision-making for cancer patientsSupport treatment monitoring and resistance identificationFor Diagnostics Labs & HospitalsOffer cost-effective precision...


> OncoRisk India offers AI-powered cancer risk assessment using single cell analytics, helping identify high-risk patients for early intervention.

- Published: 2025-05-23
- Modified: 2025-07-07
- URL: https://1cell.ai/in/oncorisk/

A Germline Test to Uncover Your Hereditary & Familial Cancer Risk OncoRisk® is a comprehensive, AI-powered hereditary cancer test designed to identify genetic mutations associated with more than 11 distinct hereditary and familial cancers. Built for both oncologists and patients, this test provides insights that enable early detection, informed decision-making, and proactive care planning for individuals and families at risk. Explore Our Technology Your Genetic Shield Against Hereditary Cancers Some cancers run in families. With a 74-gene panel covering the most relevant hereditary risk markers, OncoRisk® offers a science-backed way to uncover elevated risk across a broad spectrum of cancers—empowering clinicians and patients to take timely action with confidence. Covers 74 genes linked to 11+ hereditary and familial cancers Supports both affected patients and unaffected family members Enables informed surgical decisions (e. g. prophylactic mastectomy) Offers AI-powered reporting with personalized risk interpretation Includes pre- and post-test genetic counseling for patients Designed for actionable screening, prevention, and surveillance How It Works Genetic Sample Collection A simple blood sample is collected for germline DNA extraction. NGS-Based Germline Sequencing Our test uses deep sequencing of 74 high-priority cancer-related genes. AI-Powered Interpretation Reports are generated via the iCare™ platform and delivered with clear risk classifications and clinical action points. Genetic Counseling Support Patients receive guidance to interpret the report and discuss next steps. Applications For Clinicians & Oncology TeamsIdentify hereditary risk in affected patients and their relativesInitiate personalized screening and risk reduction plansGuide decisions on prophylactic surgery and early surveillanceFor Individuals and FamiliesUnderstand inherited...


> Review 1Cell.ai India’s terms and conditions, including service use, data handling, liability, and compliance for our AI-powered single cell platforms.

- Published: 2025-05-23
- Modified: 2025-07-07
- URL: https://1cell.ai/in/terms-and-conditions/

Last Updated: Welcome to the official website of 1Cell. Ai (OneCell Diagnostics India Private Limited), accessible at (https://1cell. ai/in/). By using this website, you agree to comply with and be bound by the following Terms and Conditions. Please review them carefully. 1. Acceptance of Terms By accessing or using this website, you acknowledge that you have read, understood, and agreed to be bound by these Terms and Conditions, as well as our Privacy Policy. If you do not agree with any part of these terms, you must not use the website. 2. Use of the Website The content provided on this website is for general informational purposes only and is subject to change without notice. You agree to use this site only for lawful purposes. Any unauthorised use of this website may result in legal action under applicable Indian laws. 3. Intellectual Property All content on this website, including but not limited to text, graphics, logos, images, audio, video, and software, is the property of 1Cell. Ai (OneCell Diagnostics India Private Limited) or its licensors, and is protected under Indian and international intellectual property laws. You may not copy, reproduce, republish, upload, post, transmit, or distribute any content from this website without prior written consent from 1Cell. Ai (OneCell Diagnostics India Private Limited). 4. Third-Party Links This website may include links to third-party websites for your convenience. These links do not imply endorsement or responsibility for the content on such websites. 1Cell. Ai (OneCell Diagnostics India Private Limited) does not...


> Meet the 1Cell.ai India team—experts in AI-powered single cell multi-omic platforms driving innovation in biomarker discovery and precision oncology.

- Published: 2025-05-23
- Modified: 2026-06-15
- URL: https://1cell.ai/in/team/

Our Team The scientists, clinicians, and engineers driving precision oncologyforward translating single-cell biology and AI into care that reaches every patient. Founders Leadership Spotlight Two complementary disciplines,strategy and science, at the center of everything we build. Co-Founder Mohan Uttawar Chief Executive Officer Leads 1Cell. Ai's mission to make precision oncology accessible across emerging and developed markets. With two decades operating across healthcare, AI, and life-sciences ventures, he architects the company's clinical, commercial, and partnership strategy from molecule to bedside. Our mission is to make precision oncology accessible and actionable — for every patient, in every clinic, anywhere in the world Co-Founder Dr. Gowhar Shafi Chief Scientific Officer Directs the science behind 1Cell. Ai's single-cell and AI-driven oncology platform. A computational genomicist with a PhD and post-doctoral training across India and the U. S. , he has authored peer-reviewed work spanning tumor biology, drug response, and translational diagnostics. When biology, computation, and the clinic move as one system, we change what is possible for cancer patients. Management Team Clinical, scientific, operational, and technology leaders driving precision oncology innovation globally. Dr. Nilesh Shah Managing Director Building scalable diagnostic ecosystems that improve access to precision oncology. Srikanth Nandiraju Chief Technology Officer Designing intelligent healthcare platforms that simplify complex clinical workflows. Parita Razdan Chief Marketing Officer Precision oncology should feel accessible, understandable, and impactful for every patient journey Dr. Ajay Pandita VP, Scientific Affairs Scientific innovation must ultimately translate into better patient outcomes Dr. Ken Bloom CMO, Lab Director Precision diagnostics should empower clinicians...


> Search careers at 1Cell.ai India to contribute to AI-driven single cell multi omic research, diagnostics, and cutting-edge biotech development.

- Published: 2025-05-23
- Modified: 2026-06-10
- URL: https://1cell.ai/in/careers/

Careers at 1Cell. Ai Build the Future of Precision Oncology At 1Cell. Ai, we are redefining how cancer is understood and treated, one cell at a time. View Open Roles Email Us Why Join 1Cell. Ai Where Science Meets Ambition Real Clinical Impact Your work doesn't end at a dashboard. It influences actualtreatment decisions for real patients. Every model trained,every pipeline shipped, touches the continuum of care. 01 Deep-Tech Platform Build systems at the intersection of molecular biology andartificial intelligence. Our stack is research-grade — and itruns in clinical environments. 02 Validated Performance You lead modules, not tickets. Within your first month, you'llhave shipped something meaningful. We believe great peopleneed room, not just resources. 03 Cross-Disciplinary Growth Work across biology, engineering, clinical affairs and medicine. The problems we solve demand that kind of breadth — andreward it. 04 What You'll Work On Science at the Frontier NGS-Based Liquid Biopsy Platforms High-sensitivity ctDNA detection through next-generation sequencing pipelines purpose-built for oncology applications. AI-Assisted IHC Panel Intelligence Computer vision and deep learning models that interpret immunohistochemistry panels with pathologist-level precision. Bioinformatics Pipelines End-to-end data flows from FASTQ to clinical insight — robust, reproducible, and validated across multiple cancer types. Lab Workflow Intelligence Systems Software that reduces TAT, flags anomalies, and gives lab directors real-time visibility into quality and throughput. Blood Single Cell Molecular Data AI Clinical Insight Our Culture Serious about Science. Human about Everything Else. Mission-First Data-Driven Deeply Collaborative Intellectually Honest We move fast, but never at the cost of scientific...


> Read 1Cell.ai India’s privacy policy—learn how we collect, store, and protect single cell multi omic data in compliance with local regulations.

- Published: 2025-05-23
- Modified: 2026-06-03
- URL: https://1cell.ai/in/privacy-policy/

THIS NOTICE OF PRIVACY PRACTICES DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. Please review it carefully. Version Number: 1. 0 Last Updated On 25-11-2022 Overview Your access to, and use of, the 1Cell. Ai services which includes this website https://1cell. ai/ and the information, community, products and services (collectively, the “1Cell. Ai Services”) that we provide to you are subject to the 1Cell. Ai Services Terms of Use and this Privacy Policy. 1Cell. Ai has created this Privacy Policy to explain what information we gather from you when you visit a 1Cell. Ai Services, how we may use this information, the security approaches we use to protect your information, and how you can access and request modification of certain information that we may store about you. Please note that this Privacy Policy applies only to information collected via the 1Cell. Ai Services. It does not apply to information you disclose to 1Cell. Ai through other means. This Privacy Policy is incorporated and made part of the 1Cell. Ai Services Terms of Use. Your Acceptance of This Privacy Policy and Changes to it By accessing, viewing or otherwise using any 1Cell. Ai Service, you consent to the collection and use of your information by 1Cell. Ai in accordance with this Privacy Policy. If you do not agree to this Privacy Policy, you may not use any 1Cell. Ai Service. 1Cell. Ai reserves the right to change, modify, add...


> Access 1Cell.ai India’s resource hub—white papers, case studies, webinars, and data insights on AI-powered single cell analysis for oncology research.

- Published: 2025-05-23
- Modified: 2026-06-05
- URL: https://1cell.ai/in/resources/

Knowledge Hub Precision Oncology Resources Curated insights, clinical evidence, and expert knowledge to advance decision-making in molecular diagnostics and cancer care. Knowledge Categories Explore by Resource Type Distinct formats, each designed for a different mode of clinical and scientific knowledge. Publications Peer-reviewed research, clinical trial findings, and validated genomic data advancing precision oncology science. Latest: ctDNA Profiling in Treatment-Naive NSCLC — Nature Medicine Learn More Case Studies Real-world clinical applications demonstrating diagnostic outcomes and therapeutic decision-making impact. Featured: MRD Monitoring in HR+ Breast Cancer — Multi-site Study Learn More Whitepapers & Reports In-depth technical analyses, regulatory perspectives, and market intelligence for healthcare leaders. New: Liquid Biopsy CDx Market Intelligence Report 2025 Learn More Expert Insights Commentary and guidance from leading oncologists, molecular pathologists, and genomic medicine specialists. Recent: Dr. Mehta on cfDNA Integration in Standard-of-Care Protocols Learn More Guides & Explainers Clear, structured overviews of complex genomic concepts — designed for clinical teams, administrators, and partners. Popular: Understanding TMB, MSI & PD-L1 in Clinical Practice Learn More Blogs Accessible perspectives on precision oncology developments, technology updates, and evolving clinical practice insights. Latest: How AI-Assisted Variant Classification Is Reshaping Tumor Boards Learn More Editor's Selection Featured Resources Publications MIRAGE: A ctDNA Methylation-Driven Computational Algorithm Designed for Sensitive Detection of Minimal Residual Disease The Problem That Drives MIRAGE A patient finishes surgery. Their scans look clear. Their ctDNA levels appear low. By conventional measures, they... Authors Dr Gowhar S. Published April 2026 Read Time 3 min Learn More Case Studies Circulating Tumor Cell (CTC)...


> Explore 1Cell.ai India’s portfolio—AI-powered single cell multi omic products for biomarker discovery, therapy monitoring, and precision oncology.

- Published: 2025-05-23
- Modified: 2025-07-07
- URL: https://1cell.ai/in/products/

Products Powering Precision Oncology with AI and Single Cell Innovation We develop advanced tools at the intersection of molecular science, bioinformatics, and artificial intelligence. Our suite of products is designed to provide clinicians, researchers, and pharma/biopharma partners with high-resolution, real-time insights to improve cancer diagnosis, monitoring, and treatment. Each product is purpose-built to address the most pressing challenges in precision oncology — from capturing rare circulating tumor cells to unlocking singlecell multi-omics data. Explore our portfolio below and discover how our technologies are reshaping the future of cancer care. Explore Our AI-Powered Oncology Solutions Technology at Work: AI Meets Multi-omics Redefining the Future of Cancer Care OneCell Ai’s technology is driving a new standard in oncology, drug development, and precision medicine. By unlocking cell-level intelligence with AI, we empower healthcare professionals with the tools needed to make smarter, faster, and more personalized treatment decisions. Next-Generation Sequencing (NGS) High-throughput genomic analysis. Machine Learning & Bioinformatics AI models trained on diverse oncology datasets. Data-Driven Biomarker Discovery Multiomics insights for precision treatment planning. Collaboration AI models trained on diverse oncology datasets. Interested in learning how 1Cell. Ai’s solutions can support your clinical or research goals?


> Explore 1Cell.ai India’s patents on AI-driven single cell multi omic technologies and see how our innovations protect advanced oncology applications.

- Published: 2025-05-23
- Modified: 2025-07-07
- URL: https://1cell.ai/in/patents/

Patents and Certifications Each innovation is the result of deliberate design, advanced engineering, and rigorous validation—backed by scientific discipline and protected through global patents and certifications.


> Discover 1Cell.ai India’s mission in AI-powered single cell multi omic diagnostics—empowering biomarker discovery, therapy monitoring, and clinical impact.

- Published: 2025-05-23
- Modified: 2026-06-05
- URL: https://1cell.ai/in/about/

Our Vision A World Where Cancer is a Manageable Condition Redefining the future of precision oncology through the power ofDeep Cell Science and AI — one cell at a time. Explore Our Technology Why 1Cell. Ai Exists? The Problem Clinicians today are buried in fragmented signals. Reports arrive in pieces. Biomarkers live in silos. Decisions get harder when the evidence doesn't connect. Fragmented reports across systemsDisconnected biomarkers and panelsOverwhelming, unstructured complexity The Solution 1Cell. Ai turns complexity into structured clinical clarity. We unify molecular signals into one connected intelligence layer— built so precision oncology becomes truly actionable at the point of care. Simplify molecular complexityUnify insights into one decision viewMake precision oncology actionable What We Believe Six convictions that shape how we build, partner, and care. 01 Every Patient Deserves Personalized Care Precision oncology should not be limited to a small subset of patients or institutions. 02 Complexity Should Lead to Clarity Advanced molecular science shouldsimplify decisions, not complicate them. 03 Accessibility Matters Meaningful innovation must be scalableand relevant to real-world healthcaresystems. 04 AI Should Empower Clinicians Technology should support clinical judgment with deeper and more actionable insights. 05 Science Must Translate intoImpact Breakthroughs matter only when they improve patient outcomes. 06 Collaboration Drives Progress The future of oncology depends on clinicians, scientists, and technologists working together. Our Mission To make Precision Oncology actionable, accessible, & affordable thereby impacting a Million cancer patients through better-informed treatment decisions Actionable Detect resistance earlyIdentify molecular vulnerabilitiesEnable confident treatment decisions Accessible Non-invasive blood-based testingAI-powered...


> Reach out to 1Cell.ai India for AI-driven single cell multi omic solutions, diagnostics partnerships, and precision oncology support.

- Published: 2025-05-23
- Modified: 2025-12-02
- URL: https://1cell.ai/in/contact/

Connect with our team today! Please fill in the form to get in touch with us for any enquiries and business opportunities. 1Cell. Ai support team shall review your query and revert to you at the earliest. Alternatively, you could send an email to the following address:Product Demo:demo@1cell. aiCareers:jobs@1cell. aiCall:1800 123 12355 (toll-free)090221 37932 Get in touch India Office 701, Sigma Building, Hiranandani Gardens, Powai, Mumbai 400076, Maharashtra, India India Lab 3rd Floor, Laxmi Avenue Commercial Tower, Shankar Kalat Nagar, Wakad, Pimpri-Chinchwad, Pune 411057 US Office 20380 Town Center Lane, #218 Cupertino, CA 95014, California, United States US Laboratory 320, Hatch Drive, Foster City, CA 94404California, United States


> Explore 1Cell.ai India’s advanced single cell analysis and multi-omic solutions to accelerate biomarker discovery and precision medicine locally.

- Published: 2025-05-23
- Modified: 2026-07-15
- URL: https://1cell.ai/in/

Trusted by Leading Clinicians Precision Oncology. Made Actionable. From advanced molecular profiling to real-time clinical insights, 1Cell. Ai helps you make confident, personalized cancer treatment decisions. Explore Tests Browse Case Studies https://1cell. ai/wp-content/uploads/2026/07/HeroPageLoopvideo2. mp4 Trusted By 1000+ Clinicians 50,000+ Patients 100+ Hospitals Certified By CAP Accredited CLIA Certified NABL Accredited ISO Certified Lab What we do Supporting Decisions Across the Cancer Journey Tumor Profiling Integrated genomic analysis from tissue and liquid biopsy, complemented by transcriptomic profiling from tissue—enabling confident targeted therapy decisions. Liquid Biopsy & Monitoring Non-invasive detection and longitudinal tracking for disease progression, treatment response, and early recurrence signals. Therapy Guidance Actionable insights aligned with NCCN, ESMO, and ASCO guidelines — translated into clear, treatment-ready recommendations. Longitudinal Management Track the entire patient journey over time with integrated multi-modal data, enabling proactive clinical decisions. Powered by 1Cell. AI Cancer Care Platform Product Portfolio A Unified Portfolio Every Critical Oncology Decision From risk assessment to molecular monitoring, 1Cell. Ai empowers clinicians with precision oncology insights across the patient journey. Stage 01 Diagnosis & Profiling Molecular characterization and advanced diagnostic profiling at point of detection. 1 Advanced Genomics OncoIndx Comprehensive genomic profiling for advanced solid tumors, delivering actionable molecular insights for personalized treatment planning. Explore Test Explore the All Tests Stage 02 Treatment Planning Deep genomic profiling to guide targeted therapies & precision oncology decisions. 1 Precision Profiling Flagship Test OncoIndx Prime+ Multi-sample genomic profiling combining tissue, liquid biopsy, and matched normal DNA for comprehensive precision oncology insights. Explore Test Explore the...


> 1Cell iCore delivers AI powered single cell informatics in India, optimizing biomarker-driven oncology trials with data integration and real‑time insights.

- Published: 2025-05-23
- Modified: 2025-07-07
- URL: https://1cell.ai/in/1-cell-icore/

1Cell iCore™ — AI-Powered Informatics for Precision Trials AI-Powered Informatics for Biomarker-Driven Trials Biomarker-Driven Trials 1Cell iCore™ is an advanced informatics platform built to accelerate translational research and optimize biomarker-rich clinical trials. Designed for oncology teams and research partners, the platform integrates multi-modal biological data with real-world evidence to deliver real-time, actionable insights that drive personalized cancer care. How It Works Built for Real-World Precision From multi-omics and imaging to real-world clinical data, 1Cell iCore™ harmonizes fragmented datasets through AI-driven integration and analysis. The platform transforms raw data into predictive models, dynamic visualizations, and stratified insights—empowering faster, smarter trial decisions. Data Ingested:Genomic, transcriptomic, and proteomic dataRadiology and pathology imagesClinical records, toxicity data, and public datasetsCore AI Functions:Integrate & Analyze: Harmonize and structure complex inputsPredict & Correlate: Identify biomarker-drug relationshipsVisualize & Interrogate: Generate clear, audit-ready outputsStratify: Guide patient matching and therapy selection Learn More 1Cell iCore™ powers two integrated modules tailored for key users:iDiscover – Research ConsoleEnables scientists and study teams to explore high-throughput data, simulate trial protocols, and accelerate biomarker validation. iCare – Oncologist ConsoleDelivers a real-time view of individual patients’ molecular profiles and AI-guided therapy recommendations at the point of care. Learn More From multi-omics and imaging to real-world clinical data, 1Cell iCore™ harmonizes fragmented datasets through AI-driven integration and analysis. The platform transforms raw data into predictive models, dynamic visualizations, and stratified insights—empowering faster, smarter trial decisions. Data Ingested:Genomic, transcriptomic, and proteomic dataRadiology and pathology imagesClinical records, toxicity data, and public datasetsCore AI Functions:Integrate & Analyze: Harmonize and...


> Join 1Cell.ai to advance AI powered single cell multi omic analysis and help shape the future of biomarker discovery and precision medicine.

- Published: 2025-05-22
- Modified: 2025-07-07
- URL: https://1cell.ai/careers/

Careers Join Our Mission to Transform Cancer Care Be Part of a Team That's Redefining Cancer DiagnosticsAt 1Cell. Ai, we are driven by a mission to make precision oncology accessible and actionable. We’re combining advanced molecular science with AI-powered platforms to transform how cancer is detected, monitored, and treated. If you’re passionate about innovation and want to contribute to meaningful change in healthcare, explore our current openings below. Our Mission To make precision oncology actionable, accessible, and affordable. We aim to improve patient outcomes by providing non-invasive, real-time diagnostic solutions that support early detection, personalized therapy, and continuous monitoring. Our Vision A world where cancer care is driven by data, guided by technology, and tailored to each individual patient at the molecular level. We envision a future where every patient receives timely, personalized care informed by science and powered by AI — eliminating uncertainty and unlocking better outcomes. Open Positions Marketing Coordinator Location: San Francisco or BostonNOTE : Please apply only if you are resident of either San Francisco Bay Area or Boston. Employment Type: Full-TimeRole Overview:We are seeking a dynamic, enthusiastic, and organized Marketing Coordinator to lead OneCell’s marketing and communication efforts. This role is perfect for an early-career professional looking to make a tangible impact in a fast-paced, growing organization. You will be responsible for executing key marketing initiatives, organizing events, and driving demand generation activities that promote our brand and solutions. Key Responsibilities :Marketing Collateral:Create marketing brochures and other collateral for Onecell’s product and service offerings. Event...


> Join 1Cell.ai at ASCO 2025 to explore AI powered single cell multi omic analysis for biomarker discovery, therapy monitoring, and patient selection.

- Published: 2025-05-08
- Modified: 2025-07-31
- URL: https://1cell.ai/oncology-annual-meeting-2025/

Revolutionizing Next-Gen Translational Research Meet Us at ASCO® 2025 Download Posters JOIN US AT ASCO® May 30 - June 3 Discover how 1Cell. Ai is advancing precision oncology at the intersection of science and technology Pushing the boundaries of translational research and real-time disease monitoring. Our platform leads the way in AI-driven, single cell multi-omic solutions, built to enable:Patient selection with higher specificityTherapy monitoring across treatment timelinesBiomarker discovery at the cellular levelVisit us at Booth #33166 to see the future of precision oncology. Featured Poster Presentation: Explore the power of live single CTC capture and breakthrough insights across 19 new abstracts. Schedule a Meeting today Join us to discuss how 1Cell. Ai can help your precision oncology initiatives: Cutting-Edge Platforms: Learn how our proprietary OncoIncytes and iCORE platforms can enhance your clinical and research outcomes. Revolutionizing Precision Oncology: Explore our Cell Biopsy technology with more than 82% single-cell capture efficiency. Customized Solutions: Discover tailored partnership opportunities designed to meet your specific needs. Poster title: Featured Research Highlights Explore a few standout abstracts from our ASCO 2025 presentations:6036 (Poster): ctDNA-based clinicogenomic analysis in head and neck cancer4164 (Poster): True single-CTC clonal evolution in pancreatic cancerBrowse the full list of 19 abstracts below: Full List of ASCO 2025 Abstracts #Abstract IDTitle1e15036PD-L1 expression on CTCs in breast cancer2e15029Affinity ligands on glass substrate for CTC capture3e14540Comparative PD-L1 expression across follow-ups4e14012CSF-derived ctDNA and CTC analysis5e15038PD-L1 expression in colorectal CTCs6e15070PD-L1 on CTCs vs IHC in NSCLC7e16379KRAS + TP53 mutations in pancreatic cancer86036ctDNA analysis in head &...


> Join 1Cell.ai at AACR 2025 to discover AI-powered single cell multi omic solutions advancing biomarker discovery and therapy monitoring.

- Published: 2025-04-17
- Modified: 2025-07-07
- URL: https://1cell.ai/aacr-2025/

Revolutionizing Next-Gen Translational Research Meet Us at AACR 2025 JOIN US AT AACR APRIL 25-30, 2025 Discover how 1Cell. Ai is advancing precision oncology at the intersection of science and technology Our team is leading the way with AI-powered, single cell multi-omic solutions designed to help in patient selection, therapy monitoring and biomarker exploration. Visit us at Booth #202 to learn more about our cutting-edge advancements. Featured Poster Presentation: Explore the latest in live single circulating tumor cell capture and precision oncology breakthroughs. Discover how innovation is redefining the future of oncology care! Schedule a Meeting today Join us to discuss how 1Cell. Ai can help your precision oncology initiatives: Cutting-Edge Platforms: Learn how our proprietary OncoIncytes and iCORE platforms can enhance your clinical and research outcomes. Revolutionizing Precision Oncology: Explore our Cell Biopsy technology with more than 82% single-cell capture efficiency. Customized Solutions: Discover tailored partnership opportunities designed to meet your specific needs. Poster title: True live single circulating tumor cell capture with no leukocyte contaminant assay for multi-omics in large cancer patient population Session Title: Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2Poster Abstract Number: 10881Location: Poster Section 52Poster Board Number: 13Abstract Presentation Number: LB350 We look forward to connecting with you and sharing how 1Cell. Ai is shaping the future of oncology. Don’t miss the chance to experience firsthand the power of precision.


> Explore 1Cell iCore, the AI-powered platform for single cell multi omic analysis, enabling therapy monitoring, biomarker discovery, and patient stratification.

- Published: 2025-04-14
- Modified: 2025-07-07
- URL: https://1cell.ai/icore/

1Cell iCore™ — AI-Powered Informatics for Precision Trials AI-Powered Informatics for Biomarker-Driven Trials 1Cell iCore™ is an advanced informatics platform built to accelerate translational research and optimize biomarker-rich clinical trials. Designed for oncology teams and research partners, the platform integrates multi-modal biological data with real-world evidence to deliver real-time, actionable insights that drive personalized cancer care. How It Works Built for Real-World Precision From multi-omics and imaging to real-world clinical data, 1Cell iCore™ harmonizes fragmented datasets through AI-driven integration and analysis. The platform transforms raw data into predictive models, dynamic visualizations, and stratified insights—empowering faster, smarter trial decisions. Data Ingested:Genomic, transcriptomic, and proteomic dataRadiology and pathology imagesClinical records, toxicity data, and public datasetsCore AI Functions:Integrate & Analyze: Harmonize and structure complex inputsPredict & Correlate: Identify biomarker-drug relationshipsVisualize & Interrogate: Generate clear, audit-ready outputsStratify: Guide patient matching and therapy selection Learn More 1Cell iCore™ powers two integrated modules tailored for key users:iDiscover – Research ConsoleEnables scientists and study teams to explore high-throughput data, simulate trial protocols, and accelerate biomarker validation. iCare – Oncologist ConsoleDelivers a real-time view of individual patients’ molecular profiles and AI-guided therapy recommendations at the point of care. Learn More From multi-omics and imaging to real-world clinical data, 1Cell iCore™ harmonizes fragmented datasets through AI-driven integration and analysis. The platform transforms raw data into predictive models, dynamic visualizations, and stratified insights—empowering faster, smarter trial decisions. Data Ingested:Genomic, transcriptomic, and proteomic dataRadiology and pathology imagesClinical records, toxicity data, and public datasetsCore AI Functions:Integrate & Analyze: Harmonize and structure complex...


> Explore 1Cell.ai’s patents on AI-powered single cell multi‑omic platforms, showcasing our innovation and leadership in oncology diagnostics and research.

- Published: 2025-04-14
- Modified: 2025-07-07
- URL: https://1cell.ai/patents/

Patents and Certifications Each innovation is the result of deliberate design, advanced engineering, and rigorous validation—backed by scientific discipline and protected through global patents and certifications.


> 1Cell.ai offers live circulating tumor cell analysis for liquid biopsy, rare cell capture, and functional testing to advance precision oncology.

- Published: 2025-03-28
- Modified: 2025-07-07
- URL: https://1cell.ai/oncoincytes/

Live Circulating Tumor Cell Analysis Next-generation liquid biopsy platform capturing live CTCs for deeper insights and more personalized cancer care. Explore Our Technology Revolutionizing Liquid Biopsy with Single Cell Precision Beyond ctDNA — Real-Time Insights from Live Circulating Tumor Cells OncoIncytes delivers a powerful alternative to traditional liquid biopsies by isolating intact, viable circulating tumor cells (CTCs) — not just circulating tumor DNA fragments. This unique approach termed Cell Biopsy®, provides clinicians and researchers with richer molecular data and true single cell resolution to detect cancer earlier, track disease progression, and inform therapy decisions with confidence. Captures and analyzes live CTCs, not just ctDNA Enables real-time monitoring of tumor evolution Provides actionable insights for therapy selection and response prediction Uncovers tumor heterogeneity at the cellular level Seamlessly integrates into existing clinical and research workflows How It Works 1) Liquid Biopsy Sample Collection A simple blood draw is used to obtain patient samples, making the process minimally invasive. 2 ) Live CTC Isolation Proprietary technology isolates intact, viable circulating tumor cells from the blood. 3) Detailed Molecular Profiling Enables genomic, transcriptomic, and proteomic analysis of live cells, providing a dynamic picture of the tumor. 4) Actionable Insights Insights guide early detection, disease monitoring, and personalized therapy decisions. Applications For CliniciansEarly detection of cancer and disease recurrenceReal-time therapy response monitoringEnhanced precision in treatment planningFor Research & BiopharmaSingle cell based biomarker discoveryUncovering tumor evolution and heterogeneitySupporting drug development and clinical trials Why OncoIncytes? OncoIncytes elevates the standard of liquid biopsy by going beyond...


> 1Cell SOLO enables easy, efficient single cell sample preparation for multi omic analysis, empowering translational and clinical research workflows.

- Published: 2025-03-28
- Modified: 2025-07-07
- URL: https://1cell.ai/solo/

AI-Powered Single Cell Isolation Advancing precision oncology through automated, high-purity single cell capture. Explore Our Technology Unlock True Single Cell Insights Traditional bulk sequencing and liquid biopsy methods often overlook critical details hidden within tumor heterogeneity. 1Cell SOLO changes this by enabling the capture and analysis of intact, viable single cells—powered by AI and advanced microfluidics. Whether used for research, clinical diagnostics, or drug development, Solo delivers unmatched resolution, accuracy, and efficiency. True single cell resolution for precise tumor and biomarker profiling AI-driven selection ensures high-purity and reproducible results Fully automated, reducing manual handling and contamination risk Scalable, high-throughput processing for clinical and research settings Seamlessly integrates into single cell sequencing and multi-omics workflows How It Works 1) Microfluidic Isolation Solo captures intact, live tumor cells from biological samples using advanced microfluidics. 2 ) AI-Powered Selection Proprietary AI algorithms identify and isolate viable tumor cells, eliminating non-target cells and impurities. 3) Single Cell Multi-omics Ready The system delivers single cells compatible with downstream genomic, transcriptomic, and proteomic analysis. 4) Scalable & Automated Workflow Solo is designed to handle multiple samples simultaneously, minimizing hands-on time while maximizing output. Applications For Research & BiopharmaSingle-cell sequencing for deep genomic insightsTargeted biomarker discoveryAccelerated drug development and screeningFor Clinicians & Oncologists Identifying rare cell populations and tumor heterogeneitySupporting precision oncology decisionsEnabling early detection and longitudinal disease monitoring Why 1Cell SOLO? SOLO bridges the gap between AI and oncology, delivering actionable, patient-relevant data from the most granular source—individual cells. By empowering researchers, clinicians, and diagnostics labs...


> Explore how 1Cell.ai applies AI-powered single cell oncology solutions in biomarker discovery, live CTC analysis, therapy monitoring, and precision care.

- Published: 2025-03-28
- Modified: 2025-07-07
- URL: https://1cell.ai/solutions/

Solutions Tailored Precision Oncology Solutions for Every Partner We understand that every stakeholder in cancer care—from clinicians to researchers to biopharma—faces unique challenges. Our AI-driven, single-cell multi-omics platform delivers customizable, real-time insights designed to meet the needs of each audience. Clinicians & Oncologists Pharma and Bio-pharma Partners KOLs and Researchers Cancer Patients Empowering Real-Time, Personalized Cancer CareWe provide clinicians with non-invasive, advanced diagnostic tools to detect cancer earlier, guide treatment decisions, and monitor patient progress. Key Benefits:Live circulating tumor cell (CTC) analysis via OncoIncytesHigh-resolution tumor profiling at the single-cell levelAI-powered molecular insights for therapy selectionReal-time monitoring of disease progression and treatment response Learn More Accelerating Drug Development & Oncology ResearchOur technology supports biopharma and research partners with deep molecular insights and scalable data solutions to advance clinical trials, biomarker discovery, and targeted therapies. Key Benefits:Single cell multi-omics analysis through 1Cell SOLOPatient stratification based on dynamic molecular dataAI-driven biomarker identification and validationScalable platforms for precision medicine trials Learn More Empowering KOLs & Researchers with Real-Time Multi-Omics IntelligenceWe equip oncology thought leaders and translational researchers with scalable tools to accelerate discovery, decode tumor biology, and validate biomarkers with precision and speed. Key Benefits:True single-cell and ctDNA platforms for high-resolution tumor profilingAI-enabled biomarker discovery and multi-omics data integrationCustomizable pipelines for exploratory, preclinical, or clinical researchAccess to integrated consoles (iDiscover™) for data interrogation and insight generation Learn More Personalized Insights for Better Outcomes Our AI-powered, single cell diagnostics provide cancer patients with earlier detection, more precise treatment planning, and continuous monitoring—empowering clinicians to deliver...


> Explore 1Cell.ai’s products—AI-powered single cell oncology solutions for biomarker discovery, live CTC analysis, therapy monitoring, and precision diagnostics.

- Published: 2025-03-28
- Modified: 2025-07-07
- URL: https://1cell.ai/products/

Products Powering Precision Oncology with AI and Single Cell Innovation We develop advanced tools at the intersection of molecular science, bioinformatics, and artificial intelligence. Our suite of products is designed to provide clinicians, researchers, and pharma/biopharma partners with high-resolution, real-time insights to improve cancer diagnosis, monitoring, and treatment. Each product is purpose-built to address the most pressing challenges in precision oncology — from capturing rare circulating tumor cells to unlocking singlecell multi-omics data. Explore our portfolio below and discover how our technologies are reshaping the future of cancer care. Explore Our AI-Powered Oncology Solutions OncoIncytes® Investigating Live Circulating Cancer CellsOncoIncytes is our proprietary next generation liquid biopsy platform focused on isolating and analyzing live circulating tumor cells (CTCs) in real time. Unlike traditional liquid biopsies that focus on circulating tumor DNA (ctDNA), OncoIncytes captures intact, viable CTCs—providing critical molecular information. Detect cancer earlier Monitor disease progression Guide personalized therapy decisions Understand tumor heterogeneity at the cellular level By delivering a deeper, more dynamic profile of each patient’s cancer, OncoIncytes empowers oncologists with actionable insights when it matters most. 1Cell SOLO® Automation to Capture True Single Cells1Cell SOLO is an AI-driven single cell isolation system designed to capture and analyze individual tumor cells with unparalleled precision. Built to support high-resolution research and clinical applications. Precise capture of true single cells High-throughput processing with minimal contamination Multi-omics analysis at the cellular level Acceleration of oncology research, drug development, and biomarker discovery With the SOLO, researchers and clinicians can explore cancer at its...


> Single Cell Multi-Omics with 1Cell.ai. Our AI-driven platforms integrate multi-omic analysis to advance biomarker discovery, therapy monitoring, and precision oncology.

- Published: 2025-03-17
- Modified: 2025-09-24
- URL: https://1cell.ai/technology/

Technology Where Advanced Science Meets AI-Powered Precision At 1Cell. Ai, technology is at the core of how we redefine cancer diagnostics. Our platform merges cutting-edge innovations in molecular science, single cell analysis, bioinformatics, and artificial intelligence—delivering real-time, actionable insights to clinicians, researchers, and biopharma and pharma partners worldwide. Core Technology Pillars AI-Driven Insights Machine learning models optimized for real-time molecular interpretation. Single Cell Multi-Omics True single-cell resolution across genomics, transcriptomics, and proteomics. Integrated Bioinformatics Dynamic multi-omics data processing and interpretation at scale. Scalable Precision Platform Built to support research, diagnostics, and clinical deployment worldwide. AI-Powered Precision Oncology We leverage advanced machine learning and AI algorithms designed specifically for oncology. Our AI models analyze complex genomic, transcriptomic, and proteomic data, providing:By integrating AI at every step, we enable faster, more accurate decision-making in precision oncology. Real-time molecular insights for treatment selection Predictive analytics to assess therapy response and resistance Pattern recognition across large-scale clinical datasets Automated, scalable interpretation of multi-omics biomarkers Technology at Work: AI Meets Multi-omics Redefining the Future of Cancer Care OneCell Ai’s technology is driving a new standard in oncology, drug development, and precision medicine. By unlocking cell-level intelligence with AI, we empower healthcare professionals with the tools needed to make smarter, faster, and more personalized treatment decisions. Next-Generation Sequencing (NGS) High-throughput genomic analysis. Machine Learning & Bioinformatics AI models trained on diverse oncology datasets. Data-Driven Biomarker Discovery Multiomics insights for precision treatment planning. Collaboration Cross-functional platforms connecting clinicians and oncologists, researchers and labs pharma and bio-pharma partners...


> Review 1Cell.ai’s terms and conditions outlining user agreements, data usage, and service guidelines for our AI-powered single cell platforms.

- Published: 2024-07-16
- Modified: 2025-07-07
- URL: https://1cell.ai/terms-and-conditions/

Last Updated: Welcome to the official website of 1Cell. Ai Inc. (OneCell Diagnostics Inc. ), located at (https://1cell. ai). By accessing or using this website, you agree to comply with and be bound by the following Terms and Conditions. Please review them carefully. 1. Acceptance of Terms By using this website, you confirm that you have read, understood, and agreed to be bound by these Terms and Conditions, along with our Privacy Policy. If you do not agree with any of the terms, you should not access or use this site. 2. Use of the Website This website is intended for informational and lawful purposes only. The content may change without notice. You agree not to use the website for any unlawful or prohibited activity. Unauthorized use of this site may give rise to a claim for damages and/or be a criminal offense under applicable laws. 3. Intellectual Property All content on this website—including text, images, logos, graphics, audio, video, and software—is the exclusive property of 1Cell. Ai Inc. (OneCell Diagnostics Inc. ) or its content providers, and is protected by U. S. and international intellectual property laws. You may not copy, reproduce, republish, upload, post, transmit, or distribute any content without prior written permission from 1Cell. Ai Inc. (OneCell Diagnostics Inc. ). 4. Third-Party Links This website may contain links to third-party websites for your convenience. These links do not signify endorsement by 1Cell. Ai Inc. (OneCell Diagnostics Inc. ), and we assume no responsibility for the content, security,...


- Published: 2024-06-09
- Modified: 2025-03-17
- URL: https://1cell.ai/mohan-uttarwar/

Chief Executive Officer Mohan Uttarwar Serial entrepreneur who co-founded 5 companies, raised over $50M in investment and created the share-holder value of over $500M. Strategic thinker who can identify holes in the marketplace and attract a great team to build innovative products & solutions to fill those holes and get the first mover advantage. Visionary with a mission of touching the lives of 1B patients and making a societal impact around the world. Angel Investor with real world experience of helping entrepreneurs building business & creating value


> Meet the 1Cell.ai leadership team—visionaries in AI-powered single cell oncology research, diagnostics, and multi omic innovation.

- Published: 2024-06-08
- Modified: 2026-02-05
- URL: https://1cell.ai/team/

Team Leadership Chief Executive Officer Mohan Uttarwar Read More Chief Medical Geneticist Dr Gowhar Shafi Read More Chief Technology Officer Srikanth Nandiraju Read More Vice President Business Development Arshad Ahmed Read More Vice President Scientific Affairs Ajay Pandita Read More Medical Director Dr. Ken Bloom, MD, FCAP Read More Board Members Chief Executive Officer Mohan Uttarwar Read More Chief Medical Geneticist Dr Gowhar Shafi Read More Chief Scientific Officer Dr Jayant Khandare Read More


> Access 1Cell.ai’s resources—white papers, case studies, and webinars on AI-powered single cell oncology analysis, biomarker discovery, and diagnostics.

- Published: 2024-06-08
- Modified: 2025-07-07
- URL: https://1cell.ai/resources/

News & Events


- Published: 2024-06-08
- Modified: 2024-06-08
- URL: https://1cell.ai/global-styles/

Global Styles Colors Fonts buttons This page previews Global Fonts and Colors for this Kit. Changes made in Site Settings will be displayed here. Global Colors SYSTEM Primary Secondary Body text accent custom BG kIt Blue Element Blue Light BG White Element Transparent Overlay bg Global Fonts SYSTEM Primaryabcd Secondaryabcd body textLooking to change global styles? Click on top left menu in sidebarand then select Site Settings. accent textabcd custom 404 titleabcd Hero headlineabcd Box Titleabcd Subtitleabcd Special Titleabcd Body Text Italic Capitalizeabcd Accent Text Underlineabcd Buttons & Links Buttons and links inherit their style from Global Fonts and Colors settings in Site Settings. Main CTA button Underline Accent This is Hyperlink


> Learn how 1Cell.ai uses AI powered single cell multi omic analysis to advance biomarker discovery, therapy monitoring, and patient selection.

- Published: 2024-06-08
- Modified: 2025-07-07
- URL: https://1cell.ai/about/

About Us Advancing Precision Oncology at the Intersection of Science & Technology At 1Cell. Ai, we are redefining what’s possible in cancer diagnostics by combining the power of advanced molecular science with cutting-edge AI technology. Our mission is to transform cancer care by delivering real-time, clinically actionable insights through single cell multi-omics analysis, AI-driven bioinformatics, and dynamic data platforms. We believe that progress happens when scientific innovation meets technological excellence—and we’re dedicated to bringing this synergy to every clinician, researcher, and biopharma partner we serve. Our Mission To make precision oncology actionable, accessible, and affordable. We aim to improve patient outcomes by providing non-invasive, real-time diagnostic solutions that support early detection, personalized therapy, and continuous monitoring. Our Vision A world where cancer care is driven by data, guided by technology, and tailored to each individual patient at the molecular level. We envision a future where every patient receives timely, personalized care informed by science and powered by AI — eliminating uncertainty and unlocking better outcomes. Our Approach We operate at the unique intersection of:Single Cell Analysis & Multi-Omics ProfilingNext-Generation Sequencing (NGS)AI & Machine Learning AlgorithmsDynamic Data Analytics & Bioinformatics This integrated approach allows us to deliver deeper, more precise insights—enabling clinicians and researchers to make informed decisions faster and more confidently. At our core Guided by Purpose, Driven by Values Innovation Developing cutting-edge solutions for unmet patient needs. Patient Centricity Delivering care that respects individual patient needs. Integrity Upholding our values with authenticity. Agility Adapting to evolving medical and technological...


> Unlock advanced patient insights with AI-powered single-cell multi-omic analysis for therapy monitoring, biomarker discovery, and patient selection.

- Published: 2024-06-08
- Modified: 2025-12-17
- URL: https://1cell.ai/

Revolutionizing Next-Gen Translational Research True Single Cell Multi-Omics Explore Our Technology Transforming Cancer Care—One Cell at a Time At 1Cell. Ai, we are transforming cancer diagnostics and care by combining cutting-edge molecular science with advanced AI technology. Our next-generation, single-cell multi-omics platform delivers real-time, precision insights—empowering clinicians, researchers, and biopharma partners to make smarter, faster decisions. Real-World Impact (Case Studies & Success Metrics) Transforming Cancer Care Through AI-Powered Insights 0 % Faster detection of aggressive cancers. + Patients impacted worldwide through AI-driven treatment 0 % Accuracy in predicting therapy response. Learn more today Our Mission Where Science Meets Technology We are committed to making precision oncology accessible, actionable, and affordable. By fusing scientific rigor with AI-powered technology, we deliver solutions that support earlier detection, personalized treatment, and continuous monitoring. Precision Meets AI Transforming Cancer Care at the Molecular Level Traditional cancer diagnostics often miss key molecular signals—but OneCell Ai’s breakthrough AI-driven genomics captures every detail, delivering precision insights when it matters most. AI-Powered Analysis Advanced machine learning deciphers complex cancer profiles, providing comprehensive insights in real-time. Single Cell Multi-omics High-resolution single cell analysis uncovers tumor heterogeneity and disease evolution at the molecular level providing actionable insights. Personalized Oncology Tailored treatment strategies informed by real-world data utilizing AI-enhanced interpretation. Next-Generation Oncology Tools Delivering precision insights when it matters most Live CTC and ctDNA investigation one cell at a time A proprietary multi-omic cell biopsy® platform that combines CTC and ctDNA analysis providing comprehensive insights into molecular alterations, facilitating personalized therapeutic decisions....


> Connect with 1Cell.ai to learn how AI powered single cell multi omic analysis can advance your research and clinical programs.

- Published: 2024-06-08
- Modified: 2026-05-27
- URL: https://1cell.ai/contact/

Connect with our team today! Please fill in the form to get in touch with us for any enquiries and business opportunities. 1Cell. Ai support team shall review your query and revert to you at the earliest. Alternatively, you could send an email to the following address:Product Demo:demo@1cell. aiCareers:jobs@1cell. ai Get in touch US Office 20380 Town Center Lane, #218 Cupertino, CA 95014, California, United States US Laboratory 320, Hatch Drive, Foster City, CA 94404California, United States


> Review 1Cell.ai’s privacy policy outlining how we collect, use, and protect data within our AI-powered single cell platforms and oncology solutions.

- Published: 2024-06-04
- Modified: 2025-07-07
- URL: https://1cell.ai/privacy-policy/

Privacy Policy for 1Cell. Ai Inc. (OneCell Diagnostics Inc. )Last Updated: 1Cell. Ai Inc. (OneCell Diagnostics Inc. ) (“we,” “us,” or “our”) values your privacy and is committed to protecting the personal information you share with us through our website, https://1cell. ai (“Site”). This Privacy Policy outlines how we collect, use, disclose, and protect your information. 1. Information We Collect We collect two types of information when you use our Site: a. Personal Information This includes any information that identifies you as an individual. You may voluntarily provide: Full name Email address Phone number (optional) Company name (optional) Other details provided through forms on the Site b. Usage Data Collected automatically through your interactions with our Site, this may include: IP address Browser type and version Device type and operating system Pages visited, time spent, and referring URLs General location data (with your consent) Other analytics and diagnostic data 2. How We Use Your Information We use your data to: Operate, maintain, and improve the Site Respond to inquiries or customer support requests Send service updates and promotional emails (only with your consent) Understand how visitors interact with the Site Detect and prevent fraud, abuse, or technical issues Comply with legal obligations and enforce our terms 3. Sharing Your Information We do not sell or rent your personal information. We may share it in the following limited situations: With trusted third-party service providers who help operate our Site (under confidentiality agreements) When required by law, regulation, or legal process To...




## Posts

- Published: 2026-07-08
- Modified: 2026-07-09
- URL: https://1cell.ai/analytical-validation-and-clinical-implementation-of-a-1080-gene-comprehensive-genomic-profiling-assay-with-integrated-cloud-based-analysis-for-solid-tumor-molecular-oncology/
- Categories: India, Publications

The Problem With Small Panels Precision oncology depends on knowing the full genomic landscape of a patient's tumour. Yet most clinical laboratories continue to rely on gene panels covering only 50 to 100 genes- panels that routinely miss critical hotspots, emerging driver mutations, and pan-tumour biomarkers like microsatellite instability and tumour mutational burden. The result is an incomplete molecular picture that constrains therapeutic decision-making before it even begins. At 1Cell. ai, we built OncoIndx to change that. And in this independently conducted study at the Medical College of Georgia at Augusta University : a CLIA-certified molecular diagnostics laboratory- our 1080-gene comprehensive genomic profiling assay received its most rigorous external validation to date. The Study Researchers at Augusta University retrospectively evaluated the analytical performance and clinical utility of OncoIndx across 140 solid tumour samples representing 18 cancer types, benchmarked against the TruSight Oncology 500 (TSO-500) panel- one of the most widely used clinical NGS assays in the world. Concordance was assessed across 81 genes, covering 176 single-nucleotide variants, 8 copy number variations, 4 deletions, 1 duplication, and 4 gene fusions. Limit of detection studies, inter- and intra-run reproducibility assessments, and MSI/TMB quantification were all independently performed and evaluated. Results That Speak for Themselves The performance of OncoIndx across all variant classes was exceptional: >99% sensitivity and 100% specificity for SNV detection across 176 variants 100% sensitivity, specificity, and accuracy for CNVs, indels, duplications, and gene fusions 100% concordance for gene fusion detection across all five samples with known fusions including NCOA4-RET,...


- Published: 2026-07-06
- Modified: 2026-07-06
- URL: https://1cell.ai/1cell-era-newsletter-june-2026/
- Categories: India, Newsletter, Uncategorized
- Tags: Newsletter

ASCO 2026 delivered a defining moment for precision oncology, and the 1Cell. Ai June 2026 Edition Newsletter captures why. From landmark trial data reshaping treatment sequencing to a deeper understanding of how tumours evolve resistance in real time, this month's research signals that the field is moving faster than ever toward truly individualized cancer care. If you're trying to keep pace with where the science is heading, this issue is a must-read. At the heart of this issue is a compelling look at why KRAS mutation status alone doesn't tell the whole story in metastatic pancreatic cancer. In collaboration with the Medical College of Wisconsin, 1Cell. Ai's team uncovered striking findings using longitudinal ctDNA profiling: 65% of genomic alterations detected via cell-free DNA were completely missed in matched tissue biopsies, and 5 timepoints of dynamic clonal evolution were tracked in real time. For clinicians managing KRAS-targeted therapy decisions, this research offers a sobering and actionable reminder that monitoring clonal evolution may be just as critical as the initial mutation call. Beyond the pancreatic cancer deep-dive, this issue also unpacks how OncoIndx® is evolving into a comprehensive multimodal profiling platform — integrating genomics, transcriptomics, and protein biomarkers into a single, more complete picture of each patient's tumour biology. Add to that a roundup of the month's top oncology headlines (from a KRAS-targeted therapy nearly doubling survival in metastatic pancreatic cancer, to AI models predicting drug response with multi-omic precision), and this issue gives you a fast, high-signal way to stay current...


- Published: 2026-07-02
- Modified: 2026-07-02
- URL: https://1cell.ai/potential-of-urine-liquid-biopsy-in-detecting-of-clinically-relevant-genomic-alterations-in-advanced-genitourinary-cancers/
- Categories: India, Publications

When Plasma Can't Find It; Urine Can Plasma-based liquid biopsy has transformed how we detect and monitor cancer genomically. But it has a quiet blind spot: in patients with low circulating tumour DNA burden, clonal evolution, or treatment-related suppression of ctDNA shedding, plasma assays can return negative, leaving clinicians without the molecular information they need. For genitourinary cancers: renal, urothelial, and prostatic, there is a biological reason to look elsewhere. Tumour DNA fragments shed proximally into urine, offering a complementary biofluid that may capture what plasma misses. At 1Cell. ai, in collaboration with Bombay Hospital Mumbai, we investigated whether urine-based liquid biopsy could close that detection gap. Our Study: Multi-Specimen Genomic Profiling in 23 GU Cancer Patients We retrospectively performed molecular spectrum analysis in 23 patients with bladder or prostate cancer, analysing both plasma and urine specimens simultaneously using our OncoIndx NGS panel. ctDNA detection was assessed for concordance and discordance across cancer types and sampling timepoints, with urine findings as the primary focus. What We Found The results make a compelling case for urine as a frontline complementary biospecimen: Plasma alone detected ctDNA positivity in 39. 1% of patients (9/23) Urine alone detected ctDNA positivity in 17. 4% of patients (4/23) Combined plasma + urine analysis increased overall ctDNA detection to 56. 5% (13/23)- identifying an additional 17. 4% of ctDNA-positive cases that plasma testing alone would have missed entirely This enhanced detection enables earlier molecular identification of relapse and more timely clinical intervention Why This Matters For genitourinary...


- Published: 2026-06-09
- Modified: 2026-07-02
- URL: https://1cell.ai/1cell-era-newsletter-may-2026/
- Categories: India, Newsletter, Uncategorized
- Tags: Newsletter

The fast-moving world of precision oncology demands an operational engine that is just as sophisticated as the science behind it. In the May 2026 edition of the 1Cell. Ai newsletter, CEO Mohan Uttarwar introduces a purposeful organizational transformation. Led by industry veteran Dr. Nilesh Shah, the company has tightened laboratory turnaround times and introduced key clinician-centric initiatives—including a no-cost, on-demand Molecular Helpline to discuss complex reports and a partnership-first clinical team. A major highlight of this issue is the official launch of OncoIndx 360 Endometrium. Endometrial cancer management has long faced a classification problem, with critical molecular subtypes often sequenced one at a time or missed entirely. This comprehensive new panel collapses the entire diagnostic workflow into a single tissue sample, simultaneously evaluating POLE, MMR/MSI, TP53, NSMP, HER2, and pharmacogenomics to deliver a complete molecular portrait from Day 1. This edition also features a compelling real-world case study where OncoIndx 360 completely altered the treatment path for a 54-year-old woman initially classified with low-risk endometrial cancer. The panel uncovered a critical CTNNB1 mutation—invisible to conventional workup—reclassifying her risk to intermediate and enabling targeted, timely intervention. Check out the full newsletter to read more about this case and catch up on global oncology news, including the rising prominence of autonomous AI frameworks in cancer discovery Download Newsletter


- Published: 2026-06-08
- Modified: 2026-06-28
- URL: https://1cell.ai/single-cell-circulating-tumor-cell-genomics-reveals-kras-independent-oncogenic-sub-populations-and-longitudinal-clonal-evolution-in-metastatic-pancreatic-adenocarcinoma/
- Categories: India, Publications

Pancreatic Cancer's Moving Target:- Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers and one of the hardest to treat precisely, because it doesn't stay still. PDAC tumours exhibit profound intratumoral heterogeneity, with multiple genetically distinct cell populations evolving rapidly under treatment pressure. Conventional tissue biopsy and bulk ctDNA analysis, both of which sample the tumour at a single point in time and at a population level, simply cannot keep pace with this evolution. Recent research has identified KRAS-independent tumour subclones within KRAS-mutant PDAC- populations of cancer cells that appear to be driven by entirely different oncogenic pathways than the dominant KRAS mutation. If true, this has major implications for treatment resistance. But detecting these subclones requires a tool with far higher resolution than bulk genomic profiling can offer. This study, conducted in collaboration with the Medical College of Wisconsin Cancer Center under an IRB-approved protocol (NCT05802069), set out to determine whether longitudinal single-cell CTC genomics could reveal these hidden subpopulations and complement matched ctDNA profiling in patients with metastatic PDAC. Our Approach: Paired Single-Cell CTC and ctDNA Profiling Over Time:- Sixteen advanced metastatic PDAC patients were enrolled, with serial blood collection at baseline and every 3 months for up to 12 months, generating up to five serial timepoints per patient. At each timepoint, live single CTCs were isolated using our OncoIncytes™ platform, and individual CTC-DNA was profiled using our OncoIndx™ 1080-gene panel. In parallel, matched ctDNA was analysed at 8,000x sequencing depth. All variant calling and analysis...


- Published: 2026-05-26
- Modified: 2026-05-26
- URL: https://1cell.ai/tissue-genomic-profiling-in-a-case-of-endometrioid-adenocarcinoma-of-the-endometrium/
- Categories: Case Studies, Uncategorized
- Tags: India

74y female diagnosed with metastatic endometrioid carcinoma. • Findings: Total hysterectomy with BSO & B/L pelvic lymph nodes dissection. Histopathology revealed endometrioid carcinoma of uterine corpus, FIGO GII; 3 left pelvic lymph nodes show metastatic carcinoma, FIGO stage IB, pT1bpN1a. IHC shows endometrial tumor cells positive ER. PR. PAX and p16 patchy positivity, WT1, NapsinA, GATA 3 TTF1, Calretinin, CD10 were negative. SATB2 positive in squamous morules, Wild type p53, MMR protein deficient (loss of expression of MLH1 & PMS2- MSI-H). Histopathology of right ovary Benign cystic Brenner tumor epithelial cells positive for CK7,GATA 3and EMA. • Further evaluation: Genomic profiling via OncoIndx 360 Tbx to identify actionable alterations and guide personalized therapy. Clinical Challenges How should adjuvant treatment be tailored in node-positive disease with MMR deficiency


- Published: 2026-05-26
- Modified: 2026-05-26
- URL: https://1cell.ai/high-risk-endometrial-carcinosarcoma-in-a-heavily-pretreated-breast-cancer-survivor-molecular-insights-guiding-targeted-strategies/
- Categories: Case Studies, Uncategorized
- Tags: India

74y female diagnosed with metastatic endometrioid carcinoma. • Findings: Total hysterectomy with BSO & B/L pelvic lymph nodes dissection. Histopathology revealed endometrioid carcinoma of uterine corpus, FIGO GII; 3 left pelvic lymph nodes show metastatic carcinoma, FIGO stage IB, pT1bpN1a. IHC shows endometrial tumor cells positive ER. PR. PAX and p16 patchy positivity, WT1, NapsinA, GATA 3 TTF1, Calretinin, CD10 were negative. SATB2 positive in squamous morules, Wild type p53, MMR protein deficient (loss of expression of MLH1 & PMS2- MSI-H). Histopathology of right ovary Benign cystic Brenner tumor epithelial cells positive for CK7,GATA 3and EMA. • Further evaluation: Genomic profiling via OncoIndx 360 Tbx to identify actionable alterations and guide personalized therapy. Clinical Challenges How should adjuvant treatment be tailored in node-positive disease with MMR deficiency


- Published: 2026-05-26
- Modified: 2026-05-26
- URL: https://1cell.ai/comprehensive-tissue-genomic-profiling-reveals-alk-eml4-fusionand-tp53-splice-site-mutation-in-metastatic-lung-adenocarcinoma-2/
- Categories: Case Studies, Uncategorized
- Tags: India

74y female diagnosed with metastatic endometrioid carcinoma. • Findings: Total hysterectomy with BSO & B/L pelvic lymph nodes dissection. Histopathology revealed endometrioid carcinoma of uterine corpus, FIGO GII; 3 left pelvic lymph nodes show metastatic carcinoma, FIGO stage IB, pT1bpN1a. IHC shows endometrial tumor cells positive ER. PR. PAX and p16 patchy positivity, WT1, NapsinA, GATA 3 TTF1, Calretinin, CD10 were negative. SATB2 positive in squamous morules, Wild type p53, MMR protein deficient (loss of expression of MLH1 & PMS2- MSI-H). Histopathology of right ovary Benign cystic Brenner tumor epithelial cells positive for CK7,GATA 3and EMA. • Further evaluation: Genomic profiling via OncoIndx 360 Tbx to identify actionable alterations and guide personalized therapy. Clinical Challenges How should adjuvant treatment be tailored in node-positive disease with MMR deficiency


- Published: 2026-05-26
- Modified: 2026-05-26
- URL: https://1cell.ai/liquid-biopsy-reveals-erbb3-pik3ca-activation-and-myc-amplification-driving-resistance-in-metastatic-cervical-cancer/
- Categories: Case Studies, Uncategorized
- Tags: India

50 y/ female diagnosed with poorly differentiated squamous cell carcinoma of cervix • Initial Treatment: Initially treated with chemotherapy, brachytherapy, radiotherapy. Later, disease recurrence with multiple nodal mets -> Pac+Carbo+Bev. Further progression, treated with Gem+Nab-Pac. • Further evaluation: Presently on Pem+Carbo+ZA. Comprehensive molecular profiling via OncoIndx Liquid Biopsy to understand molecular cause for recurrence and aggressiveness and identify possible treatment resistance and directives


- Published: 2026-05-26
- Modified: 2026-05-26
- URL: https://1cell.ai/comprehensive-liquid-biopsy-profiling-reveals-dual-pik3ca-and-esr1-mutations-in-hormone-receptor-positive-metastatic-breast-carcinoma-2/
- Categories: Case Studies, India
- Tags: India

73-year-old female, invasive ductal carcinoma (IDC) of the right breast (ER 7, PR 8, HER2/neu +1, Ki-67 20%), luminal B–like, HR-positive/HER2-negative phenotype. • Treatment: Patient received EPCT (Nab-Paclitaxel + Carboplatin) followed by bisphosphonate therapy. MRI and PET revealed metastases to the liver, bones, lungs, and residual breast mass. After 18 cycles of EPCT, she was started on Abemaciclib + Fulvestrant, but showed disease progression with liver and bone lesions and was maintained on the same regimen due to chemotherapy intolerance. • Further evaluation: Comprehensive liquid biopsy (OncoIndx, cfDNA) was performed to evaluate resistance mechanisms and guide therapy. Clinical Challenges: • Endocrine resistance despite CDK4/6 + SERD therapy. • Low HRD/TMB restricting immunotherapy or PARP inhibitor use. • Chemotherapy intolerance requiring precision-guided, non-invasive monitoring. • Need for dynamic monitoring using liquid biopsy for resistance evolution.


- Published: 2026-05-26
- Modified: 2026-05-26
- URL: https://1cell.ai/molecular-drivers-of-tumorigenesis-and-metastasis-in-squamous-cell-lung-carcinoma/
- Categories: Case Studies, India
- Tags: India

A 50-year-old male suspected of lung carcinoma. Biopsy of the left scapular lesion was done. Histopathological findings consistent with metastatic squamous cell carcinoma. Challenges: • Targeted therapy gap: Most Squamous Cell Lung Cancer tumours lack well-defined actionable mutations • Aggressive disease biology - Genomic complexity leading to high proliferation and early metastatic potential, leading to rapid progression despite standard treatments • Tumor Heterogeneity: Significant intra-tumoral heterogeneity complicates biomarker testing and consistent treatment response • Treatment Resistance: Primary and acquired resistance to immune checkpoint inhibitors (ICIs) is common.


- Published: 2026-05-26
- Modified: 2026-05-26
- URL: https://1cell.ai/a-tale-of-two-primaries-hepatocellular-and-pancreatic-carcinomas-integrating-tissue-and-liquid-biopsy-insights/
- Categories: Case Studies, India
- Tags: India

70y Male diagnosed with dual malignancy of hepatocellular carcinoma & pancreatic carcinoma • Findings: Histopathology of pancreas lesion - ductal adenocarcinoma and liver lesion - carcinoma with hepatoid morphology. CTlesion in both liver lobe, mid distal body, tail of pancreas, D11 vertebrae, pre-aortic lymphadenopathy suggestive of metastatic malignancy with a probable pancreatic primary. IHC (liver) – Arginase and HAS diffusely positive confirming of hepatocellular differentiation • Initial Treatment: FOLFOX chemotherapy • Further evaluation: Comprehensive molecular profiling via OncoIndx prime plus multiomics multi specimen (tissues and blood) and multi analyte (DNA and RNA) to detect actionable mutation and guide personalized therapy.


- Published: 2026-05-26
- Modified: 2026-05-26
- URL: https://1cell.ai/relapsed-metastatic-ewings-sarcoma-with-comprehensivegenomic-profiling/
- Categories: Case Studies, India
- Tags: India

Diagnosis: 16 year old male, Ewingʼs sarcoma (right 10th rib), CD99+/FLI1+/NKX2. 2+, skeletal metastases at presentation. • Treatment: Progressed through irinotecan+ etoposide (6 cycles) and VACM (6 cycles). Post therapy PET CT: persistent diffuse FDG uptake in bone marrow- chemorefractory metastatic disease. • Further Evaluation: OncoIndx Prime (Paired NGS, FFPE + plasma cfDNA) performed after two lines of therapy to identify actionable drivers and resistance mechanisms. Clinical Challenges: • Relapsed/refractory metastatic Ewingʼs sarcoma in an adolescent with limited evidence-based therapeutic options beyond second-line NCCN regimens. • Empiric chemotherapy offers low probability of durable response; precision strategy urgently needed. • Need for precision-guided strategy to avoid ineffective or toxic regimens. • Germline VUS in CBLB requires longitudinal reinterpretation and genetic counselling. • Balancing aggressive treatment strategies with quality-of-life considerations. Clinical Implications: • Homozygous CDKN2A/CDKN2B deletions (tissue and plasma confirmed) result in dysregulation of the cyclin-dependent kinase pathway. • Treatment option 1: CDK4/6 inhibitors (palbociclib etc. ) within a clinical trial setting. • Treatment option 2: Guideline-aligned salvage chemotherapy: Cyclophosphamide/topotecan or irinotecan/temozolomide ± vincristine. • TYMS 6-bp deletion: Potential reduced efficacy and/or increased toxicity with antifolate-based agents. • Low TMB, MSS, absence of CHIP: Low probability of benefit from immune checkpoint inhibitors. • BARD1 in-frame deletion (Tier II): Emerging evidence; clinical trial enrolment may provide future therapeutic relevance. • Overall, integrated biopsy profiling shifted management from empiric chemotherapy selection to pathway-informed, biologically rational strategy.


- Published: 2026-05-26
- Modified: 2026-06-16
- URL: https://1cell.ai/rare-or-uncommon-cancers-where-tissue-specific-guidelines-are-limited-and-broad-genomic-insight-is-critical/
- Categories: Case Studies, India
- Tags: India

Precision Reclassification and Targeted Intervention in Advanced Hepatocellular Carcinoma Patient Profile: • Age/Sex: 66-year-old male with chronic hepatitis B. • Diagnosis: Advanced hepatocellular carcinoma (HCC) with multifocal liver lesions and lung metastases mediastinal mass with no clear primary lesion. • Clinical Course: Initial stable disease, now showing progression with new lung nodules. Problem: • Disease progression despite standard ICI + anti-VEGF combo. • Need to identify molecular drivers and potential resistance mechanisms for salvage therapy. • Histology is moderately differentiated, but tumor biology remains unclear


- Published: 2026-05-26
- Modified: 2026-05-26
- URL: https://1cell.ai/from-fragmented-results-to-precision-carean-endometrial-cancer-case-study/
- Categories: Case Studies, India
- Tags: India

Co-Morbidities: Obesity, Hypertension, Type 2 diabetes presented with intermittent postmenopausal bleeding. Initial Diagnosis: Transvaginal ultrasound revealed a heterogeneous endometrial thickening of 16mm, and endometrial biopsy confirmed high-grade (HG) endometrioid carcinoma. Clinical Challenges Traditional Diagnostic Workflow Delayed Diagnosis / Tissue Exhaustion POLE-mutant status justifies treatment de-escalation and confers excellent prognosis Morphology based classification (high-grade) often leads to overtreatment of cases where molecular classification recommends de-escalation


- Published: 2026-05-26
- Modified: 2026-05-26
- URL: https://1cell.ai/circulating-tumor-cell-ctc-analysis-identifies-actionable-dna-repair-deficiency-in-advanced-nsclc-undetected-by-ctdna/
- Categories: Case Studies, India
- Tags: India

A 67-year-old male with Stage IV non–small cell lung cancer (NSCLC) experienced disease progression following standard-of-caretherapies. A comprehensive circulating tumor DNA (ctDNA) genomic panel failed to identify actionable alterations, leaving no cleartargeted treatment options. Based on clinical trajectory, estimated life expectancy was limited (on the order of months), and care wasapproaching a palliative setting.


- Published: 2026-05-26
- Modified: 2026-05-26
- URL: https://1cell.ai/circulating-tumor-cell-ctc-analysis-identifies-actionable-dna-repair-deficiency-in-advanced-nsclc-undetected-by-ctdna-2/
- Categories: Case Studies, India
- Tags: India

A 67-year-old male with Stage IV non–small cell lung cancer (NSCLC) experienced disease progression following standard-of-care therapies. A comprehensive circulating tumor DNA (ctDNA) genomic panel failed to identify actionable alterations, leaving no clear targeted treatment options. Based on clinical trajectory, estimated life expectancy was limited (on the order of months), and care was approaching a palliative setting.


- Published: 2026-05-26
- Modified: 2026-07-02
- URL: https://1cell.ai/oncoincytes-white-paper-real-time-cancer-insights-with-integrated-single-cell-multi-omics/
- Categories: India, White Papers
- Tags: Clinical, India, Multi-omics

Cancer treatment is evolving rapidly, but one major challenge still remains — tumors constantly change. Traditional tissue biopsies and standard liquid biopsy methods often fail to capture these real-time changes, making it difficult to accurately identify the right patients, monitor treatment response, or detect emerging resistance early. This whitepaper introduces OncoIncytes, an advanced AI-powered precision oncology platform designed to address these critical gaps. By combining single-cell circulating tumor cell (CTC) analysis, ctDNA profiling, transcriptomics, and proteomics from a single blood draw, OncoIncytes delivers a deeper and more dynamic understanding of tumor biology. The paper explores how this integrated multi-omics approach can improve patient selection, monitor target expression in real time, identify resistant tumor clones earlier, and support the development of next-generation therapies like ADCs and bispecific ancttibodies. If you are involved in oncology research, drug development, clinical trials, or precision medicine, this whitepaper provides valuable insights into how real-time tumor intelligence can help improve treatment decisions and clinical outcomes. Download the full whitepaper to explore the future of precision oncology. Download OncoIncytes WhitePaper


- Published: 2026-05-26
- Modified: 2026-07-02
- URL: https://1cell.ai/redefining-precision-oncology-insights-from-dr-razelle-kurzrock-on-the-future-of-cancer-care/
- Categories: Expert Insights, India

In this insightful Expert Insights webinar, globally recognized precision oncology leader Dr. Razelle Kurzrock shares her perspective on how precision medicine is transforming the future of cancer treatment. Drawing from decades of groundbreaking research and clinical leadership, Dr. Kurzrock explores the shift from conventional “one-size-fits-all” therapies toward highly personalized treatment strategies driven by genomics, biomarkers, and patient-specific data. The discussion highlights the growing importance of molecular profiling, rare cancer research, and early-phase clinical trials in improving patient outcomes. Dr. Kurzrock also explains how emerging technologies and data-driven approaches are helping clinicians better understand tumor behavior, identify actionable mutations, and develop targeted therapies that can significantly improve treatment precision. A major focus of the session is the evolving role of precision oncology in rare and difficult-to-treat cancers — an area where Dr. Kurzrock has made pioneering contributions throughout her career. She shares valuable insights into the challenges researchers and clinicians face in translating genomic discoveries into real-world therapies, while also emphasizing the importance of collaboration, innovation, and patient-centered research. The webinar offers a compelling look at the future of oncology, where treatment decisions are increasingly guided by each patient’s unique molecular profile rather than cancer type alone. From advances in genomics to the promise of individualized combination therapies, this session provides valuable perspectives for researchers, clinicians, healthcare professionals, and anyone interested in the next era of cancer care. With more than 950 scientific publications and leadership in over 100 early-phase clinical trials, Dr. Kurzrock brings unmatched expertise and practical insight into...


- Published: 2026-05-22
- Modified: 2026-05-22
- URL: https://1cell.ai/uncovering-tumor-evolution-in-multi-treated-breast-cancer-using-liquid-biopsy-and-longitudinal-ngs/
- Categories: Case Studies, Uncategorized
- Tags: India

A 52-year-old pre-menopausal woman was diagnosed in November 2015 with stage T2N2M0 breast carcinoma. She underwent surgery, chemotherapy, radiotherapy, and started adjuvant hormonal therapy. Despite multiple recurrences and disease progressions over almost a decade, sequential lines of endocrine therapy, chemotherapy, and targeted agents were administered, including Tamoxifen, Fulvestrant, Exemestane, Capecitabine, Gemcitabine, Palbociclib, and others. • In July 2025, liver metastases were confirmed with progression despite all prior treatments.


- Published: 2026-05-22
- Modified: 2026-05-22
- URL: https://1cell.ai/genomic-profiling-of-rapidly-dedifferentiating-msi-highendometrial-carcinoma/
- Categories: Case Studies, Uncategorized
- Tags: India

64y Female diagnosed with Grade 3 Endometrioid adenocarcinoma; history of left axillary lump • Initial Treatment: Underwent total uterine hysterectomy • Further evaluation: Molecular profiling via OncoIndx 360 Tissue Biopsy to understand progression & identify actionable therapeutic targets Clinical Challenges • Rapid progression to metastatic undifferentiated carcinoma with new abdominal mass, complicating primary site confirmation and treatment planning.


- Published: 2026-05-22
- Modified: 2026-05-22
- URL: https://1cell.ai/multi-omics-insights-driving-personalized-therapy-in-breast-cancer/
- Categories: Case Studies, Uncategorized
- Tags: India

A 55-year-old female was diagnosed with carcinoma of the left breast. She underwent neoadjuvant chemotherapy followed by surgery. Post-treatment imaging in March 2025 revealed extensive disease progression as well as lesions in the lung, liver, and bone. Pathology confirmed metastatic breast cancer with immunohistochemistry (IHC) showing negativity for ER, PR, and HER2 (score 1), and a high Ki-67 proliferation index (55%), consistent with triple-negative breast cancer (TNBC).


- Published: 2026-05-22
- Modified: 2026-05-22
- URL: https://1cell.ai/molecular-risk-reclassification-in-stage-ii-endometrialcarcinoma-when-biology-redefines-prognosis/
- Categories: Case Studies, Uncategorized
- Tags: India

64-year-old female diagnosed with High Grade Endometrial Carcinoma. • Findings Histopathology confirmed pT1b pN0 disease (FIGO Stage II C), favoring dedifferentiated carcinoma with >50% myometrial invasion. Bilateral pelvic lymph nodes, retroperitoneal lymph nodes, and omentum free of metastatic involvement ; focal LVSI identified. • Initial treatment: Underwent definitive surgical management consisting of total abdominal hysterectomy + bilateral salpingo-oophorectomy, bilateral pelvic lymph node dissection, retroperitoneal lymph node sampling, and omentectomy, achieving complete macroscopic tumor resection. • Further evaluation: Targeted NGS Panel (OncoIndx 360) was performed on FFPE tissue to identify prognostic/predictive markers, enabling molecular risk stratification and adjuvant therapy decisions. Clinical Challenges • Aggressive histologic features appeared disproportionate to anatomic staging, raising concern that surgical clearance might not fully represent underlying biological behavior. • Stage II node-negative disease with myometrial invasion and focal LVSI created uncertainity regarding the need for adjuvant therapy. • Identification of a TP53 mutation was critical, as molecular subtype in early-stage endometrial carcinoma directly determines escalation or de-escalation of adjuvant therapy


- Published: 2026-05-22
- Modified: 2026-05-22
- URL: https://1cell.ai/metastatic-prostate-adenocarcinoma-withtmprss2-erg-fusion-and-msi-high-immunogenic-profile/
- Categories: Case Studies, Uncategorized
- Tags: India

Clinical History & Chronological Summary: • Diagnosis: 70-year-old male with metastatic prostate adenocarcinoma (T3bN3M1), Gleason 9 (5+4), with seminal vesicle invasion, bladder wall infiltration, and necrotic pelvic lymph nodes. • Imaging: PET-CT revealed prostatomegaly with locally invasive lesion. • Histopathology: TURP chips and urethral polyp biopsy confirmed poorly differentiated adenocarcinoma, IHC positive for PSA, AMACR, NKX3. 1. • Treatment: Initiated Degarelix and Denosumab (X-Geva). • Further evaluation: Comprehensive molecular profiling (OncoIndx Prime) performed on FFPE tissue and plasma cfDNA/RNA to guide targeted treatment options. Clinical Challenges: • Aggressive disease biology with high Gleason grade and local invasion. • Therapeutic resistance was expected due to strong AR signaling from TMPRSS2-ERG fusion and FOXA1 overexpression. • Dual molecular phenotype (MSI-High, PD-L1 positive) creating uncertainty in therapy sequencing. • Variants of uncertain significance (CHD4, SMARCA4, DICER1) complicated interpretation


- Published: 2026-05-22
- Modified: 2026-05-22
- URL: https://1cell.ai/from-genomics-to-therapy-a-precision-medicine-approachin-advanced-endometrial-cancer/
- Categories: Case Studies, Uncategorized
- Tags: India

74y female diagnosed with metastatic endometrioid carcinoma. • Findings: Total hysterectomy with BSO & B/L pelvic lymph nodes dissection. Histopathology revealed endometrioid carcinoma of uterine corpus, FIGO GII; 3 left pelvic lymph nodes show metastatic carcinoma, FIGO stage IB, pT1bpN1a. IHC shows endometrial tumor cells positive ER. PR. PAX and p16 patchy positivity, WT1, NapsinA, GATA 3 TTF1, Calretinin, CD10 were negative. SATB2 positive in squamous morules, Wild type p53, MMR protein deficient (loss of expression of MLH1 & PMS2- MSI-H). Histopathology of right ovary Benign cystic Brenner tumor epithelial cells positive for CK7,GATA 3and EMA. • Further evaluation: Genomic profiling via OncoIndx 360 Tbx to identify actionable alterations and guide personalized therapy. Clinical Challenges How should adjuvant treatment be tailored in node-positive disease with MMR deficiency


- Published: 2026-05-21
- Modified: 2026-05-21
- URL: https://1cell.ai/case-study-05-lung-cancer-2/
- Categories: Case Studies, Uncategorized
- Tags: India

Patient: 52 years - Male diagnosed with Adenocarcinoma Lung with Brain metastasis Clinical Testing: Alterations: P278T, G509R, E337*, Fusion Gene: TP53, BRAF, NF1, CAD-ALK Treatment Options: Osimertinib is standard of care (NCCN) for Non-small cell lung cancer with brain metastases. Mutations in EGFR indicate potential efficacy from TKIs. MSH6 gene indicates potential benefit from Immunotherapy agents. Immunotherapy (Pembrolizumab), either as a single agent or in combination with Osimertinib has shown enhanced response and progression free survival in several studies of NSCLC with brain metastasis. Indication: This is the case of Adenocarcinoma Lung with symptomatic brain metastasis. Research Findings: The tumor has pathogenic mutations in EGFR, MSH6, TP53 and DDR2 genes. EGFR leads to increased cell proliferation and growth and is found in a variety of tumors, including non-small cell lung cancer and colorectal cancer. According to AACR genie studies, MSH6 is altered in 2. 44% of all cancers with colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, and prostate adenocarcinoma. The tumor shows loss of function in the TP53 gene, which is associated with a worse prognosis and relatively more resistant to chemotherapy and radiation. MMR mutations (MSH6) in NSCLC are statistically correlated with resistance to Cisplatin and Carboplatin.


- Published: 2026-05-20
- Modified: 2026-05-20
- URL: https://1cell.ai/abstract-78-9-aacr-annual-meeting-2026/
- Categories: India, Press Releases

San Diego  Presented by Dr.  Gowhar Shafi et al | April 19, 2026 | Session PO. BCS01. 06: Digital Pathology  Seeing What Pathologists Miss  In breast cancer diagnostics, the stakes of accurate biomarker assessment could not be higher. The expression levels of ER, PR, HER2, and Ki67 measured through immunohistochemistry (IHC) directly determine which treatments a patient receives, and whether they qualify for life-changing therapies such as second-generation antibody-drug conjugates (ADCs).  Yet today, this assessment is largely done manually; by pathologists visually examining tissue slides: a process that is inherently subjective, variable, and prone to error.   Consider this: the inter-pathologist concordance for distinguishing HER2 0 vs. HER2 1+ stands at just 26%. For patients with HER2-ultralow tumours, a population that now qualifies for ADC therapies:- this diagnostic gap is not just a quality issue. It is a matter of access to life-saving treatment.   Introducing OncoPredikt  We developed OncoPredikt: an AI-powered deep-learning model built to bring objectivity, consistency, and unprecedented precision to tumour detection and biomarker quantification in breast cancer IHC whole-slide images.   Our model was designed and trained on H&E images,130 training samples and 53 validations from TCGA and in-house cohorts:- and tested on IHC whole-slide images for cross-stain generalisation, enabling automated tumour detection and biomarker quantification of ER, PR, HER2, and Ki67 within detected tumour regions. All workflows were validated against pathologist annotations.   Results That Redefine the Standard  OncoPredikt delivered results that speak for themselves:  Tumour masks achieved Dice Similarity Coefficient >0. 8 on H&E images, and even better performance on IHC whole-slide images  For 2 pathologist-analysed IHC 0 (Neg) HER2 samples, our AI approach yielded Ultra-Low (0+) and (1+) predictions:- identifying subtle positivity that visual assessment...


- Published: 2026-05-19
- Modified: 2026-05-19
- URL: https://1cell.ai/oncoindx-whitepaper-the-science-behind-smarter-cancer-treatment/
- Categories: India, White Papers
- Tags: Clinical, India, Multi-omics

Cancer treatment works best when it is guided by a clear understanding of a patient's unique tumor biology. OncoIndx® is a comprehensive genomic profiling test by 1Cell. Ai that analyzes over 1,000 genes using next-generation sequencing and AI-powered reporting. For oncologists, it means sharper visibility into targetable mutations, therapy resistance, and clinical trial eligibility, all from a single test using either a tissue sample or a simple blood draw. For patients, especially those with advanced or treatment-resistant cancers, OncoIndx® takes the guesswork out of treatment decisions. Instead of a one-size-fits-all approach, your oncologist can use your tumor's genetic profile to find therapies most likely to work for you. The test covers a wide range of cancers including lung, breast, colorectal, ovarian, and more, with results delivered in 10 to 14 days through the AI-driven iCare™ platform. Our whitepaper dives deeper into the clinical evidence, technical validation, and real-world applications of OncoIndx®. Whether you are a clinician looking to integrate precision oncology into your practice or a patient wanting to understand your options, this resource is built for you. Download the whitepaper below to learn more. Download the OncoIndx White Paper


- Published: 2026-05-19
- Modified: 2026-05-19
- URL: https://1cell.ai/oncotarget-whitepaper-smarter-cancer-testing-built-for-every-patient/
- Categories: India, White Papers
- Tags: Clinical, India, Multi-omics

Cancer treatment works best when it is guided by the right information. OncoTarget® by 1Cell. Ai is a targeted genomic testing solution designed to identify key mutations across major cancers including Lung, Breast, Colorectal, Ovarian, Prostate, Bladder, and more. Unlike broad, expensive genomic panels, OncoTarget® focuses only on clinically actionable genes recommended by global guidelines such as NCCN, ASCO, and ESMO, making precision oncology affordable and accessible across India's healthcare settings. For oncologists, OncoTarget® delivers fast, easy-to-read reports powered by the iCare AI platform, helping you make confident therapy decisions without getting lost in unnecessary data. The panel can be customized with up to 20 disease-specific genes, works with both tissue and blood samples, and includes optional PD-L1 expression testing. For patients, it means getting the right treatment sooner, without the burden of high testing costs. Download our whitepaper to explore the science, clinical evidence, and real-world application behind OncoTarget®. Understand how targeted genomic testing can change the course of your cancer care journey, whether you are a clinician looking to enhance your practice or a patient seeking clarity on your treatment options. Download OncoTarget WhitePaper


- Published: 2026-05-19
- Modified: 2026-06-09
- URL: https://1cell.ai/oncohrd-whitepaper-smarter-cancer-treatment-starts-with-the-right-test/
- Categories: India, White Papers
- Tags: Clinical, India, Multi-omics

Not all cancers are the same, and neither should their treatment be. OncoHRD® by 1Cell. Ai is an advanced genomic test that detects Homologous Recombination Deficiency (HRD), a specific DNA repair defect found in breast, ovarian, prostate, and pancreatic cancers. By identifying this defect, OncoHRD® helps oncologists decide whether treatments like PARP inhibitors or platinum-based chemotherapy are the right fit for each patient, taking the guesswork out of critical treatment decisions. For patients, this means a clearer path to therapies that are more likely to work for your specific cancer. For oncologists, it means actionable insights backed by deep sequencing of 50+ HRR genes, genomic scar analysis, and AI-powered reporting through the iCARE™ platform, all delivered with fast turnaround and clinical precision. Our whitepaper dives deeper into the science, clinical evidence, and real-world impact of HRD testing in precision oncology. Whether you are a clinician looking to enhance treatment accuracy or a patient seeking the best possible care, this resource is designed for you. Download the OncoHRD® WhitePaper below to learn how smarter testing leads to better outcomes. Download OncoHRD WhitePaper


- Published: 2026-05-19
- Modified: 2026-06-09
- URL: https://1cell.ai/oncomonitor-white-paper-smarter-cancer-monitoring-starts-with-a-blood-test/
- Categories: India, White Papers
- Tags: Clinical, India, Multi-omics

Cancer treatment is not a one-time decision, it is an ongoing journey that requires constant monitoring. OncoMonitor® by 1Cell. Ai is a liquid biopsy test that tracks how cancer is responding to treatment, using just a blood sample. By measuring circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) over time, oncologists can see in real time whether a therapy is working, if resistance is building, or if the disease is returning, often before it shows up on a scan. For patients, this means fewer invasive procedures and faster, more personalized care. For oncologists, it means data-driven decisions backed by AI-powered reporting through the iCARE platform. OncoMonitor® covers two key needs: treatment response monitoring through OncoMonitor® TRM and minimal residual disease detection through OncoMonitor® MRD, applicable across cancers like lung, breast, colorectal, ovarian, and more. Download our white paper to understand the clinical evidence, validation results, and how longitudinal liquid biopsy monitoring can change outcomes for your patients. Download OncoMonitor WhitePaper


- Published: 2026-05-04
- Modified: 2026-05-04
- URL: https://1cell.ai/1%f0%9d%98%be%f0%9d%99%9a%f0%9d%99%a1%f0%9d%99%a1-%f0%9d%98%bc%f0%9d%99%9e-aacr-2026/
- Categories: Press Releases

1Cell. Ai, a leader in precision oncology diagnostics, is proud to announce the presentation of seven research studies at the 𝘼𝙢𝙚𝙧𝙞𝙘𝙖𝙣 𝘼𝙨𝙨𝙤𝙘𝙞𝙖𝙩𝙞𝙤𝙣 𝙛𝙤𝙧 𝘾𝙖𝙣𝙘𝙚𝙧 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝 (AACR) Annual Meeting 2026. These studies collectively demonstrate the power of AI-powered multi-omic approaches in advancing cancer detection, monitoring, and treatment decision-making. "Our presence at AACR this year marks a pivotal moment for 1Cell. Ai," said Mohan Uttarwar, Founder and CEO of 1Cell. Ai. Key highlights from the presentations were categorized across 𝙛𝙤𝙪𝙧 critical areas of oncology: 𝘼𝙙𝙫𝙖𝙣𝙘𝙚𝙢𝙚𝙣𝙩𝙨 𝙞𝙣 𝙈𝙞𝙣𝙞𝙢𝙖𝙡 𝙍𝙚𝙨𝙞𝙙𝙪𝙖𝙡 𝘿𝙞𝙨𝙚𝙖𝙨𝙚 (𝙈𝙍𝘿) & 𝙇𝙞𝙦𝙪𝙞𝙙 𝘽𝙞𝙤𝙥𝙨𝙮: Novel computational and assay-based approaches to improve detection sensitivity. • MIRAGE: A ctDNA methylation-driven algorithm for sensitive MRD detection. • Ultrasensitive cfDNA fragmentomics assay for early treatment response assessment in solid tumors. 𝘼𝙄-𝘿𝙧𝙞𝙫𝙚𝙣 𝙄𝙢𝙖𝙜𝙞𝙣𝙜 & 𝘽𝙞𝙤𝙢𝙖𝙧𝙠𝙚𝙧 𝙌𝙪𝙖𝙣𝙩𝙞𝙛𝙞𝙘𝙖𝙩𝙞𝙤𝙣: Leveraging deep learning to extract deeper biological insights from standard pathology. • OncoPredikt: A deep-learning framework for tumor detection and biomarker quantification in breast cancer IHC whole-slide images. 𝙄𝙣𝙩𝙚𝙜𝙧𝙖𝙩𝙚𝙙 𝙈𝙪𝙡𝙩𝙞-𝙊𝙢𝙞𝙘 & 𝙋𝙝𝙖𝙧𝙢𝙖𝙘𝙤𝙜𝙚𝙣𝙤𝙢𝙞𝙘 𝙋𝙧𝙤𝙛𝙞𝙡𝙞𝙣𝙜: Combining diverse data types to enable more precise and actionable clinical insights. • Integrative genomic analysis revealing pharmacogenomic determinants of chemotherapy response. • Enhancing variant interpretation and reducing uncertainty in clinical genomics through systematic multi-database classification. 𝙍𝙚𝙖𝙡-𝙒𝙤𝙧𝙡𝙙 𝙀𝙫𝙞𝙙𝙚𝙣𝙘𝙚 & 𝙋𝙤𝙥𝙪𝙡𝙖𝙩𝙞𝙤𝙣-𝙎𝙥𝙚𝙘𝙞𝙛𝙞𝙘 𝘼𝙥𝙥𝙡𝙞𝙘𝙖𝙩𝙞𝙤𝙣𝙨: Expanding the reach of precision medicine to diverse cohorts and complex mutations. • Comprehensive genomic profiling expanding accessibility to targeted therapies in underserved populations. • Precision profiling of TP53alterations in advanced cancers, linking mutation class to genomic instability and actionable drivers. "𝘿𝙧. 𝙂𝙤𝙬𝙝𝙖𝙧, Chief Medical Informatics Officer, added:...


- Published: 2026-05-04
- Modified: 2026-06-16
- URL: https://1cell.ai/1cell-era-newsletter-april-2026/
- Categories: India, Newsletter, Uncategorized
- Tags: Newsletter

Cancer care is not just about reports, scans, and treatments. It is also about the long journey patients, caregivers, and doctors go through every single day. In this edition of the 1Cell. Ai April Newsletter, we explore how technology and precision oncology are helping make cancer care more connected, informed, and patient-friendly. Inside this issue, you’ll find major updates from the world of precision oncology from AI-designed cancer drugs entering human trials to breakthroughs in pancreatic cancer treatment and the growing role of AI in clinical decision-making. We also share a real-life case study showing how genomic profiling helped shape a more personalized treatment plan for advanced endometrial cancer. The newsletter also highlights 1Cell. Ai’s latest initiatives, including the launch of a Molecular Helpline for oncologists and our research presentations at AACR 2026. If you want a simple and meaningful look at where cancer care is heading and how precision medicine is making a difference in real clinical practice this newsletter is worth reading. Download Newsletter


- Published: 2026-04-30
- Modified: 2026-04-30
- URL: https://1cell.ai/ngs-testing-faqs-for-oncologists/
- Categories: FAQs, India

FAQ #1 - When should NGS testing be ordered in cancer patients? NCCN guidelines strongly recommend broad-panel Next-Generation Sequencing (NGS) to identify actionable genomic alterations in advanced, metastatic, or high-risk cancers, particularly for NSCLC, breast, and gastrointestinal tumors FAQ #2 - What is the clinical utility of NGS in oncology? Next-generation sequencing (NGS) provides high clinical utility in precision medicine by simultaneously analyzing multiple genes to guide targeted therapy, identify hereditary cancer risks, and monitor treatment response. It enables personalized care in oncology by identifying actionable mutations, improving survival in selected patients FAQ #3 - Which cancers benefit most from NGS testing? Key cancer types include non-small cell lung cancer (NSCLC), cholangiocarcinoma, prostate cancer, ovarian cancer, colorectal cancer, advanced breast cancer, thyroid cancer, sarcoma, gastrointestinal stromal tumors (GIST), and cancers of unknown primary


- Published: 2026-04-30
- Modified: 2026-04-30
- URL: https://1cell.ai/ctdna-testing-faqs-for-oncologists/
- Categories: FAQs, India

FAQ #1 - When should ctDNA testing be preferred over tissue biopsy? NCCN guidelines generally recommend tissue biopsy as the "gold standard" for initial cancer diagnosis, as it confirms histology. However, for molecular profiling in advanced or metastatic diseases (especially NSCLC), NCCN recognizes liquid biopsy (ctDNA/blood) as a complementary, highly concordant, and faster, minimally invasive alternative to identify actionable genetic alterations FAQ #2 - What does “ctDNA not detected” mean clinically? ctDNA not detected" (or "ctDNA negative") means that the test did not find evidence of cancer-derived DNA in the blood, indicating no measurable minimal residual disease (MRD) FAQ #3 - Can ctDNA detect resistance mutations? Yes, circulating tumor DNA (ctDNA) is highly effective at detecting acquired resistance mutations to targeted therapies and immunotherapies, often serving as a non-invasive, "liquid biopsy" alternative to tissue sampling FAQ #4 - How reliable is ctDNA for treatment monitoring? ctDNA is used to monitor treatment response, detect minimal residual disease (MRD), and identify mechanisms of resistance in various cancers


- Published: 2026-04-30
- Modified: 2026-04-30
- URL: https://1cell.ai/ctdna-multi-omics-ai-ngs-testing-faqs/
- Categories: FAQs, India

FAQ #1 - Why is circulating tumor DNA (ctDNA) important? Circulating tumor DNA (ctDNA) is essential as a non-invasive "liquid biopsy" to detect, monitor, and treat cancer. By analyzing small fragments of tumor DNA in the blood, it enables real-time monitoring of tumor burden, early detection of relapse, identification of resistance mutations, and personalized treatment adjustments, often outperforming traditional imaging FAQ #2 - What is multi omics technology? Multi-omics technology is an integrative, high-throughput approach that combines data from multiple biological layers—genomics, transcriptomics, epigenomics, proteomics, and metabolomics—to provide a comprehensive, holistic understanding of molecular mechanisms, disease pathology FAQ #3 - What is the role of Ai in NGS testing? AI in Next-Generation Sequencing (NGS) accelerates and improves the accuracy of genomic analysis by automating complex, data-intensive tasks across the entire workflow, from laboratory quality control (QC) to clinical diagnosis FAQ #4 - What samples types can 1Cell. Ai perform NGS tests on? 1Cell. Ai lab has the capability to test Whole blood, Bone marrow aspirate,Tissue,Ascitic fluid & CSF samples FAQ #5 - Is your lab facility certified to perform quality NGS testing? The state of the art lab facility at Pune is NABL & CAP accredited with qualified genomic specialists which ensure best process for NGS testing


- Published: 2026-04-30
- Modified: 2026-04-30
- URL: https://1cell.ai/order-ngs-test-support-faqs-1cell-ai/
- Categories: FAQs, India

FAQ #1 - How can I order for an NGS test from 1Cell. Ai? Tests can be ordered by reaching out on 180012312355, 90221 37932 or submitting a request on info@1cell. ai or contacting the 1Cell representative FAQ #2 - How will I receive the patient test report? The test report is sent to the patients on the email id shared with us at time of sample collection, can also be shared with you if requested FAQ #3 - Whom should I contact if I have questions on the test results? The 1Cell. Ai team of Genomic specialists are available to answer your queries on the test results FAQ #4 - What happens if the sample is not viable or report is inconclusive? The 1Cell. Ai team of Genomic specialists will contact you incase the results are inconclusive FAQ #5 - Does 1Cell. Ai have genetic counselling services? Yes 1Cell. Ai provides genetic counselling services as requested


- Published: 2026-04-30
- Modified: 2026-04-30
- URL: https://1cell.ai/ctc-vs-ctdna-testing-oncology-faqs/
- Categories: FAQs, India

FAQ #1 - What is the clinical role of CTC testing in oncology? A circulating tumor cell (CTC) is a cancer cell. The detection and analysis of CTCs can assist early patient prognoses and determine appropriate treatment plans by your treating Dr FAQ #2 - How is CTC testing different from ctDNA testing? CTC testing detects living cancer cells shed from tumors, offering insights into metastatic potential and drug sensitivity, whereas ctDNA testing analyzes fragments of DNA from dead cancer cells to identify specific genetic mutations


- Published: 2026-04-30
- Modified: 2026-04-30
- URL: https://1cell.ai/ngs-tissue-requirements-test-failures-ffpe-faqs/
- Categories: FAQs, India

FAQ #1 - What is the minimum tissue requirement for NGS? The minimum tissue requirement for NGS generally requires 10–50 ng of DNA, though some targeted assays can function with as little as 1–10 ng, depending on the panel used by the testing lab. FAQ #2 - Why do tissue NGS tests fail? NGS tests in oncology fail in approximately 20–40% of cases, with most these failures caused due to pre-analytical issues related to tissue quantity or quality FAQ #3 - How does FFPE age affect sequencing quality? Older FFPE samples generally produce lower-quality sequencing data due to increased nucleic acid degradation, lower yields, and shorter fragment sizes, particularly in samples over 5–10 years old


- Published: 2026-04-30
- Modified: 2026-04-30
- URL: https://1cell.ai/ngs-report-interpretation-vaf-actionable-mutations-vus-faqs/
- Categories: FAQs, India

FAQ #1 - How should low VAF variants be interpreted? Low VAFs often suggest subclonal populations that might not be targeted by current therapies, or they can represent early, emergent resistance mutations FAQ #2 - What are actionable mutations in NGS reports? Actionable mutations in NGS reports are specific tumor DNA alterations that, when identified, predict a patient's response to a targeted therapy FAQ #3 - How are VUS reported and interpreted? A Variant of Uncertain Significance (VUS) is reported when genetic testing identifies a DNA change, but insufficient or conflicting evidence exists to classify it as clearly disease-causing or benign. These variants, often found in 30% of hereditary cancer panels, are generally considered inconclusive, and should not be used to guide clinical management or treatment FAQ #4 - How should an NGS report be read? Your Dr is trained to read & interpret an NGS report. An NGS (Next-Generation Sequencing) report should be read by first reviewing the patient and sample details, then focusing on the executive summary to identify actionable genetic variants FAQ #5 - What is NGS? NGS enables scientists and researchers to perform high-throughput sequencing of patient DNA samples, often to identify genetic variation associated with diseases


- Published: 2026-04-20
- Modified: 2026-06-15
- URL: https://1cell.ai/abstract-lb118-5-aacr-annual-meeting-2026/
- Categories: India, Publications

Why TP53 Matters More Than We Thought TP53 is the most frequently altered tumour suppressor gene in human cancer.   Yet for all its clinical relevance, our understanding of how different classes of TP53 mutations behave across different tumour types, at different disease stages; has remained incomplete. Standard genomic testing often reports a TP53 mutation without fully characterising its functional consequences, its co-mutation patterns, or its implications for treatment selection.   Our team set out to change that: at real-world scale.   The Largest TP53 Study of Its Kind in Our Dataset  In what represents one of the most comprehensive real-world analyses of TP53 alterations in our dataset, we performed comprehensive genomic profiling on 1,187 patients with advanced solid tumours:- 827 using ctDNA and 360 using tissue-derived DNA (tDNA) across breast (BC), colorectal (CRC), and lung (LC) cancers.   Sequencing was conducted using our OncoIndx 1080-gene hybrid-capture NGS assay, interrogating SNVs, small indels, structural variations, and genome-wide metrics including Tumour Mutation Burden (TMB) and Homologous Recombination Deficiency (HRD) scores.   Striking Findings Across Tumour Types  Our analysis revealed tumour-type-specific patterns that have direct clinical implications:  TP53 mutations were detected in 50. 5% of all cases:- with the highest prevalence in CRC (57. 33%), followed by BC (53%) and LC (45%)  Missense variants accounted for 65. 8% of all mTP53, including recurrent GOF hotspots at R175, R248, R273, and G245 with G245 being most prominent in CRC  GOF mutations were significantly associated with higher TMB across the cohort- a finding with direct implications for immunotherapy eligibility  In breast cancer, mTP53 was associated with low HRD scores, demonstrating lineage-specific genomic behaviour distinct...


- Published: 2026-04-20
- Modified: 2026-06-22
- URL: https://1cell.ai/mirage-a-ctdna-methylation-driven-computational-algorithm/
- Categories: India, Publications

The Problem That Drives MIRAGE  A patient finishes surgery. Their scans look clear. Their ctDNA levels appear low. By conventional measures, they are in remission. But somewhere, invisible to current detection methods, residual cancer cells may still be present: dormant, waiting, and capable of returning. This is the challenge of Minimal Residual Disease (MRD) and it is one of the most consequential unsolved problems in oncology.   At 1Cell. Ai, we developed MIRAGE:- Minimal Residual Assessment using Genome-wide Epigenomics- a proprietary computational algorithm designed to detect MRD with a level of sensitivity that conventional ctDNA methods cannot match.   The Science Behind MIRAGE  When CTCs are undetectable or ctDNA levels fall below the thresholds of conventional detection methods, standard liquid biopsy approaches reach their limits. MIRAGE goes further; leveraging DNA methylation analysis across genome-wide differentially methylated regions (DMRs) to detect the faintest traces of tumour signal, even in cancers with as low as 0. 001% circulating tumour fraction.   MIRAGE quantifies methylation by evaluating the number of methylated and unmethylated cytosines at each CpG site across the genome, integrating these values into a composite methylation score that reflects overall hyper- or hypomethylation. This score is then normalised against a predefined cut-off established from a reference cohort of non-cancerous healthy individuals, enabling standardised, reproducible clinical interpretation.   Validated Results  Our validation study tested MIRAGE across 156 samples:- including 127 clinical samples (64 tumour samples and 63 non-cancerous healthy controls):  Specificity of 96. 8% across 127 clinical samples, demonstrating that MIRAGE reliably distinguishes true tumour signal from background noise  64% of clinical tumour samples (n=41/64) were detected as ctDNA-positive, demonstrating an overall sensitivity of 64. 1%  The algorithm demonstrated robust performance across the full spectrum of tumour fractions tested. Why This Matters ...


- Published: 2026-04-19
- Modified: 2026-06-15
- URL: https://1cell.ai/abstract-6272-2-aacr-annual-meeting-2026/
- Categories: India, Publications

The Challenge We Set Out to Solve  One of the most persistent challenges in precision oncology today is the interpretation of Variants of Uncertain Significance (VUS):- genetic mutations detected in a patient’s tumour that cannot be immediately classified as harmful or benign. As comprehensive genomic profiling (CGP) becomes standard practice in oncology, the volume of VUS data is growing rapidly and so is the clinical burden of not knowing what these variants mean for individual patients.   At 1Cell. ai, we believed there had to be a smarter way.    So we built one.   Our Approach  Using our OncoIndx® panel for next-generation sequencing (NGS)-based CGP, we developed a proprietary in-house automated precision classification and interpretation system:- a machine learning model that integrates multiple lines of evidence to systematically reclassify VUS with high clinical utility.   Our system evaluates variants across multiple dimensions simultaneously including; in silico evidence, evolutionary conservation scores, functional RNA studies, patient and family history, and genomic co-findings such as microsatellite instability and protein expression data, to generate a coherent, biologically consistent explanation for disease causation.   What We Found  The results validated the power of our multi-evidence approach. In one illustrative case, several VUS intronic variants, initially flagged as uncertain, were reclassified as likely pathogenic based on in silico evidence (PP5, PM2, BP4) and low evolutionary conservation scores (-0. 423).  Our system also identified the presence of Lynch Syndrome and associated genomic findings including high microsatellite instability and loss of MSH2 protein on IHC insights that would have been missed by conventional single-database classification approaches.   When complementary lines of evidence are integrated including; functional loss of a variant, segregation-consistent family history, rarity in population...


- Published: 2026-04-19
- Modified: 2026-06-15
- URL: https://1cell.ai/abstract-3141-9-aacr-annual-meeting-2026/
- Categories: India, Publications

The Problem With One-Size-Fits-All Chemotherapy Every oncologist knows the reality:- Two patients with the same cancer diagnosis can respond very differently to the same chemotherapy regimen. Some tolerate it well and respond powerfully. Others suffer severe toxicity with minimal benefit. The difference often lies not in the tumour alone, but in the patient’s own pharmacogenomic (PGx) profile:- the genetic variations that determine how their body metabolises chemotherapeutic agents. At 1Cell. ai, we believe that understanding a patient’s PGx profile before treatment begins is not optional: it is essential. This study demonstrates exactly why. Our Study Using our OncoIndx® NGS panel for comprehensive genomic profiling (CGP), we retrospectively investigated pharmacogenomic markers in 124 cancer patients across a broad spectrum of tumour types including breast, colon, lung, melanoma, pancreatic, stomach, ovarian, rectal, and hepatobiliary cancers. Our study also included a significant cohort from the Uzbek population, reflecting our commitment to expanding precision oncology beyond traditionally studied populations. What We Found The findings were striking. Three critical PGx markers emerged from our analysis: 92% of patients (n=114) had the DPYD wildtype genotype, associated with reduced risk of adverse events when treated with 5-FU/fluoropyrimidine-based chemotherapy 2. 4% of patients (n=3) carried the DPYD c. 1129-5923C (HapB3) variant :- a finding that predicts increased toxicity at standard dosing levels, warranting dose modification before treatment begins 4% of patients carried wildtype TYMS genotype, and 4. 8% (n=6) were identified with a 6bp deletion associated with increased toxicity and adverse drug reactions 9. 7% (n=12) were detected...


- Published: 2026-04-19
- Modified: 2026-06-15
- URL: https://1cell.ai/abstract-2510-17-aacr-annual-meeting-2026/
- Categories: India, Publications

Precision Oncology Must Be Global At 1Cell. ai, we believe that the benefits of precision oncology should not be confined to patients in well-resourced healthcare systems. Cancer does not discriminate by geography and neither should access to advanced diagnostics. This study reflects that conviction in action. In collaboration with ILBOZA Med Hospital in Tashkent, Uzbekistan, and Tashkent Medical Park LLC, we undertook one of the first comprehensive genomic profiling studies in the Uzbek cancer patient population:- a population where the mortality-to-incidence ratio stands at a sobering 67%, reflecting how late most cancers are detected and how limited access to personalised treatment options remains. Our Study We performed comprehensive genomic profiling (CGP) on 124 cancer patients of Uzbek ethnicity, aged 25 to 85 years, using next-generation sequencing with our OncoIndx® panel. The cohort spanned multiple tumour types, providing one of the broadest cross-tumour genomic analyses of this population to date. What We Found The genomic landscape of our Uzbek cohort revealed a rich and clinically significant mutational profile: 331 pathogenic/likely pathogenic variants were detected across the cohort TP53 variants were the most prevalent, constituting 20. 2% (67) of all variants including; frameshift and truncating variants suggesting impairment of TP53 protein function Key oncogenic drivers were also identified: PIK3CA (8. 5%), APC (6. 3%), KRAS (6%), EGFR (4. 5%), PTEN (2. 7%), and BRCA1/2 (1. 8%) :- all representing actionable targets for existing or emerging therapies Mismatch Repair (MMR) genes including; MSH6, MSH3, MLH1, PMS2, MUTYH, and MSH2 were found to be...


- Published: 2026-04-19
- Modified: 2026-06-15
- URL: https://1cell.ai/abstract-1035-3-aacr-annual-meeting-2026/
- Categories: India, Publications

The Gap in Treatment Monitoring  For patients undergoing cancer treatment, one of the most critical and underserved clinical questions is simple but profound: Is this therapy working?    Traditional imaging lacks the spatial and temporal resolution to detect early shifts in tumour burden:- meaning oncologists often wait weeks or months before knowing whether a treatment is effective, ineffective, or causing resistance.   At 1Cell. ai, we developed OncoAlibrex : a highly sensitive, NGS-independent cfDNA fragmentomics assay designed to answer that question earlier, faster, and with far greater precision than conventional monitoring methods.   The Science of Fragmentomics  OncoAlibrex is built on a powerful biological insight: cancer cells release cfDNA fragments into the bloodstream in patterns that are distinctly different from those released by healthy cells. By characterising the fragmentation patterns of cell-free DNA, rather than simply detecting mutations: OncoAlibrex can detect tumour-specific signals even at extremely low tumour fractions, making it a powerful tool for Therapy Response Monitoring (TRM) and Minimal Residual Disease (MRD) detection.   Our assay evaluates cfDNA fragment distributions at three key size ranges -- >80 bp, >105 bp, and >265 bp, using fragment-specific primer pairs designed based on high copy number Alu and SVA retrotransposons across the genome. Therapy response is then predicted using an integrated algorithm that interprets cfDNA fragment distribution in real time.   Analytical Validation Results  OncoAlibrex was analytically validated using cfDNA extracted from healthy plasma and cancer patient samples (n=140), analysed in triplicate across multiple days, operators, and reagent lots. The results demonstrated exceptional analytical performance:  Intra-assay variability ≤1% for ct value and ≤13% for ratiometric quantity  Inter-assay precision 98% across all tested concentrations  100% specificity: the cfDNA fragmentation pattern of cancer patients showed high progression scores, reliably distinguishing therapy non-response from healthy controls  Fragmentation patterns of...


- Published: 2026-04-14
- Modified: 2026-04-14
- URL: https://1cell.ai/join-us-at-aacr-april-17-22-2026/
- Categories: Events, US
- Tags: US

Discover how 1Cell. Ai is advancing precision oncology at the intersection of science and technology Our team is leading the way with AI-powered, single cell multi-omic solutions designed to help in patient selection, therapy monitoring and biomarker exploration. Visit us at Booth #510 to learn more about our cutting-edge advancements. Featured Poster Presentation: Explore the latest in live single circulating tumor cell capture and precision oncology breakthroughs. Discover how innovation is redefining the future of oncology care! Explore Our Full Lineup at AACR


- Published: 2026-04-02
- Modified: 2026-04-02
- URL: https://1cell.ai/1cell-era-newsletter-march-2026/
- Categories: India, Newsletter, Uncategorized
- Tags: Newsletter

The March edition of the 1Cell. Ai Newsletter takes a closer look at how AI is changing the future of cancer care in ways that are becoming more practical and meaningful for doctors and patients alike. From the growing discussion around AlphaGenome to real-world applications of AI in breast cancer care, this issue brings together some of the most important developments in precision oncology today. One of the highlights is OncoPredikt BreastRS, an AI-powered solution that helps assess breast cancer recurrence risk using routine pathology slides making advanced insights more accessible and affordable for patients across India. The newsletter also shares a real patient case where AI-supported analysis helped avoid unnecessary chemotherapy and reduce treatment burden. You’ll also find updates from the global oncology space, including new biomarker-driven therapies, advances in lung cancer treatment, and how AI is helping researchers discover better drug targets faster. If you want to understand how technology is quietly reshaping cancer treatment and decision-making, this edition is a thoughtful and easy read worth downloading. Download Newsletter


- Published: 2026-03-02
- Modified: 2026-03-02
- URL: https://1cell.ai/1cell-era-newsletter-february-2026/
- Categories: India, Newsletter, Uncategorized
- Tags: Newsletter

The February edition of the 1Cell. Ai Newsletter brings together some of the most important conversations shaping the future of cancer care today. Released around World Cancer Day, this special issue explores how recent Nobel Prize-winning discoveries are helping researchers better understand cancer, immune response, and the role of AI in modern medicine. One of the key highlights is the introduction of Dr G — 1Cell. ai’s AI-powered oncology companion designed to help doctors simplify complex cancer data and support faster, more informed treatment decisions. The newsletter also features a powerful real-world case study showing how liquid biopsy helped uncover treatment resistance in metastatic cervical cancer when traditional tissue testing was difficult. You’ll also find important updates from the global precision oncology space, including rising cancer rates in younger adults, new blood biomarkers for brain metastasis risk, and advances in targeted therapies for multiple myeloma. Download and read this edition to get a simple and meaningful overview of how science, technology, and patient care are coming together to shape the future of oncology. Download Newsletter


- Published: 2026-02-02
- Modified: 2026-06-16
- URL: https://1cell.ai/1cell-era-newsletter-january-2026/
- Categories: India, Newsletter, Uncategorized
- Tags: Newsletter

Cancer care is not just about reports, scans, and treatments. It is also about the long journey patients, caregivers, and doctors go through every single day. In this edition of the 1Cell. Ai April Newsletter, we explore how technology and precision oncology are helping make cancer care more connected, informed, and patient-friendly. Inside this issue, you’ll find major updates from the world of precision oncology from AI-designed cancer drugs entering human trials to breakthroughs in pancreatic cancer treatment and the growing role of AI in clinical decision-making. We also share a real-life case study showing how genomic profiling helped shape a more personalized treatment plan for advanced endometrial cancer. The newsletter also highlights 1Cell. Ai’s latest initiatives, including the launch of a Molecular Helpline for oncologists and our research presentations at AACR 2026. If you want a simple and meaningful look at where cancer care is heading and how precision medicine is making a difference in real clinical practice this newsletter is worth reading. Download Newsletter


- Published: 2026-01-19
- Modified: 2026-01-19
- URL: https://1cell.ai/directory-of-services-2/
- Categories: DOS, India, Uncategorized
- Tags: Newsletter

Directory of Services of all diagnostic tests offered across our company’s portfolio.


- Published: 2026-01-05
- Modified: 2026-01-05
- URL: https://1cell.ai/1cell-era-newsletter-december-2025-2/
- Categories: India, Newsletter, Uncategorized
- Tags: Newsletter

The December 2025 edition of the 1Cell. Ai Newsletter reflects on a year that brought major changes in precision oncology and how cancer care is becoming more connected, data-driven, and patient-focused. From advances in liquid biopsy and AI-assisted decision making to the growing role of multi-omics testing, this issue gives readers a simple and practical look at where oncology is heading next. One of the key highlights is the opening of 1Cell. ai’s new globally accredited Precision Diagnostics Laboratory in Pune, designed to deliver high-quality molecular testing with faster turnaround times and strong quality standards. The newsletter also introduces OncoIndx® TBx, a new integrated genomic and transcriptomic profiling solution aimed at helping doctors uncover deeper treatment insights in difficult cancer cases. This edition also features a real clinical case showing how combined tissue, liquid biopsy, and RNA analysis helped identify important treatment options in advanced lung cancer that may have otherwise been missed. Download and read this edition to get a simple and meaningful overview of how science, technology, and patient care are coming together to shape the future of oncology. Download Newsletter


- Published: 2025-12-18
- Modified: 2025-12-18
- URL: https://1cell.ai/beyond-the-hype-the-real-bottlenecks-in-breast-cancer-innovation/
- Categories: Expert Insights

A Deep Dive into the Current Landscape of SERDs, ADCs, and Precision Oncology The pace of breast cancer drug development has never been faster. From the practice-changing durability of oral selective estrogen receptor degraders (SERDs) to the increasingly crowded post-CDK4/6 landscape, the therapeutic arsenal continues to expand at a remarkable rate. Yet, a critical gap is widening: while therapies are becoming more sophisticated, our ability to reliably select the right patient for the right therapy at the right time is lagging. An analysis of the recent clinical trial readouts, coupled with insights from ongoing field discussions, reveals a consistent pattern: therapeutic innovation is outpacing precision stratification. Below is our in-depth assessment of where the field currently stands and where the most consequential gaps remain. 1. The Oral SERD Revolution: Breaking the 6-Month PFS Barrier For the first time, the field has surpassed the long-standing ~6-month progression-free survival (PFS) ceiling in the second-line setting for patients with HR+/HER2-, ESR1-mutated metastatic breast cancer (mBC) following CDK4/6 and aromatase inhibitors. The New Standard: Oral SERDs are rapidly establishing themselves as practice-changing therapies. Elacestrant (Stemline) and the recently approved Imlunestrant (Lilly) are leading the charge. Emerging Powerhouses: Momentum continues to build as next-generation demonstrate increasing durability. Vepdegestrant (Arvinas/Pfizer) and Giredestrant (Genentech) have shown particularly compelling results, with Giredestrant demonstrating a PFS exceeding 10 months in ESR1-mutated patients. Moving to First-Line? Camizestrant (AstraZeneca) has shown a safety and efficacy profile that suggests potential utility in the first-line setting for ESR1-mutated populations. The Takeaways:  As these...


- Published: 2025-11-03
- Modified: 2026-07-01
- URL: https://1cell.ai/ctcs-as-prognostic-markers-in-oral-squamous-cell-carcinoma-2/
- Categories: India, Publications
- Tags: India

When Blood Can’t See It: CSF Can For patients with EGFR-mutant non-small cell lung cancer (NSCLC) who develop leptomeningeal metastases, the blood-brain barrier isn’t just a clinical obstacle, it’s a diagnostic one. Circulating tumour DNA shed by CNS lesions often fails to cross into peripheral blood, leaving conventional liquid biopsy blind to the very drivers causing the most devastating disease progression. This case report demonstrates how cerebrospinal fluid (CSF)-based NGS sequencing, combined with live single circulating tumour cell (sCTC) isolation, can reveal what blood alone cannot, and change the course of treatment. The Patient A 64-year-old non-smoking female presented in December 2020 with metastatic EGFR-mutant lung adenocarcinoma harbouring an EGFR Exon 19 deletion. She was started on Osimertinib per FLAURA trial guidelines and achieved a complete metabolic response lasting nearly two years. After disease progression and several treatment modifications; including SBRT, gefitinib, and a platinum doublet, she developed leptomeningeal disease in May 2024. Blood-based liquid biopsy at this point showed no actionable information. CSF profiling was the only path forward. What CSF Sequencing Revealed Using 1Cell. ai’s OncoIncytes™ platform for live sCTC isolation and OncoIndx® 1080-gene panel for comprehensive genomic profiling, CSF analysis uncovered a dual-driver profile invisible in plasma: EGFR Exon 19 deletion at 92% variant allele fraction, confirming continued EGFR dependency in the CNS compartment ERBB2 amplification at 21 copies; a bypass resistance mechanism entirely absent in matched blood samples TP53 co-mutations further characterising the tumour’s evolving genomic landscape These findings directly guided a combination therapy strategy: osimertinib...


- Published: 2025-10-14
- Modified: 2025-10-14
- URL: https://1cell.ai/1cell-ai-partners-with-accugenomics-to-expand-ultra-sensitive-liquid-biopsy-testing-across-asia/
- Categories: India, Press Releases, Press Releases

Strategic collaboration aims to advance early cancer detection and precision oncology through AI-powered liquid biopsy solutions   1Cell. Ai has announced a strategic partnership with AccuGenomics to expand access to ultra-sensitive liquid biopsy testing across Asia. This collaboration combines advanced genomic diagnostics with artificial intelligence to enable earlier detection of cancer and more precise treatment monitoring.   Through this partnership, AccuGenomics will leverage 1Cell. Ai’s proprietary AI-driven analytical capabilities to enhance the sensitivity and accuracy of circulating tumor DNA (ctDNA) detection. The integration of these technologies is expected to significantly improve the identification of minimal residual disease (MRD) and enable real-time tracking of tumor dynamics.   Liquid biopsy has emerged as a transformative approach in precision oncology, offering a non-invasive alternative to traditional tissue biopsies. By detecting tumor-derived genetic material in blood samples, clinicians can make faster, more informed decisions regarding diagnosis, prognosis, and treatment strategies. The addition of AI-driven insights further strengthens the clinical utility of these tests by uncovering patterns that may otherwise go undetected.   The collaboration will initially focus on expanding access to advanced liquid biopsy solutions across key Asian markets, with plans to scale into additional regions, including the United States. By combining regional expertise in diagnostics with cutting-edge AI infrastructure, the partnership aims to bridge gaps in cancer detection and bring next-generation technologies closer to patients and healthcare providers.   Leaders from both organizations emphasized the importance of this collaboration in accelerating innovation within oncology. The partnership reflects a shared commitment to improving patient outcomes through early detection, personalized treatment strategies, and continuous disease monitoring.   About 1Cell. Ai  1Cell. Ai is a precision oncology...


- Published: 2025-10-13
- Modified: 2025-10-13
- URL: https://1cell.ai/accugenomics-and-1cell-ai-partner-to-bring-ultra-sensitive-liquid-biopsy-testing-across-asia-with-plans-for-u-s-expansion/
- Categories: Press Releases

Collaboration integrates per-sample NGS internal standards with multi-omic precision oncology platform to enhance cancer diagnostics accuracy and access WILMINGTON, N. C. and MUMBAI, India, Oct. 13, 2025 /PRNewswire/ -- AccuGenomics, Inc. , a US-based leader in next-generation sequencing (NGS) quality standards, and 1Cell. Ai, a US-based precision oncology company specializing in single-cell and liquid biopsy diagnostics, today announced a strategic collaboration to deliver ultra-sensitive, clinically actionable liquid biopsy testing through their clinical laboratory in India serving cancer patients across Asia. Under this partnership, 1Cell. Ai will integrate AccuGenomics' Accukit™ CRC/NSCLC Internal Standards into its ultra-sensitive NGS-based OncoIndx panel to provide per-sample quality control and sensitivity verification. The company expects to process tens of thousands of patient samples in the next year, significantly increasing access to high-precision cancer testing across Asia. 1Cell. Ai also plans to introduce this assay at its Foster City, California facility to support precision multi-omic testing for the United States market soon. The Accukit™ CRC/NSCLC Internal Standards are synthetic, gene-specific quality controls that validate assay performance and ensure sensitivity for detecting clinically relevant mutations in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). By embedding internal standards within every patient sample tested, laboratories can confirm per-sample analytical accuracy, improve reproducibility, and reduce false negatives, a critical advancement in clinical NGS testing where small-variant detection directly influences patient management and therapeutic decisions. "We are thrilled to partner with 1Cell. Ai, a leader in multi-omic precision diagnostics," said Nick Lazaridis, President of AccuGenomics. "By integrating our Accukit™ CRC/NSCLC Internal Standards...


- Published: 2025-10-13
- Modified: 2025-10-13
- URL: https://1cell.ai/join-us-at-esmo-2025/
- Categories: Events

Poster ePostersOur team will share new data across multiple tumor types using AI-powered single cell analysis. Presentation 840P: Circulating biomarkers in colorectal cancer Presentation 2040eP: SWI/SNF mutations in metastatic lung cancer Presentation 264eP: Live single circulating tumor cells in prostate cancer Explore Our Full Lineup at ESMO


- Published: 2025-10-13
- Modified: 2025-10-28
- URL: https://1cell.ai/islb-2025-orlando-fl-november-1-3/
- Categories: Events

Booth #307 - Learn how live single circulating tumor cell capture is redefining biomarker discovery and precision oncology. Poster PresentationPP. 36: (111) — ctDNA clearance of epigenetic regulators and HRR mutations predicts immunotherapy response in advanced head and neck cancer Available: November 1, 10:00 AM – November 3, 10:00 AM Meet Us at ISLB


- Published: 2025-10-13
- Modified: 2025-10-13
- URL: https://1cell.ai/world-adc-san-diego-ca-november-5-6/
- Categories: Events

Booth #86 - See how 1Cell. Ai technology supports translational research and biomarker validation for next-generation ADC programs. Visit Us at World ADC


- Published: 2025-10-13
- Modified: 2025-10-13
- URL: https://1cell.ai/sabcs-san-antonio-tx-december-9-12/
- Categories: Events

Booth #1446 - Discover our latest breast cancer research and AI-driven insights shaping precision oncology. Plan Your Visit to SABCS


- Published: 2025-06-20
- Modified: 2026-06-15
- URL: https://1cell.ai/live-ctc-genomic-profile-pik3ca-hrr-breast/
- Categories: India, Publications

Genomic profiling of true live single circulating tumor cells (CTCs) identified significant enrichment of PIK3CA mutations and homologous recombination repair (HRR) pathway alterations in breast cancer patients. The study demonstrates the ability of single-cell CTC genomics to detect clinically actionable mutations that may influence targeted therapy decisions and precision oncology strategies. Single-cell sequencing of circulating tumor cells revealed substantial intra-patient tumor heterogeneity, highlighting genetic diversity among tumor cell populations that may contribute to therapy resistance. Many of these molecular alterations were not fully captured by conventional bulk tumor tissue sequencing, emphasizing the advantage of single-cell liquid biopsy approaches. Detection of PIK3CA mutations through CTC analysis may inform the use of targeted therapies such as PI3K pathway inhibitors in appropriate patient populations. Identification of HRR pathway alterations provides potential insights into DNA damage response deficiencies, which may guide treatment strategies involving PARP inhibitors or other DNA repair–targeting therapies. High-resolution CTC-based single-cell genomics enables better understanding of tumor evolution, clonal diversity, and metastatic potential in breast cancer. Overall, liquid biopsy–driven single-cell molecular profiling offers a powerful non-invasive approach to support precision oncology, biomarker discovery, and personalized treatment planning in breast cancer. (Read Abstract)


- Published: 2025-06-19
- Modified: 2026-06-15
- URL: https://1cell.ai/ai-hrd-prediction-histopathology-breast-ovarian-cancer/
- Categories: India, Publications
- Tags: Breast Cancer, OncoPredikt, Ovarian Cancer, Poster

AI-driven HRD biomarker prediction using OncoPredikt® deep learning inference engine trained on 1,892 whole slide images (WSIs) from TCGA datasets, split into 80/10/10 train-validation-test sets ResNet50 deep learning model processes H&E-stained diagnostic slides via 256×256 tile segmentation and quality control, eliminating need for expensive multi-technique HRD testing (~USD 4,000) HRD aggregate score derived from loss of heterozygosity (LOH), large-scale genomic instability, and telomeric allelic imbalance — validated against BRCA1/2 and HRR gene status 99. 3% accuracy, 100% sensitivity, and 99% specificity achieved on 120 external Ambry Genetics WSIs, with ROC/AUC = 1. 00 demonstrated on receiver operating characteristic curve Sample-level prediction table shows consistent concordance between standard HRD results and AI predictions across 10 patient samples with turnaround times of 2. 5–6. 4 minutes Clinical advantage over conventional HRD testing: faster, affordable, operable on limited tissue samples, directly applicable to routine diagnostic H&E slides for PARP inhibitor patient selection (Read Abstract)


- Published: 2025-05-28
- Modified: 2025-05-28
- URL: https://1cell.ai/1cell-ai-completes-clia-validation-study-of-oncoincytes-1080-gene-ngs-panel/
- Categories: Press Releases
- Tags: US

FOSTER CITY, Calif. , May 28, 2025 /PRNewswire/ -- 1Cell. Ai, a precision oncology company developing advanced cell and molecular profiling platforms, announced the successful completion of a CLIA-grade analytical validation study of its OncoIncytes 1080-gene NGS panel and proprietary iCare™ informatics pipeline at the Georgia Cancer Centre's GEM Lab. The study was led by Dr.  Ravindra Kolhe, Professor and Chair of Pathology and Associate Director for Genomics at the Georgia Cancer Center, and a recognized authority in translational genomics. The OncoIncytes panel demonstrated high concordance with FDA approved orthogonal NGS platforms and consistent performance across FFPE, blood, and bone marrow samples spanning over 15 tumor types. "Our goal was to rigorously validate the OncoIncytes 1080-gene NGS panel across a broad spectrum of cancers and sample types," said Dr.  Ravindra Kolhe. "The panel met all key performance thresholds set by CAP and AMP guidelines and is well-suited to support molecular profiling in research and clinical trial settings. " The OncoIncytes 1080-gene NGS panel interrogates SNVs, CNVs, indels, fusions, and splice variants across key cancer genes. Combined with the AI-assisted iCare™ pipeline, the system provides scalable variant classification and interpretation across diverse cancer types, including lung, breast, GI, ovarian, and CNS malignancies. "This milestone enables the translational use of OncoIncytes 1080-gene NGS panel in exploratory biomarker discovery and patient stratification efforts," said Dr.  Gowhar Shafi, Chief Medical Geneticist at 1Cell. Ai. "Further, our ability to evaluate multi-omic signatures on single live CTCs offers unmatched granularity for oncology research. " The 1080-gene NGS panel is...


- Published: 2025-05-23
- Modified: 2025-05-27
- URL: https://1cell.ai/1cell-ai-formerly-onecell-diagnostics-launches-oncoincytes-integrating-multi-modal-data-for-precision-oncology-2/
- Categories: India, Press Releases
- Tags: India

AI-powered precision oncology leader to enhance early-stage clinical studies with the introduction of next-generation technology Foster City, CA. & Mumbai, India (April 22, 2025) – OneCell Diagnostics today announced its launch of OncoIncytes, a comprehensive multi-modal cancer diagnostic panel that integrates multiple types of data including Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) at single cell resolution, RNA transcriptomics and Proteomics (150 proteins at the single cell level). Marking its evolution from a genomics-based diagnostic company to an AI-powered leader in precision oncology, the firm is also rebranding as 1Cell. Ai, focused on combining its deep science expertise with advanced data science capabilities. "By integrating true single cell level multi-omics data with ctDNA, OncoIncytes provides unparalleled information to oncologists that enhances critical clinical decisions,” said Mohan Uttarwar, CEO and co-founder of 1Cell. Ai. “This approach offers unprecedented sensitivity and specificity to optimize clinical trial successes, particularly in early-stage research. For antibody-drug conjugate studies, this represents a unique way to select the most appropriate patients, and address one of the most significant challenges in translational research. " OncoIncytes’ technology employs a 1080 gene panel and leverages artificial intelligence and machine learning models to deliver deeper insights into clinical decision-making. Its primary innovation enables pharmaceutical and biotech companies to advance antibody-drug conjugates (ADCs) development during early-stage clinical studies by detecting protein expression on cell surfaces that other liquid biopsy tests cannot identify. The technology is transforming cancer research, drug development, patient selection, and therapy response monitoring with unprecedented granularity. Healthcare providers...


- Published: 2025-05-23
- Modified: 2025-05-27
- URL: https://1cell.ai/1cell-ai-featured-in-the-journal-of-liquid-biopsy/
- Categories: India, Press Releases
- Tags: India

Advancing the Science of ctDNA and CTC-Based Diagnostics Across Cancer Types We’re proud to be featured in five recent publications in the Journal of Liquid Biopsy, the official journal of the International Society of Liquid Biopsy (ISLB). These peer-reviewed studies highlight 1Cell. Ai’s growing impact in translational cancer research and innovation in liquid biopsy-based precision diagnostics. Each study leverages ctDNA or CTC analysis to uncover critical biomarkers linked to resistance, metastasis, and real-time tumor monitoring across multiple cancers. 1. Early-Stage Breast Cancer: Broader Mutation Detection with ctDNA ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients. Read Full Publication 2. CTC Movement Post-Radiotherapy in Pan-Cancer Patients Transit of Circulating Tumor Cells (CTC) POST radiotherapy at irradiated tumor regions in pan-cancer patients. Read Full Publication 3. EGFR Mutations & Resistance in Lung Cancer Downstream effector mutations indicate potential tyrosine kinase inhibitor resistance in EGFR mutated lung cancer patients. Read Full Publication 4. PD-L1 Expression on CTCs in Pancreatic Cancer Expression of programmed death-ligand 1 as a dynamic biomarker on circulating tumor cells in pancreatic cancer patients. Read Full Publication 5. ctDNA + CTC Analysis Correlated with PET Imaging Comprehensive analysis of ctDNA and CTCs reveals resistance signatures and correlations with PET scan outcomes in cancer patients. Read Full Publication These studies reflect 1Cell. Ai’s continued mission to accelerate cancer detection, personalize treatment strategies, and power data-driven oncology through AI, liquid biopsy, and single-cell innovation.


- Published: 2025-05-23
- Modified: 2025-05-27
- URL: https://1cell.ai/islb-annual-congress-2024-3/
- Categories: Events, India
- Tags: India

Join us as we look back on an incredible gathering of scientists, clinicians, and innovators shaping the future of cancer care. Hosted in Denver, this event showcased 1Cell. Ai’s latest breakthroughs in AI, single-cell technology, and multi-omics diagnostics—all built to drive real-world impact across the oncology ecosystem. Venue: Denver, Colorado, USA Date: 23-25 November, 2024 https://youtu. be/MzP8334l-KE


- Published: 2025-05-23
- Modified: 2025-05-27
- URL: https://1cell.ai/join-us-at-medlab-asia-2024-2/
- Categories: Events, India
- Tags: India

Expanding Access to Precision Diagnostics in Asia 1Cell. Ai was proud to participate in Medlab Asia 2024, where we showcased our latest advances in AI-driven diagnostics and single-cell technology. Held in Bangkok, the event brought together leading voices in laboratory medicine and innovation across the region. Venue: Queen Sirikit National Convention Center – BangkokDate: July 10–12, 2024 https://youtu. be/e0iMsh09WnA


- Published: 2025-05-23
- Modified: 2025-05-27
- URL: https://1cell.ai/oncology-think-tank-conclave-delhi-2/
- Categories: Events, India
- Tags: India

Collaborating to Shape the Future of Cancer Care At the 2024 Oncology Think Tank Conclave in Delhi, 1Cell. Ai joined top clinicians, researchers, and industry leaders for a high-impact exchange on the future of precision oncology in India. From emerging technologies to clinical integration, the discussions set the tone for innovation and collaboration in cancer diagnostics. Venue: New Delhi, IndiaDate: June 1, 2024 https://youtu. be/uW_RI2fP6z0


- Published: 2025-05-23
- Modified: 2025-05-27
- URL: https://1cell.ai/artificial-intelligence-redefining-patients-eligibility-for-immunotherapy-2/
- Categories: Expert Insights, India
- Tags: India

Watch Now: Dr. Gowhar Shafi at Indian Cancer Congress 2023 Artificial Intelligence Redefining Patient Eligibility for Immunotherapy Hear from Dr. Gowhar Shafi as he presents at the 3rd Indian Cancer Congress 2023, exploring how AI is transforming patient selection for immunotherapy. In this talk, Dr. Shafi discusses how advanced AI-driven analysis is enabling more precise, personalized eligibility assessments—ensuring the right patients receive the right treatments at the right time. https://youtu. be/zhF7F7Ok_zc


- Published: 2025-05-23
- Modified: 2025-05-27
- URL: https://1cell.ai/ai-based-prediction-of-homologous-recombination-deficiency-hrd-2/
- Categories: India, Publications
- Tags: India

Published in Journal of Clinical Oncology, 2022 | Abstract #3019, ASCO This study showcases the use of artificial intelligence (AI) to predict homologous recombination deficiency (HRD) directly from histopathology images. The research demonstrates the potential of AI-enabled image analysis to serve as a non-invasive, rapid screening tool for HRD status—helping guide treatment decisions in oncology with greater speed and scalability. Authors: Gowhar Shafi, Shivamurthy P M, Anand Ulle, Krithika Srinivasan, Aravindan Vasudevan, Vikas Jadhav, Sujit Joshi, Nirmal Vivek Raut, Jayant Khandare, Mohan Uttarwar, Kenneth Joel Bloom. Read Full Abstract on ASCO


- Published: 2025-05-23
- Modified: 2025-05-23
- URL: https://1cell.ai/oncoindx-ai-powered-genomic-profiling-for-precision-oncology-2-2/
- Categories: India, White Papers
- Tags: Clinical, India, Multi-omics

Some cancers are passed down through families, and knowing your genetic risk early can make all the difference. OncoRisk® by 1Cell. Ai is a comprehensive germline test that analyzes 74 genes linked to more than 11 hereditary and familial cancers, including breast, ovarian, colorectal, prostate, and lung cancer. Using next-generation sequencing and AI-powered reporting, it helps identify individuals who carry inherited mutations before cancer even develops. For oncologists, OncoRisk® provides clinically actionable insights to guide personalized screening plans, preventive surgeries, and treatment decisions. For patients and their families, it offers clarity, allowing them to understand their inherited risk and take proactive steps toward their health. The test also supports cascade testing, meaning at-risk family members can be evaluated using the same findings. Download the OncoRisk® WhitePaper to explore the science behind the test, the clinical evidence supporting its use, and how it can be integrated into your care journey. Whether you are a clinician or someone concerned about your family history, this whitepaper is your guide to making informed decisions about hereditary cancer risk. Download OncoRisk WhitePaper


- Published: 2025-05-21
- Modified: 2025-05-28
- URL: https://1cell.ai/aacr-2024-san-diego-2/
- Categories: Events, India
- Tags: India

Pioneering the Future of Translational Cancer Research At AACR 2024, 1Cell. Ai showcased how AI, live-cell analytics, and multi-omics platforms are accelerating translational cancer research. From engaging scientific discussions to meaningful collaborations, our presence in San Diego marked a bold step forward in redefining what's possible in oncology. Venue: San Diego, California, USADate: April 5–10, 2024


- Published: 2025-05-07
- Modified: 2026-06-15
- URL: https://1cell.ai/effect-of-cell-proliferation-pathway-on-accessibility-to-targeted-therapeutics-in-the-spectrum-of-co-occurring-prognostic-cellular-pathways-in-pan-cancers/
- Categories: India, Publications

The Promise and the Complexity- of Targeted Therapy Targeted therapies represent one of the greatest advances in modern oncology, offering the potential to attack cancer with precision, minimise side effects, and overcome drug resistance that conventional chemotherapy cannot address. But realising that potential depends on one critical prerequisite: understanding which cellular pathways are driving a patient’s cancer, and how those pathways interact with each other. This study investigates exactly that: mapping the landscape of co-occurring prognostic cellular pathways across multiple cancer types to identify how cell proliferation alterations interact with other pathway abnormalities, and what that means for targeted therapy selection. Our Study: 82 Pan-Cancer Patients Across 12 Tumour Types In a retrospective analysis of 82 pan-cancer patients spanning 12 tumour types, including breast, colorectal, endometrial, gall bladder, gastric, head and neck, lung, melanoma, ovarian, pancreatic, prostate, and urothelial cancers; comprehensive genomic profiling was performed using our OncoIndx NGS assay to map the distribution and co-occurrence of key cellular pathways. The pathways interrogated included cell proliferation, cell progression, double-strand DNA (dsDNA) repair, mismatch repair (MMR), tumour suppression, and cell signalling; providing a comprehensive, multi-pathway view of each patient’s tumour biology. What the Genomic Landscape Revealed Across the full cohort, 99 genomic alterations were detected and mapped to their respective cellular pathways: Cell proliferation pathway alterations were the most frequent; accounting for 43 mutations in 34. 14% of patients; establishing this pathway as the dominant driver of oncogenic activity across the pan-cancer cohort Tumour suppressor gene alterations were equally prevalent, identified...


- Published: 2025-05-07
- Modified: 2026-06-15
- URL: https://1cell.ai/mutational-spectrum-of-cell-proliferation-genes-as-early-predictive-markers-for-aggressive-disease-in-endometrial-cancers/
- Categories: India, Publications

The Challenge of Predicting Aggressiveness in Endometrial Cancer Endometrial cancer is one of the most molecularly heterogeneous malignancies in oncology. Its four recognised molecular subtypes, defined by replicative polymerase mutations, microsatellite stability, copy number high/serous-like profiles, and microsatellite instability, reflect a diverse landscape of genomic aberrations that drive vastly different clinical behaviours. Yet despite this complexity, predicting which patients will develop aggressive, progressive, or metastatic disease remains one of the most difficult challenges in endometrial cancer management. Conventional clinical and pathological assessments often fall short of capturing the full molecular picture, leaving oncologists without the precision they need to make early, proactive treatment decisions. This study demonstrates how comprehensive genomic profiling using our OncoIndx CGP assay can bridge that gap:- mapping the mutational landscape of endometrial cancer and establishing clear molecular correlates of disease aggressiveness. Our Study: 40 Endometrial Cancer Patients In a retrospective analysis of 40 endometrial cancer patients, we investigated the association between comprehensive genomic mutational profiles generated using our OncoIndx CGP assay; and clinical disease status determined from PET scans and histopathological examination (HPE) reports. This dual-evidence approach allowed us to directly correlate molecular findings with clinical disease behaviour; establishing whether specific genomic pathway alterations could serve as early predictors of progression and metastasis. What We Found The findings reveal a clear and clinically significant relationship between genomic pathway alterations and disease aggressiveness in endometrial cancer: 65% of patients (n=26/40) had progressive or metastatic disease confirmed by PET scans and HPE, reflecting the high prevalence of aggressive...


- Published: 2025-05-06
- Modified: 2026-06-15
- URL: https://1cell.ai/circulating-tumor-cells-and-clusters-exhibiting-pd-l1-expression-in-colorectal-cancer-patients/
- Categories: India, Publications

A Gap in Colorectal Cancer Surveillance  Colorectal cancer (CRC) is one of the most common and deadly cancers worldwide and yet, some of the most critical clinical questions in its management remain unanswered by current diagnostic tools. After surgery with curative intent, how do we know if residual disease remains?   During treatment, how do we assess whether therapy is truly working? After remission, how do we detect recurrence at its earliest, most treatable stage?   Conventional imaging and tissue biopsy are simply not equipped to answer these questions in real time. This study makes the case for a more powerful approach: CTC-based PD-L1 profiling as a dynamic surveillance tool in colorectal cancer patients.   The Clinical Significance of PD-L1 on CTCs in Colorectal Cancer  When tumour cells overexpress PD-L1 on their surface, they gain the ability to evade immune elimination, effectively cloaking themselves from the body's T cell defences and establishing dormancy in circulation. In the context of colorectal cancer, this has two critical implications.   First, PD-L1-positive CTCs may signal incomplete tumour resection indicating that residual disease remains even when surgical margins appear clear.  Second, their presence in circulation, particularly in early-stage or post-treatment patients may reveal cell dormancy that conventional monitoring would entirely miss, until the cancer returns at an advanced stage.   Our Study: 666 Colorectal Cancer Patients  In a retrospective analysis of 666 colorectal cancer patients (63. 06% male, 36. 94% female) spanning early to late-stage disease, peripheral blood samples were analysed for CTC presence, CTC clusters, and PD-L1 expression using the CDSCO-approved OncoDiscover platform, processing just 1. 5 mL of blood per...


- Published: 2025-05-06
- Modified: 2026-06-15
- URL: https://1cell.ai/ctdna-based-clinicogenomic-analysis-of-advanced-head-and-neck-cancer-patients-treated-with-immune-checkpoint-inhibitors/
- Categories: India, Publications

A Cancer With an Urgent Unmet Need  Head and Neck Cancer (HNC) is the most prevalent malignancy in Southeast Asia and one of the most devastating. Despite significant advances in treatment, the five-year survival rate for HNC remains below 50%, and the majority of patients receiving frontline therapy eventually experience locoregional or incurable metastatic relapse.   For relapsed patients, Immune Checkpoint Inhibitors (ICIs) represent one of the most promising treatment avenues available. But there is a critical problem; only 20% of patients treated with ICIs show a measurable response. The remaining 80% are exposed to a treatment that will not work for them, while losing precious time and experiencing significant side effects. And today, there are no validated predictive biomarkers to tell oncologists in advance who will respond and who will not.   This study set out to change that using comprehensive ctDNA genomic profiling to identify the genomic markers that predict ICI response and resistance in advanced HNC patients.   Our Approach: Serial ctDNA Profiling with OncoIndx  We serially profiled ctDNA from 69 advanced HNC patients receiving combinational immune-chemotherapy, capturing genomic snapshots at both baseline (BL) and post-treatment (Tx) using our OncoIndx 1080-gene hybrid capture CGP panel. This longitudinal design allowed us to track how the tumour’s genomic landscape evolved in response to treatment and to identify the molecular features that separated responders from non-responders.   Genomic findings were correlated with Progression-Free Survival (PFS) and Overall Survival (OS) using Kaplan-Meier statistics and multivariate analysis:- the gold standard for establishing the clinical significance of biomarkers in oncology.   Striking Findings With Direct Clinical Implications  The results of this study are among the most clinically significant we have generated in head and neck cancer to date:  58% of patients (n=40/69)...


- Published: 2025-05-05
- Modified: 2026-06-15
- URL: https://1cell.ai/using-a-dynamic-blood-flow-device-with-affinity-ligands-to-capture-circulating-tumor-cells-in-cancer-patients/
- Categories: India, Publications

The Challenge We Set Out to Solve  Metastasis: the spread of cancer from its primary site to distant organs accounts for a staggering 90% of all cancer-related deaths. At the heart of this process are Circulating Tumor Cells (CTCs): rare cells shed by primary tumours into the bloodstream that act as the seeds of metastatic spread. Capturing and reducing these cells from circulation represents one of the most promising and underexplored frontiers in oncology.   This study demonstrates a novel approach to doing exactly that:- using a specially designed dynamic blood flow device to selectively capture CTCs directly from a patient’s blood.   The OncoDialysis Assay and Our 3D Glass Substrate Device  Our team designed a bi-spiral, plano-horizontal, optically transparent blood circulation device fabricated using a 3D printer with biocompatible resin, featuring multiple channels for continuous blood flow. The device holds 17. 5 mL of blood across 14 loops and contains 680 glass substrates (2mm diameter) conjugated with two highly specific affinity ligands:  Anti-EpCAM antibody: targeting the Epithelial Cell Adhesion Molecule expressed on the surface of epithelial-origin CTCs  Transferrin (Tf) protein: a complementary ligand that enhances capture specificity and sensitivity  Three pumps mechanise continuous blood circulation through the device, and the entire system was evaluated for systemic toxicity and pyrogenicity in a rigorous ISO:10993-11 animal safety study in New Zealand White rabbits - with all animals remaining healthy and showing no adverse temperature responses throughout.   What We Found  The study processed 27 blood samples from patients with early and late-stage cancers across 9 cancer types, including colorectal, lung, breast, and ovarian cancers.   The OncoDialysis assay successfully captured CTCs in 48. 15% of patients (n=13/27), isolating a total of 14 CTCs, including 12...


- Published: 2025-05-05
- Modified: 2025-05-05
- URL: https://1cell.ai/circulating-tumor-cell-distribution-and-pd-l1-expression-across-cancer-types-insights-from-5935-patients/
- Categories: Uncategorized

Presented by Jayant Khandare, PhD | Actorius Innovations and Research | Publication Only: Developmental Therapeutics:- Immunotherapy  The Largest CTC Study of Its Kind in the Indian Population  India’s diverse genetic landscape and unique cancer incidence patterns make it one of the most important and most underrepresented populations in global oncology research. Common cancers in India span a wide spectrum: head and neck, lung, breast, colorectal, prostate, ovarian, and gastrointestinal cancers; and the clinical behaviour of these cancers in the Indian population is shaped by genetic, environmental, and demographic factors that are not fully captured by Western datasets.   This retrospective study: one of the largest CTC analyses ever conducted in the Indian cancer patient population, sought to change that, analysing CTC distribution and PD-L1 expression across 5,935 patients to generate real-world insights that can directly inform personalised cancer management strategies.   How We Did It  All blood samples were processed using the CDSCO-approved OncoDiscover platform: analysing just 1. 5 mL of peripheral blood per patient using a multifunctional magnetonanosystem mediated by anti-EpCAM antibody. CTCs were confirmed using a stringent four-marker validation protocol: EpCAM+ve, CK18+ve, DAPI+ve, and CD45-ve, ensuring only true epithelial-origin tumour cells were counted.   PD-L1 expression on captured CTCs was evaluated using linear fluorescence intensity gradients and automated image acquisition on a Zeiss Microscope enabling precise, objective quantification of immune checkpoint marker expression at the single-cell level.   An advanced computational model was also developed to evaluate CTC frequency, mean distribution, regression analysis, and normal probability plots, enabling predictive insights into CTC numbers across cancer types, patient age, disease stage, and gender.   What the Data Revealed  The findings from this...


- Published: 2025-05-05
- Modified: 2026-06-15
- URL: https://1cell.ai/pd-l1-expression-on-circulating-tumor-cells-and-ctc-clusters-as-minimal-cellular-residual-disease-in-breast-cancer-patients/
- Categories: India, Publications

Beyond the Scan: What Imaging Cannot Tell Us  A patient completes surgery for breast cancer. Their imaging looks clear. Their oncologist is cautiously optimistic. But somewhere in their bloodstream, microscopic tumour cells may still be circulating: invisible to radiology, yet capable of driving future metastasis. This is the clinical reality of Minimal Cellular Residual Disease (MCRD), and it is one of the most pressing unsolved challenges in breast cancer management.   This study explores a powerful approach to detecting MCRD in breast cancer patients by measuring PD-L1 expression on Circulating Tumor Cells (CTCs) as a dynamic, real-time biomarker of immune evasion and metastatic risk.   Why PD-L1 on CTCs Matters  PD-L1 is well established as an immune checkpoint marker in tissue biopsies, its expression informing immunotherapy eligibility and predicting treatment response. But tissue-based PD-L1 assessment captures only a static snapshot of tumour biology at a single point in time.    CTCs, by contrast, are dynamic, shed continuously by the tumour into the bloodstream and reflective of the tumour's real-time biological state.   When CTCs overexpress PD-L1, the implications are profound.    PD-L1-positive CTCs can deactivate immune T cells in circulation, effectively shielding themselves from immune elimination and enabling the cascade of micro-metastasis to proceed unchecked. Measuring PD-L1 expression on CTCs therefore offers a window into the tumour's immune evasion strategy that tissue biopsy simply cannot provide.   Our Study: 1,294 Breast Cancer Patients  In a retrospective analysis of 1,294 breast cancer patients spanning early to late-stage disease, peripheral blood samples were analysed for CTC presence, CTC clusters, and PD-L1 expression using the CDSCO-approved OncoDiscover platform: processing just 1. 5 mL of blood...


- Published: 2025-05-05
- Modified: 2026-07-19
- URL: https://1cell.ai/trinity-ai-genomics-grade-breast-cancer-recurrence-stratification-directly-from-he-images-no-sequencing-required/
- Categories: India, Publications

The Problem That Millions of Patients Face Every Day Every year, thousands of women diagnosed with early-stage breast cancer face a critical question after surgery: Do I need chemotherapy? Genomic assays like Oncotype DX and MammaPrint are the gold standard for answering that question -analysing the biology of the tumour to predict recurrence risk and guide chemotherapy decisions with a level of precision that clinico-pathological factors alone cannot provide. But there is a profound problem. These tests are expensive, require specialised sequencing infrastructure, and have long turnaround times. For patients in low- and middle-income settings, including large parts of India and the developing world - they are simply out of reach. Thousands of women either forego the test entirely or make chemotherapy decisions without the genomic guidance that could spare them unnecessary treatment or catch them before it's too late. At 1Cell. Ai, we set out to solve this. The result is TRINITY AI. Introducing TRINITY AI - Precision Oncology From a Standard Slide TRINITY AI is our proprietary multimodal deep-learning platform that delivers genomics-grade breast cancer recurrence stratification directly from a standard H&E-stained tissue slide- the most universally available diagnostic tool in pathology, present in virtually every hospital in the world. No sequencing. No additional infrastructure. No weeks of waiting. TRINITY AI integrates three powerful data streams simultaneously: Tissue morphology: extracted from digitised H&E whole-slide images using a self-supervised transformer foundation model AI-inferred transcriptomic signatures: gene expression patterns predicted directly from the H&E image, without any sequencing Clinical variables:...


- Published: 2025-04-30
- Modified: 2026-06-16
- URL: https://1cell.ai/single-circulating-tumor-cell-multi-omics-assay/
- Categories: India, Publications

Highlights a live single circulating tumor cell (sCTC) capture assay for contamination-free cancer cell isolation. Demonstrates multi-omics profiling using isolated circulating tumor cells for genomic and molecular analysis. Showcases mutation detection and analytical validation for precision oncology applications. Presents liquid biopsy capabilities for identifying tumor biomarkers across multiple cancer types. Features single-cell genomic profiling to support cancer research and personalized treatment strategies. Includes comparative analysis between sCTCs and ctDNA for improved cancer diagnostics. Emphasizes the role of AI-powered precision oncology in advancing tumor heterogeneity assessment. Illustrates a novel platform for non-invasive cancer monitoring, biomarker discovery, and targeted therapy insights. Read Abstract


- Published: 2025-04-30
- Modified: 2025-04-30
- URL: https://1cell.ai/2025-asco-annual-meeting-3/
- Categories: India, Publications
- Tags: India

1Cell. Ai at ASCO 2025: Explore Our Latest Research We’re excited to share 19 new posters and abstracts at the 2025 ASCO Annual Meeting. Our latest findings highlight the power of single-cell, live-cell, and ctDNA analysis across a range of cancers. Read the abstracts: 1. Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. (Read abstract) 2. Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow up patients across cancer types. (Read abstract) 3. PD-L1 expression on circulating tumor cells and CTC clusters as a minimal cellular disease in breast cancer patients. (Read abstract) 4. Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients. (Read abstract) 5. ctDNA-based clinicogenomic analysis of advanced head and neck cancer patients treated with immune checkpoint inhibitors. (Read abstract) 6. Effect of cell proliferation pathway on accessibility to targeted therapeutics in the spectrum of co-occurring prognostic cellular pathways in pan-cancers. (Read abstract) 7. Mutational spectrum of cell proliferation genes as early predictive markers for aggressive disease in endometrial cancers. (Read abstract) 8. Using live true single-circulating tumor cell comprehensive genomics to show clonal evolution and tumor heterogeneity in pancreatic cancer management. (Read abstract) 9. ctDNA beyond blood: Harnessing pleural effusion circulating tumor DNA for precision lung cancer diagnostics. (Read abstract) 10. Insights into disease progression in endometrial cancers: The role of cell proliferation pathway mutations following adjuvant therapy. (Read abstract) 11. Quadrant of co-occurrence of...


- Published: 2025-04-28
- Modified: 2026-06-16
- URL: https://1cell.ai/live-single-ctc-capture-multiomics-cancer/
- Categories: India, Publications

A novel assay for true live single circulating tumor cell (CTC) capture was developed to isolate individual tumor cells from blood samples with zero leukocyte contamination, enabling ultra-high purity liquid biopsy analysis. The advanced CTC isolation platform preserves viable single tumor cells, allowing accurate downstream molecular characterization while maintaining cellular integrity for research and diagnostic applications. By eliminating background leukocyte contamination, the assay significantly improves the sensitivity and reliability of single-cell genomics and multi-omics profiling compared with conventional CTC capture technologies. The platform supports integrated multi-omics analysis, including genomics, transcriptomics, and proteomics, enabling comprehensive molecular profiling of circulating tumor cells. Scalability of the technology was demonstrated across a large and diverse cancer patient population, highlighting its potential for broad clinical adoption in oncology research and diagnostics. High-purity single-cell CTC isolation enables deeper insights into tumor heterogeneity, clonal evolution, and therapy resistance, which are critical for understanding cancer progression. The technology strengthens liquid biopsy–based disease monitoring, supporting applications such as treatment response evaluation, minimal residual disease detection, and metastatic risk assessment. This next-generation single-CTC capture technology advances precision oncology diagnostics, facilitating biomarker discovery and personalized cancer treatment strategies. (Read Abstract)


- Published: 2025-04-24
- Modified: 2025-05-24
- URL: https://1cell.ai/1cell-ai-and-bioskryb-announce-strategic-partnership-to-advance-single-cell-multi-omics-innovation/
- Categories: Press Releases, US
- Tags: US

FOSTER CITY, Calif.  and DURHAM, N. C. , April 24, 2025 /PRNewswire/ -- 1Cell. Ai, a global leader in single cell precision diagnostics, has joined forces with BioSkryb Genomics, a pioneer in single cell multi-omics, to co-develop and commercialize next-generation single cell multi-omic solutions. This collaboration will empower researchers and clinicians to detect and characterize rare mutations in single cells with unprecedented accuracy, facilitating breakthroughs in cancer research and enabling earlier detection and targeted therapy development. Collaboration DetailsThis partnership merges BioSkryb's single cell amplification and multi-omics chemistry with 1Cell. Ai's OncoIncytes platform, creating a groundbreaking solution for analyzing rare cell populations such as circulating tumor cells (CTCs). With this integrated platform, researchers can now isolate CTCs at 1 in a billion, and characterize DNA, RNA, and protein targets from these individual single cells with unprecedented precision, significantly accelerating the development of advanced therapies, including antibody-drug conjugates (ADCs). Samples will be analyzed at both 1Cell. Ai's CLIA laboratory in Foster City, California, and BioSkryb's services laboratory in Durham, North Carolina. Dr.  James Rothman, Nobel Laureate and Board Member at 1Cell. Ai, remarked: "This collaboration represents a powerful synergy of visionary science and cutting-edge technologies. By integrating BioSkryb's single cell multi-omics chemistry with 1Cell. Ai's capabilities in single cell isolation and multi-omic profiling, we are opening new frontiers in understanding cellular behavior and disease mechanisms at an unprecedented level of clarity. " This partnership addresses critical challenges in oncology research, particularly the need for accurate single cell analysis in developing antibody-drug conjugates (ADCs). The integrated solution has the potential to...


- Published: 2025-04-23
- Modified: 2025-05-27
- URL: https://1cell.ai/join-us-at-aacr-april-25-30-2025-2/
- Categories: Events, India
- Tags: India

Discover how 1Cell. Ai is advancing precision oncology at the intersection of science and technology Our team is leading the way with AI-powered, single cell multi-omic solutions designed to help in patient selection, therapy monitoring and biomarker exploration. Visit us at Booth #202 to learn more about our cutting-edge advancements. Featured Poster Presentation: Explore the latest in live single circulating tumor cell capture and precision oncology breakthroughs. Discover how innovation is redefining the future of oncology care! Explore Our Full Lineup at AACR


- Published: 2025-04-23
- Modified: 2025-05-28
- URL: https://1cell.ai/join-us-europe-launch-dinner-reception-2/
- Categories: Events, India
- Tags: India

Celebrating the Launch of 1Cell. Ai in Europe You're invited to an exclusive evening of connection, conversation, and innovation as we officially introduce 1Cell. Ai to the European oncology community. Join us for a private dinner reception in Barcelona during ESMO 2024. Venue: Barcelona, SpainDate: September 14, 2024 https://youtu. be/FvDn0k-3YPM


- Published: 2025-04-22
- Modified: 2025-05-23
- URL: https://1cell.ai/1cell-ai-formerly-onecell-diagnostics-launches-oncoincytes-integrating-multi-modal-data-for-precision-oncology/
- Categories: Press Releases, US
- Tags: US

AI-powered precision oncology leader to enhance early-stage clinical studies with the introduction of next-generation technology Foster City, CA. & Mumbai, India (April 22, 2025) – OneCell Diagnostics today announced its launch of OncoIncytes, a comprehensive multi-modal cancer diagnostic panel that integrates multiple types of data including Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) at single cell resolution, RNA transcriptomics and Proteomics (150 proteins at the single cell level). Marking its evolution from a genomics-based diagnostic company to an AI-powered leader in precision oncology, the firm is also rebranding as 1Cell. Ai, focused on combining its deep science expertise with advanced data science capabilities. "By integrating true single cell level multi-omics data with ctDNA, OncoIncytes provides unparalleled information to oncologists that enhances critical clinical decisions,” said Mohan Uttarwar, CEO and co-founder of 1Cell. Ai. “This approach offers unprecedented sensitivity and specificity to optimize clinical trial successes, particularly in early-stage research. For antibody-drug conjugate studies, this represents a unique way to select the most appropriate patients, and address one of the most significant challenges in translational research. " OncoIncytes’ technology employs a 1080 gene panel and leverages artificial intelligence and machine learning models to deliver deeper insights into clinical decision-making. Its primary innovation enables pharmaceutical and biotech companies to advance antibody-drug conjugates (ADCs) development during early-stage clinical studies by detecting protein expression on cell surfaces that other liquid biopsy tests cannot identify. The technology is transforming cancer research, drug development, patient selection, and therapy response monitoring with unprecedented granularity. Healthcare providers...


- Published: 2025-04-17
- Modified: 2026-04-14
- URL: https://1cell.ai/join-us-at-aacr-april-25-30-2025/
- Categories: Events, US
- Tags: US

Discover how 1Cell. Ai is advancing precision oncology at the intersection of science and technology Our team is leading the way with AI-powered, single cell multi-omic solutions designed to help in patient selection, therapy monitoring and biomarker exploration. Visit us at Booth #202 to learn more about our cutting-edge advancements. Featured Poster Presentation: Explore the latest in live single circulating tumor cell capture and precision oncology breakthroughs. Discover how innovation is redefining the future of oncology care! Explore Our Full Lineup at AACR


- Published: 2025-04-17
- Modified: 2025-05-23
- URL: https://1cell.ai/ctdna-based-liquid-biopsy-uncovers-broader-mutational-landscape-in-early-stage-breast-cancer/
- Categories: Publications, US
- Tags: US

Advancing the Science of ctDNA and CTC-Based Diagnostics Across Cancer Types We’re proud to be featured in five recent publications in the Journal of Liquid Biopsy, the official journal of the International Society of Liquid Biopsy (ISLB). These peer-reviewed studies highlight 1Cell. Ai’s growing impact in translational cancer research and innovation in liquid biopsy-based precision diagnostics. Each study leverages ctDNA or CTC analysis to uncover critical biomarkers linked to resistance, metastasis, and real-time tumor monitoring across multiple cancers. 1. Early-Stage Breast Cancer: Broader Mutation Detection with ctDNA ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients. Read Full Publication 2. CTC Movement Post-Radiotherapy in Pan-Cancer Patients Transit of Circulating Tumor Cells (CTC) POST radiotherapy at irradiated tumor regions in pan-cancer patients. Read Full Publication 3. EGFR Mutations & Resistance in Lung Cancer Downstream effector mutations indicate potential tyrosine kinase inhibitor resistance in EGFR mutated lung cancer patients. Read Full Publication 4. PD-L1 Expression on CTCs in Pancreatic Cancer Expression of programmed death-ligand 1 as a dynamic biomarker on circulating tumor cells in pancreatic cancer patients. Read Full Publication 5. ctDNA + CTC Analysis Correlated with PET Imaging Comprehensive analysis of ctDNA and CTCs reveals resistance signatures and correlations with PET scan outcomes in cancer patients. Read Full Publication These studies reflect 1Cell. Ai’s continued mission to accelerate cancer detection, personalize treatment strategies, and power data-driven oncology through AI, liquid biopsy, and single-cell innovation.


- Published: 2025-04-17
- Modified: 2025-05-23
- URL: https://1cell.ai/single-cell-genomics-reveals-resistance-signatures-in-colorectal-cancer/
- Categories: Publications, US
- Tags: US

Presented at ESMO Congress 2024 – Barcelona, Spain This abstract highlights how true single-circulating tumor cell (CTC) genomics can identify enriched therapy-resistance signatures in advanced colorectal cancer patients. The findings underscore the potential of single-cell approaches to guide personalized treatment strategies by capturing molecular detail often missed in bulk or ctDNA-based profiling. Read Full Abstract


- Published: 2025-04-14
- Modified: 2025-05-23
- URL: https://1cell.ai/oncoindx-ai-powered-genomic-profiling-for-precision-oncology/
- Categories: US, White Papers
- Tags: US

OncoIndx is a first-in-class comprehensive genomic profiling solution developed by OneCell Diagnostics. It leverages next-generation sequencing (NGS) to analyze over 1,000 cancer-relevant genes, including rare mutations and treatment resistance markers. Enhanced with AI/ML capabilities, OncoIndx delivers precision insights that help oncologists tailor treatments to each patient’s unique cancer profile. Designed for use with both tissue and liquid biopsy samples, OncoIndx provides deep coverage (up to 5,000x for blood samples) to ensure accurate detection of ctDNA. It supports a wide range of clinical applications—from assessing tumor mutational burden and microsatellite instability to predicting chemotherapy toxicity and matching patients to immunotherapy or targeted therapies. At the core of OncoIndx is the iCARE platform—a secure, interactive reporting system built by oncologists for oncologists. It enables real-time variant visualization, collaborative decision-making, and access to curated reference data. Whether for newly diagnosed patients or those facing treatment resistance, OncoIndx offers a smarter path forward in personalized cancer care. Download the OncoIndx White Paper


- Published: 2025-04-14
- Modified: 2025-05-23
- URL: https://1cell.ai/islb-annual-congress-2024/
- Categories: Events, US
- Tags: US

Join us as we look back on an incredible gathering of scientists, clinicians, and innovators shaping the future of cancer care. Hosted in Denver, this event showcased 1Cell. Ai’s latest breakthroughs in AI, single-cell technology, and multi-omics diagnostics—all built to drive real-world impact across the oncology ecosystem. Venue: Denver, Colorado, USA Date: 23-25 November, 2024 https://youtu. be/MzP8334l-KE


- Published: 2025-04-14
- Modified: 2025-05-23
- URL: https://1cell.ai/esmo-congress-2024/
- Categories: Events, US
- Tags: US

Shaping the Future of Precision Oncology From Barcelona, 1Cell. Ai joined global leaders at ESMO 2024 to showcase our latest innovations in AI-driven cancer diagnostics and single-cell analysis. Catch the highlights and hear how our technologies are driving new standards in real-time, personalized care. Venue: Barcelona, SpainDate: September 13–17, 2024 https://youtu. be/6SHadpkmAlE


- Published: 2025-04-14
- Modified: 2025-05-23
- URL: https://1cell.ai/join-us-europe-launch-dinner-reception/
- Categories: Events, US
- Tags: US

Celebrating the Launch of 1Cell. Ai in Europe You're invited to an exclusive evening of connection, conversation, and innovation as we officially introduce 1Cell. Ai to the European oncology community. Join us for a private dinner reception in Barcelona during ESMO 2024. Venue: Barcelona, SpainDate: September 14, 2024 https://youtu. be/FvDn0k-3YPM


- Published: 2024-11-23
- Modified: 2025-05-23
- URL: https://1cell.ai/islb-annual-congress-2024-2/
- Categories: Events, US
- Tags: US

Advancing Lung Cancer Diagnostics Through Innovation 1Cell. Ai was proud to join global experts at the ISLB Annual Congress 2024 to share our latest advancements in AI-powered liquid biopsy, live CTC analysis, and single-cell multiomics for lung cancer care. Together with leading pathologists and researchers, we explored new frontiers in minimally invasive diagnostics and precision oncology. https://youtu. be/MzP8334l-KE


- Published: 2024-09-30
- Modified: 2026-06-16
- URL: https://1cell.ai/therapy-resistance-detected-in-colorectal-cancer-by-single-circulating-tumor-cell-genomics/
- Categories: India, Publications

Highlights single circulating tumor cell (sCTC) genomic profiling in advanced colorectal cancer patients. Demonstrates detection of therapy-resistance signatures missed by conventional ctDNA analysis. Showcases mutation profiling linked to proliferative, stemness, and treatment-evasion pathways. Presents comparative analysis of sCTCs and paired ctDNA for improved cancer biomarker detection. Features genomic signatures associated with resistance mutations in colorectal cancer progression. Illustrates multi-omics insights supporting precision oncology and personalized treatment strategies. Emphasizes the value of live sCTC isolation for identifying tumor heterogeneity and actionable mutations. Supports liquid biopsy applications for therapy response monitoring and resistance prediction. Read Abstract


- Published: 2024-07-12
- Modified: 2025-05-23
- URL: https://1cell.ai/join-us-at-medlab-asia-2024/
- Categories: Events, US
- Tags: US

Expanding Access to Precision Diagnostics in Asia 1Cell. Ai was proud to participate in Medlab Asia 2024, where we showcased our latest advances in AI-driven diagnostics and single-cell technology. Held in Bangkok, the event brought together leading voices in laboratory medicine and innovation across the region. Venue: Queen Sirikit National Convention Center – BangkokDate: July 10–12, 2024 https://youtu. be/e0iMsh09WnA


- Published: 2024-06-20
- Modified: 2026-06-16
- URL: https://1cell.ai/longitudinal-ctdna-egfr-nsclc-prognosis/
- Categories: India, Publications

Serial circulating tumor DNA (ctDNA) monitoring enabled detection of resistance-associated genomic signatures in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), highlighting the clinical utility of liquid biopsy for real-time molecular surveillance. Longitudinal ctDNA analysis revealed the emergence of resistance mutations during therapy, reflecting tumor evolution and adaptive mechanisms that drive treatment failure in EGFR-driven lung cancer. Patients with detectable resistance-associated alterations demonstrated inferior progression-free survival and poorer overall prognosis, emphasizing the prognostic value of ctDNA-based genomic monitoring. Dynamic changes in ctDNA mutation profiles provided insights into molecular mechanisms of therapeutic resistance, including alterations that may impact targeted therapy effectiveness. Continuous ctDNA surveillance enables early detection of treatment resistance before clinical or radiologic progression, allowing clinicians to anticipate disease progression. Integration of longitudinal ctDNA profiling into clinical management may support adaptive treatment strategies, including timely therapy modification or combination treatment approaches. This liquid biopsy–based monitoring approach strengthens precision oncology in EGFR-mutant NSCLC, improving personalized treatment planning and disease monitoring. Overall, ctDNA-driven molecular tracking provides a non-invasive, scalable tool for real-time tumor genomics, advancing precision medicine approaches in advanced lung cancer. (Read Abstract)


- Published: 2024-06-01
- Modified: 2025-05-23
- URL: https://1cell.ai/oncology-think-tank-conclave-delhi/
- Categories: Events, US
- Tags: US

Collaborating to Shape the Future of Cancer Care At the 2024 Oncology Think Tank Conclave in Delhi, 1Cell. Ai joined top clinicians, researchers, and industry leaders for a high-impact exchange on the future of precision oncology in India. From emerging technologies to clinical integration, the discussions set the tone for innovation and collaboration in cancer diagnostics. Venue: New Delhi, IndiaDate: June 1, 2024 https://youtu. be/uW_RI2fP6z0


- Published: 2024-05-31
- Modified: 2025-05-23
- URL: https://1cell.ai/asco-2024-recap/
- Categories: Events, US
- Tags: US

Driving Impact Through AI and Single-Cell Innovation At the world’s largest oncology meeting, 1Cell. Ai joined global leaders to present our latest breakthroughs in cancer diagnostics. From AI-powered insights to live-cell technologies, ASCO 2024 was a powerful platform to showcase how we're transforming precision oncology—one cell at a time. Venue: Chicago, Illinois, USADate: May 31 – June 4, 2024


- Published: 2024-05-23
- Modified: 2026-06-16
- URL: https://1cell.ai/single-cell-genomics-reveals-resistance-signatures-in-colorectal-cancer-2/
- Categories: India, Publications
- Tags: India

When ctDNA Comes Back Negative, the Story Isn’t Over Plasma ctDNA has become a go-to biomarker for detecting genomic alterations and monitoring colorectal cancer (CRC) progression. But there’s a critical blind spot: in nearly 30% of patients, ctDNA shows no mutations detected at all, potentially leaving actionable, companion-therapy-relevant targets completely invisible. At 1Cell. Ai, we asked a simple question: What is ctDNA missing, and can single-cell CTC genomics see it? Our Study: Paired sCTC and ctDNA Profiling in Advanced CRC We retrospectively isolated live single circulating tumour cells (sCTCs) and CTC clusters from 6 patients with stage 4 colorectal cancer using our OncoRADAR technology. Whole genomes from these sCTCs were amplified and profiled using our comprehensive 1080-gene OncoIndx panel, sequenced on the Illumina NextSeq 2000 platform. Paired ctDNA samples from the same patients were sequenced in parallel at much higher depth, allowing a direct, patient-matched comparison between single-cell and bulk liquid biopsy data. What We Found The genomic landscape revealed by sCTCs told a story that ctDNA alone could not: 22 sCTCs, including 4 CTC clusters, were isolated and profiled, revealing 142 clinically relevant mutations spanning missense, nonsense, frameshift, indel, splice, and structural variants. NRAS emerged as the most frequently mutated gene across sCTCs (52%), followed by SMO, TAP1, and TP53, a markedly different mutational hierarchy than what ctDNA alone reported. Paired ctDNA instead showed TP53, KRAS, and TAP1 as the dominant mutated genes, with only 40% concordance between sCTC and ctDNA at the individual gene level. sCTCs were distinctly...